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ABSTRACT 
 
Background and clinical context: Type 2 diabetes (T2DM) is associated with an increased risk of 
adverse outcomes over a person’s lifetime. Data routinely recorded in general practice electronic 
patient records could be used to develop risk prediction models to identify those at higher risk and 
target preventative treatment. 
Objective: To develop models to predict the 5-year risk of coronary heart disease (CHD), stroke, 
chronic kidney disease (CKD), and all-cause mortality following a diagnosis of T2DM. 
Methods: Newly diagnosed T2DM patients (1998-2003) registered at a practice contributing data to a 
large UK general practice database (THIN) were included in the analyses. The risk models included 
clinical predictors routinely recorded following diabetes diagnosis plus cardiovascular preventative 
treatments. Missing baseline risk factors were estimated using multilevel regression and imputation. 
Outcomes were modelled as time-to-event. 
Results: 20041 patients diagnosed with T2DM were included. The proportion of variation explained 
by each model (R
2
) was: CHD 0.09; stroke 0.35; CKD 0.34; and mortality 0.58. Hazard ratios for 
modifiable risks in the mortality model were: current smoking 1.65; blood pressure (high/treated) 
1.07; and glycaemic control (HbA1C/%) 1.09 (p<0.01 apart from blood pressure). For non-modifiable 
risks, hazard ratios were: 1.10 age (/year); 1.29 male sex; 1.58 prior CHD; 1.47 prior stroke; and 1.33 
prior CKD. Hazard ratios were similar or lower in the morbidity models other than blood pressure 
(1.80 stroke 1.41-45 CHD/CKD, p<0.05). Raised/treated cholesterol was not a consistent risk factor. 
Conclusion: The models were predictive, particularly for mortality, and suggest that older, male, 
smokers, those with poor blood pressure and glycaemic control and those with cardiovascular co-
morbidity are at highest risk and should be targeted at the point of diagnosis. The models could be 
used to highlight such patients and potentially as an educational tool. 
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CHAPTER 1   
INTRODUCTION TO TYPE 2 DIABETES AND THE VALUE OF 
BEING ABLE TO ASSESS INDIVIDUAL RISK OF IMPORTANT 
OUTCOMES 
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1.1 Introduction 
 
This chapter introduces the disease of interest in this thesis, type 2 diabetes, and the rationale 
for developing diabetes-specific multivariate models to predict the risk of several important 
outcomes in this population. 
 
 
1.2 Type 2 diabetes 
 
Diabetes mellitus is a metabolic disorder of multiple aetiology characterised by chronic 
hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both. (1) It may be diagnosed as a result of 
screening or the investigation of symptoms such as increased thirst, urine volume, weight loss 
or recurrent infections. The testing process and cutoff values recommended for diagnosis have 
changed over time: one or more blood glucose measurements and oral glucose tolerance test 
alone were recommended until 2011, when glycated haemoglobin (HbA1C), a measure of 
average blood glucose levels over 2-3 months, was included as a method of diagnosis. (2, 3) 
The two most common categories of diabetes are type 1 and type 2. Type 2 is more prevalent 
and is caused by a combination of resistance to insulin action and impaired insulin response. 
(4) As there may be no overt symptoms after onset, it can be present for a number of years 
before it is diagnosed, and once diagnosed it is usually present for the remainder of the 
person’s life. (5) It is also relatively common and incidence and prevalence is increasing in 
countries like the UK.  (6-8)  
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Primary care is central to the management of type 2 diabetes in the UK, and there have been 
national standards of care for people with diabetes since the early 1990s (9, 10) The public 
health and clinical importance of this disease in the UK is evident in the range of diabetes 
related guidelines on its management, the management of related risk factors, and the 
remuneration offered for good quality management in primary care. (11-16) 
Type 2 diabetes, and diabetes in general, is associated with an increased risk of fatal and non-
fatal outcomes over the person’s lifetime, including damage to the eyes, kidneys, nerves, 
heart, and blood vessels. (17-22) These outcomes are costly both to individuals and to health 
services. There are known risk factors associated with these adverse outcomes, including 
blood glucose control, blood pressure, cholesterol, obesity, and smoking which can be 
modified by lifestyle changes and medical management. (23-35) 
Although nephropathy and subsequent chronic kidney disease is a microvascular complication 
of diabetes, the main risks considered in this thesis are macrovascular, that is, the increased 
risk of coronary heart disease, stroke and death that results from atherosclerosis. (17-22) 
Other diabetic-related microvascular diseases such as retinopathy and neuropathy are not 
considered here. 
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1.3 The value of being able to assess risk in a clinical setting 
 
As described in the previous section, some CVD and CKD risks are modifiable or at least the 
rate of decline in function can be reduced by appropriate treatment.  For the most part, these 
are the same risk factors that influence risk in the general population: smoking; blood 
pressure, lipid levels and obesity. (36-38) For people with diabetes, there can be additional 
predictors of risk, including poor blood glucose control. (39) Early intervention that targets 
these individual factors may reduce the risk of serious outcomes like CVD and CKD by 
delaying or preventing their occurrence. 
It may also be a better approach to assess risk factors in combination than in isolation, that is, 
to combine them into a single estimate of risk on which to base treatment decisions. There is 
evidence that blood pressure lowering and statin treatment are beneficial to people with low- 
and high cardiovascular risk (40-42), and that the benefits of treatment are proportional to 
risk. (43)  
Unlike the individual risk assessment, suggested above, risk prediction models can be used to 
assess whole populations, for example in a single general practice, quickly and in a standard 
manner. (38) This cannot be done so easily by individual clinicians, particularly as these risks 
may not be present at the point of diagnosis of diabetes, but may only become clinically 
significant at a later date. 
When applied to whole populations, the use of risk prediction models can help to allocate 
resources to those most likely to benefit as the benefits of treatment are proportional to 
baseline risk. (40-43) These models can stratify the population into groups with a similar level 
of risk and allow an appropriate intensity of treatment to be targeted to appropriate patients.   
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1.4 Why would you want to develop models specific to type 2 diabetes?  
 
The main benefit of developing diabetes-specific models is the ability to include predictors, 
like HbA1C, which are routinely available for this population and are known to have an impact 
on the risk of important outcomes. (39)This maximizes the applicability of these models to 
clinical practice. There are two additional reasons why this may be an appropriate approach to 
model development.  
Firstly, the effect of specific risk factors on risk may differ between diabetic and non-diabetic 
populations. Yudkin and colleagues developed separate models for people with and without 
diabetes based on data from the Framingham Heart Study. (44) The effect of smoking, BP and 
cholesterol on CHD risk differed in these two groups, suggesting that models which combine 
these two groups without including interactions between these risk factors and diabetes may 
result in models which predict risk in non-diabetic populations better than diabetic 
populations. Other analyses of UKPDS data, showed that there is an important distinction 
between age at diagnosis of diabetes and time since diagnosis, and that there is some evidence 
that diabetic dislipidaemia is quantitatively different from dislipidaemia in the general 
population. (45) 
Secondly, the risk of many outcomes is greater in people with diabetes than in the general 
population: 2- to 5-fold for stroke. (46) As patients at highest risk are likely to benefit most 
from intervention, it is therefore important to estimate risk in people with diabetes accurately. 
(43)   
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1.5 Summary 
 
This chapter presented the rationale for developing type 2 diabetes-specific risk prediction 
models. The next chapter describes the previous attempts to develop models that could be 
used in this population. 
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CHAPTER 2   
PREVIOUS ATTEMPTS TO PREDICT RISK  
IN PEOPLE WITH TYPE 2 DIABETES 
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2.1 Introduction 
 
As indicated in the previous chapter, this thesis focuses on the risk of CVD (separately as 
CHD and stroke), CKD and all-cause mortality following a diagnosis of type 2 diabetes. This 
chapter introduces previous models which could be used predict these outcomes. These were 
identified in a rapid review of models published between 1991 and 2012. (47) The models 
presented for CVD and mortality are specific to type 2 diabetes as a large number of examples 
were identified: the models for remaining outcome, CKD, predict risk in the general 
population and make some adjustment for the presence of diabetes as an additional 
independent risk factor. The features of these models are also described: what predictors they 
include and how specific these are to diabetes. The last section describes the range of risk 
factors that should be included in any new models, and the design and methodological 
limitations of existing models. 
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2.2 Rapid review of risk models for CVD, CKD and all-cause mortality 
 
Abstract: To identify all papers that presented a CVD (i.e. CHD or stroke), CKD, or all cause 
mortality prediction model developed in patients with diabetes or that could be applied to 
individuals with type 2 diabetes. 
Methods: Separate online PubMed searches for each outcome of interest 
(http://www.ncbi.nlm.nih.gov/pubmed). A detailed description of the search and selection 
process can be found in appendix 2.1. As there was a recent review of CVD prediction models 
in patients with type 2 diabetes (48), the PubMed search was restricted to the period 1/4/2011-
31/12/2012 to identify any additional studies published since this review. The search period 
for the remaining two outcomes was from 1/1/1991-31/12/2012. In summary, the titles, 
abstracts and full-text of the publications were reviewed to identify eligible models. The 
eligibility criteria for prediction models were as follows:  (a) The prediction model was either 
developed in people with diabetes or included diabetes as a predictor. (b) The outcome of the 
prediction model was CVD or CKD or a CVD/CKD component (i.e., CHD, stroke, end stage 
renal failure, kidney dialysis, kidney transplant), or all-cause mortality. (c) It presented a 
specific prediction rule/model with sufficient information on all variables to calculate the 
CVD, CKD risk or in a different population (beta coefficients of the model or otherwise a 
scoring system/graph/score card/nomogram was provided). Additional papers were then 
identified by reviewing the additional articles associated with studies which met the eligibility 
criteria on the PubMed website. 
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Results: Four systematic reviews were known prior to running the PubMed searches. (48-51) 
A total of 12 models that predicted the risk of incident CVD were identified by the rapid 
review or from these systematic reviews. Ten models which predicted the risk of incident 
CKD in the wider population were identified, but none that predicted the risk of incident CKD 
specifically. Six diabetes-specific models that predicted the risk of all-cause mortality were 
identified. These results and the characteristics of the prediction models are described in more 
detail in the remainder of this chapter. 
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2.3 Previous risk models for CVD, CKD and all-cause mortality 
 
This section introduces the existing risk models for CVD CKD, and all-cause mortality that 
are applicable to people with newly-diagnosed type 2 diabetes. The searches were restricted to 
models which were developed using people with diabetes, and to incident disease, where 
possible. This was possible with CVD and all-cause mortality, but not CKD as no diabetes-
specific models of incident CKD were available for inclusion. The models identified for each 
of the outcomes of interest are described separately, below, and their details are listed in 
tables 2.1 to 2.3. 
 
2.3.1 CVD models:  specific outcomes reported and populations included in 
development 
 
Twelve models that predicted the risk of incident CVD in people with diabetes were identified 
from the literature and are listed in table 2.1. (44-46, 52-60)  Five of these predicted CVD risk 
as their main or only outcome (52-56), five predicted CHD risk alone or in combination with 
CVD as separate outcomes (44, 45, 57, 59, 60), and two predicted the risk of stroke with no 
other outcomes (46, 58).  Three were exclusively UK-based (45, 46, 59): two used data from 
the UKPDS (45, 46) and one from a regional diabetes register in Scotland (59). Of the 
remaining community-based models: three were derived from US populations (44, 52, 60), 
two from Hong Kong (57, 58), and one each from New Zealand,  Austria and Sweden (54-
56). The final model was based on participants in a multi-country drug trial (53). The number 
of outcomes observed was not reported for the two earliest models (44, 45): the remaining 
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observed approximately 200 to 500 outcomes (46, 52-60), and two reported more than 1000 
outcomes (1482 and 6479) (55, 56). Overall, these CVD models were published at a rate of 
approximately one every two years, suggesting that there has been an ongoing interest in the 
prediction of CVD in people with diabetes over the past two decades (1991-2013). 
For completeness, four additional models which predict risk in the general population were 
reviewed to identify how they adjusted for the presence of diabetes in their respective model: 
Framingham, Assign and QRisk and PROCAM. (61-65) In each of these models diabetes was 
entered as a single covariate, effectively as a single adjustment to the overall predicted risk. 
This did not allow the risk of other outcomes to vary between diabetic and non-diabetic 
people, but assumed that the level of factors like age, blood pressure and cholesterol 
influenced CVD risk in the same manner in both groups. As described in the last section, this 
may not be a safe assumption. 
 
2.3.2 CKD models: populations included in development 
 
No previous diabetes-specific models that predicted the risk of incident CKD (CKD Stage 2-
5: eGFR<60 mls/min/1.73m
2
) were identified from the literature. One model was identified 
which predicted the risk of later stages of CKD in people with diabetes, but was not included 
here as it did not also predict earlier CKD stages. (66)  Nine models which predicted the risk 
of incident CKD in the wider population were identified from the literature and are listed in 
table 2.2.(67-75) One of these also predicted end-stage renal failure. (71) Only one of the 
models, based on general practices contributing to the QResearch database was UK-based 
(71): of the remaining community-based models, five were derived from US populations (of 
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which two were from separate hypertension registries) (67, 69, 72, 74, 75), two were from 
Holland (68, 70), and a further one each was derived from a Taiwanese population (73). Most 
models reported between approximately 200 and 2000 observed outcomes (67-70, 73-75), one 
reported 5236 (72), and the largest, based again on the QResearch general practice database, 
reported in excess of 25000 (71). Although the literature search included studies from 1991, 
the earliest study identified was published in 2004. (75) Seven of the nine models were 
published in the two years between 2010 and 2012 (67-73), demonstrating an increased 
interest in the prediction of CKD in recent years. 
 
2.3.3 All-cause mortality models: populations included in development 
 
Six diabetes-specific models that predicted the risk of all-cause mortality were identified from 
the literature. (76-81) These are listed in table 2.3. Three were derived from UK-based 
community populations (the UKPDS, general practices contributing to the GPRD database 
and patients referred to a diabetes service in one location in England). (79-81) Of the 
remaining community-based models, one was from Denmark and one was from Hong Kong. 
(76, 77) The final model was based on a trial population with high CVD risk. (78) The 
UKPDS and clinical trial papers did not report the numbers of deaths that it observed: the 
remaining four models observed either approximately 500 or 2000 deaths (table 2.3). Five of 
the six models were published since 2010. The first, the UKPDS-based model, was published 
about six years earlier, in 2004. The lack of diabetes-specific models identified in the 
intervening years does not suggest that publications have been missed by the literature search. 
Rather, it appears that all-cause mortality does not receive the same amount of interest as 
 14 
 
other diabetes outcomes like CVD. The UKPDS model was just one of a set of outcome 
models that resulted from this study. (81) The authors of four of the five models since the 
UKPDS publication were specifically interested in the effect of HbA1C on mortality, rather 
than developing a model to predict mortality in a clinical setting, and included the other 
predictors in an attempt to control for confounding. (76-78, 80)  
  
Table 2.1 Previous CVD models (individuals with diabetes) 
Lead author 
(reference) 
Year of publication 
(study dates) 
Study population Outcome Sample 
size 
No. of 
events 
Predictors in the model 
Mukamal  (52) 2013 (1989-1999) Patients with diabetes >=65 years from the 
CHS cohort study, three USA regions 
Incident CVD 782  265 Age, smoking status, systolic BP, total cholesterol, HDL 
cholesterol, creatinine, oral/insulin treatment, C-reactive protein, 
LVH on ECG, ankle–brachial index, internal carotid intima–media 
thickness 
Kengne  (53) 2011 (2001-2008) Individuals with type 2 diabetes from 20-
country trial (ADVANCE) (perindopril-
indapamide), aged 55 years or over 
Incident CVD 7168  473 Age at diagnosis, duration of diabetes, sex, pulse pressure, treated 
hypertension, atrial fibrillation, retinopathy, HbA1C, urinary 
albumin/creatinine ratio, non-HDL cholesterol 
Davis  (54) 2010 (1993-1998) Individuals with type 2 diabetes from 
cohort study, Australia 
Incident CVD 1240  185 Age, sex, prior CVD, albumin:creatinine ratio, HbA1C, HDL 
cholesterol, ethnicity 
Elley (55) 2010 (2000-2008) Individuals with type 2 diabetes from 
cohort study (DCS), New Zealand 
Incident CVD  36127  6479 Age at diagnosis, diabetes duration, sex, systolic BP, smoking, 
total:HDL cholesterol ratio, ethnicity, HbA1C, albumin:creatinine 
ratio 
Cederholm (56) 2008 (1998-2003) Individuals with type 2 diabetes from 
national register, aged 18-70, Sweden 
Incident CVD 11646  1482 Age at diagnosis, diabetes duration, sex, smoking, BMI, HbA1C, 
systolic BP, antihypertensive drug use lipid-lowering drug use 
Yang (57) 2008 (1995-2005) Individuals with type 2 diabetes from 
diabetes registry, free of heart failure, 
Hong Kong 
Incident CHD 3521  181 Age, diabetes duration, sex, smoking, eGFR, albumin:creatinine 
ratio, non-HDL cholesterol, total:HDL cholesterol ratio, HbA1C, 
Systolic BP 
Yang  (58) 2007 (1995-2005) Individuals with type 2 diabetes from 
diabetes registry, Hong Kong 
Incident stroke 3668  190 Age, HbA1C,  albumin:creatinine ratio, CHD 
Donnan  (59) 2006 (1995-2004) Individuals with type 2 diabetes and 
complete data from regional register 
(DARTS), Scotland 
Incident CHD 4569  243 Age at diagnosis, duration of diabetes, HbA1C, smoking, sex, 
systolic BP, treated hypertension, total cholesterol, height 
Folsom (60) 2003 (1987-1998) Individuals with diabetes in cohort study 
(ARIC), aged 45-64 years, from four 
communities in USA 
Incident CHD 1500  257 Age, race, smoking, total cholesterol, HDL cholesterol, systolic BP, 
use of antihypertensives, smoking status. BMI, waist:hip ratio, heart 
rate, physical activity, FEV, Keys score, tobacco pack-years, 
creatinine, albumin, factor VII, WBC, LVH, carotid IMTfactor 
VIII, von Willebrand factor 
Kothari (46) 2002 (1977-NR) Individuals with incident type 2 diabetes 
in cohort study (UKPDS), aged 25-65, 
without recent or multiple CHD events, 
UK 
Incident stroke 4549  188 Age at diagnosis, duration of diabetes, sex, smoking, systolic BP, 
total:HDL cholesterol ratio, atrial fibrilation 
Stevens (45) 2001 (1977-NR) Individuals with incident type 2 diabetes 
in cohort study (UKPDS), aged 25-65, 
with no recent history of CHD, UK 
Incident CHD 4540  NR Age at diagnosis, sex, ethnicity, smoking, HbA1C, systolic BP, 
total:HDL cholesterol ratio 
Yudkin (44) 1999 (NR) Individuals with diabetes from 11 cohort 
studies, USA 
Incident CHD NR 
(<2138) 
NR Age, sex, smoking, microalbuminuria, total:HDL cholesterol ratio 
  
Table 2.2 Previous CKD models (wider population and predict future risk of, not prevalent CKD) 
Lead author 
(reference) 
Year of 
publication 
(study dates) 
Study population Outcome Sample size Number 
of events 
Predictors in the model 
O'Seaghdha (67) 2012  
(1995-2008) 
Framingham Heart Study participants Incident CKD 2490 229 Age, diabetes, hypertension, baseline estimated glomerular filtration rate, 
albuminuria 
Alssema (68) 2012  
(1989-2005) 
Three population-based cohort studies 
from the Netherlands, aged 28-85 
years, no type 2 diabetes, CVD 
Incident CKD 6780 22% Age, smoking, use of antihypertensives, use of lipid-lowering drugs, BMI, waist 
circumference, family history <65 years of MI/stroke, family history diabetes, 
history of gestational diabetes 
Hanratty (69) 2011  
(2000-2007) 
Hypertension disease registry at 
Kaiser Permanente USA 
Incident CKD 43,305 5236 Age, gender, race/ethnicity, baseline eGFR, baseline and time-varying SBP, HDL 
cholesterol, BMI, diabetes, CHD, CVD, heart failure, PVD 
Halbesma (70) 2011  
(1997-2006) 
PREVEND observational cohort study 
participants, Netherlands 
Incident CKD with 
highest quintile in 
decline in renal 
function 
6809 272 Baseline eGFR, age, urinary albumin excretion, systolic BP, C-reactive protein, and 
known hypertension (diabetes was included in an early version of the model) 
Hippisley-Cox 
(71) 
2010  
(2002-2008) 
QResearch UK general practice 
database 
Incident moderate-
severe CKD. 
Incident end-stage 
kidney disease 
1574749 25320 Age, ethnicity, deprivation, smoking, BMI, systolic blood pressure, diabetes, 
rheumatoid arthritis, cardiovascular disease, treated hypertension, congestive cardiac 
failure, PVD, NSAID use, family history of kidney disease, systemic lupus 
erythematosis, kidney stones 
Hanratty (72) 2010  
(2000-2006) 
Hypertension disease registry, 
Colorado, USA 
Incident CKD 10420 429 Age, sex, race/ethnicity, marital status, language, diabetes, vascular disease, heart 
failure, dyslipidaemia, major psychiatric diagnosis, substance abuse, baseline eGFR 
Chien (73) 2010  
(2003-2009) 
Prospective cohort study, Taiwan Incident CKD 5168 190 Age, BMI, diastolic BP, type 2 diabetes, stroke, postprandial glucose, HbA1C, 
proteinuria, uric acid 
Kshirsagar (74) 2008  
(1987-2003) 
Two community-based cohort studies 
(ARIC, CHS), USA 
Incident CKD 14155 1605 Age, sex, race/ethnicity, anaemia, CVD, diabetes, heart failure, PVD, HDL 
cholesterol 
Fox (75) 2004  
(1978-2001) 
Framingham Heart Study participants Incident CKD 2585 244 Age, sex, baseline eGFR, BMI, smoking, diabetes, systolic BP, hypertension, 
hypertension treatment, total cholesterol, HDL cholesterol, impaired fasting glucose 
 
  
Table 2.3 Previous all-cause mortality models (individuals with diabetes) 
Lead author (reference) Year of publication 
(study dates) 
Study population Outcome Sample 
size 
Number of 
events 
Predictors in the model 
Xu (76) 2013 (1998-2009) Diabetic cases from Elderly 
Health Service cohort study 
(age>=65 years), Hong Kong 
All-cause mortality. 
CVD-, CHD- and 
stroke-specific 
mortality 
2137  540 Age, sex, education, smoking, alcohol use, exercise, cardiovascular 
disease history, BMI, total cholesterol, HbA1C 
Skriver  (77) 2012 (2001-2005) Individuals with type 2 
diabetes from single region 
in Denmark 
All-cause mortality 17760  1859 Age, sex, diabetes duration, mean annual HbA1C at baseline, CVD, 
arteriosclerosis, acute complication of diabetes, retinopathy, 
nephropathy, MI, stroke, neuropathy 
Andersson (78) 2012 (2003-2009) Secondary analysis of 
overweight/obese/high CVD 
risk individuals with type 2 
diabetes from SCOUT trial, 
16 countries 
All-cause mortality 7479  NR Age, sex, randomised treatment assignment (sibutramine), diabetes 
duration, history of arterial hypertension, history of congestive heart 
failure, history of cardiovascular disease, history of revascularisation, 
ethnicity, tobacco use, systolic and diastolic blood pressure, heart rate, 
HbA1C, BMI, HDL cholesterol, LDL cholesterol, urine 
albumin/creatinine ratio and use of insulin, metformin, 
thiazolidinediones and sulfonylureas 
Kerr (79) 2011 (1999-2007) Patients referred to type 2 
diabetes service, 
Bournemouth, UK 
All-cause mortality 3781  579 Age, sex, year of diagnosis, HbA1C at 3 months, systolic BP, smoking 
Currie (80) 2010 (1986-2008) GPRD patients with type 2 
diabetes, whose treatment 
was changed to combination 
therapy or insulin and were 
aged 50 years or over 
All-cause mortality 27965  2035 Age, sex, smoking status, cohort (combination therapy or insulin 
initiated), HbA1C, mean total cholesterol, LVD, Charlson Index 
Clarke (81) 2004 (1977-1989) Patients from the UK 
Prospective Diabetes Study, 
newly diagnosed with type 2 
diabetes, aged 25-65 years 
  3642  NR Age, sex, smoking status, HbA1C, total:hdl cholesterol ratio, MI, renal 
failure, amputation 
 
 
 18 
 
2.3.4 Published systematic reviews of CVD and CKD risk models 
 
Four systematic reviews of models used to predict the risk of CVD and CKD were identified: 
the CVD reviews included models which were either specific to diabetes or designed for the 
general population, but included the presence of diabetes as a predictor. (48, 49)  
The CKD model reviews had a wider scope than was required for this thesis. They aimed to 
identify all CKD models applicable to the general population, including those which did not 
list diabetes as a predictor and those which predicted the presence of undiagnosed CKD as 
well as the risk of future CKD. (50, 51)   
The review led by Echouffo-Tcheugui (51) was more optimistic about model quality than that 
led by Collins (50): it focused on the outcome measures reported and suggested that the use of 
predictive models in nephrology was not as well established as it is in other clinical areas. The 
Collins review was more methodological in its critique of the models and found that they 
were often developed using inappropriate methods and were generally poorly reported. 
Collins went on to recommend appropriate approaches to the development and validation of 
prediction models. These are applicable to all prediction models: basing the models on data of 
appropriate quality; selecting predictors based on the literature and clinical guidelines; 
handling missing data and continuous covariates appropriately; internal validation using 
bootstrapping rather than splitting a ‘non-massive’ dataset into two halves (and using the 
second half for validation); and reporting methods and results appropriately. Both of the CKD 
model reviews highlighted the need to externally validate risk prediction models.  Collins also 
pointed out one QResearch paper as an example of good reporting and mentions the 
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validation of the two models reported in this paper in a second large general practice database. 
(71)  
However, both internal and external validation using routinely collected electronic patient 
records rely on the same kind of data that were used to develop these prediction models. The 
predictors and outcomes recorded in routine general practice and used in model development 
are likely to be affected by the same recording bias as routine GP records from any other 
source. These sources are, therefore, too similar to the data used in model development to 
allow their true predictive ability in a clinical setting to be assessed. A more realistic approach 
to the validation of these models for use in clinical settings would be a prospective clinical 
study where the model was used to identify those at high and low risk. The predicted and 
actual level of risk could be compared using data collected from patients participating in the 
study. Any under- or over-estimation of risk could be assessed by prospective data collection 
using linked data from primary and secondary care, death certification and disease-specific 
registries, as appropriate. 
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2.4 What factors do the existing models identify as predictive of the risk of 
CVD, CKD and death? 
 
This section identifies the risk factors that should be included in future models that predict the 
risk of CVD, CKD and mortality in people with type 2 diabetes based on the covariates 
included in previous models. 
 
2.4.1 CVD  
 
Twelve models were developed to predict CVD risk in people with diabetes: some are single 
models which predict overall CVD risk and some are specific to CHD and stroke. (44-46, 52-
60) These models are listed in table 2.1. Table 2.4 provides an overview of the variables 
included in each model. The most common single risk factor was current age/age at diagnosis 
(12 models): this included duration of diabetes in six of the models. The most common group 
of risk factors included were blood test results: cholesterol values (10 models); 
albumin/creatinine/eGFR (9); HbA1C (8); microalbuminuria (1); C-reactive protein (1); and 
carotid IMT factor VII/ factor VII/Von Willebrand factor and WBC count (all mentioned in a 
single model). The next most common single risk factor was smoking (9 models), followed by 
demographic factors: sex (9 models) and ethnicity/race (4).  Systolic BP was included in 8 
models, with pulse pressure, heart rate and ankle-brachial index included in one model each. 
BMI, waist:hip ratio and height appeared in four models. Current drug treatments were 
included in several models: antihypertensives (4 models); oral/insulin treatment (1); and lipid-
lowering drugs (1). The last group of risk factors consisted of comorbidities at baseline: atrial 
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fibrillation (2 models); left ventricular hypertrophy (2); prior CVD event (1); and CHD (1). 
The last two single risk factors were forced expiratory volume (FEV) and Keys score (lipid 
content of diet), each of which appeared in a single model. 
 
  
Table 2.4 Variables included in previous CVD models (individuals with diabetes) 
 Mukamal  
(52) 
Kengne  
(53) 
Davis  
(54) 
Elley 
(55) 
Cederholm 
(56) 
Yang 
(57) 
Yang  
(58) 
Donnan  
(59) 
Folsom 
(60) 
Kothari 
(46) 
Stevens 
(45) 
Yudkin 
(44) 
Age, age at diagnosis, diabetes duration X X X X X X X X X X X X 
Blood/ urine test results 
(cholesterol, albumin, creatinine, eGFR, HbA1C, 
microalbuminuria,  C-reactive protein, carotid IMT factor 
VII/ factor VII/Von Willebrand factor,  WBC count) 
X X X X X X X X X X X X 
Smoking X 
  
X X X  X X X X X 
Sex 
 
X X X X X  X  X X X 
Ethnicity/race 
  
X X 
  
  X  X  
Systolic BP, pulse pressure, heart rate or ankle-brachial index X X 
 
X 
 
X  X X X X  
BMI, waist:hip ratio or height 
    
X 
 
 X X    
Current drug treatment  
(antihypertensives, oral antidiabetic / insulin, lipid lowering) 
X X 
  
X 
 
 X X    
Comorbidity 
(atrial fibrillation, left ventricular hypertrophy, prior CVD 
event, CHD, retinopathy) 
X X X 
   
X X  X   
Forced expiratory volume, Keys score, physical activity 
      
  X    
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2.4.2 CKD 
 
Nine models that predicted the risk of future CKD in the general population are listed in table 
2.2. (67-75) Table 2.5 provides an overview of the variables included in each model. These 
included a covariate for diagnosed diabetes in their development (1 model) or in their final 
model (8), or for a history of gestational diabetes (1). Six of the models included measured 
blood pressure or diagnosed hypertension. The most common group of risk factors were blood 
test results: eGFR (5 models); uric acid/urinary albumin/proteinuria (5); cholesterol values/ 
diagnosed hypercholesterolaemia (4); HbA1C/glucose/impaired fasting glucose (3); and C-
reactive protein (1). Demographic variables were the next most common group of risk factors: 
age (all 9 models); sex (4); race/ethnicity/language (4); material deprivation (1); and marital 
status (1). BMI/waist measurement was included in five models and smoking status in three. 
Prior comorbidity was the next most common group of covariates: CVD, heart failure and 
PVD appeared in a model on three occasions each; and anaemia, kidney stones, substance 
abuse, major psychiatric disorder, systemic lupus erythematosis, and rheumatoid arthritis on 
one occasion each.  Drug treatments were also included in several models: antihypertensives 
(2 models); lipid-lowering drugs (1); and NSAID use (1). Family history was the last group of 
risk factors: family history of CVD, kidney disease and diabetes appeared on one occasion 
each. 
  
Table 2.5 Variables included in previous CKD models (wider population and predict future risk of, not prevalent CKD) 
 
O'Seaghdha 
(67) 
Alssema 
(68) 
Hanratty 
(69) 
Halbesma 
(70) 
Hippisley-
Cox (71) 
Hanratty 
(72) 
Chien 
(73) 
Kshirsagar 
(74) 
Fox 
(75) 
Diabetes as comorbidity or history of gestational diabetes 
X X X 
 
X X X X X 
Blood pressure or diagnosed hypertension 
X 
 
X X X 
 
X  X 
Blood/ urine test results 
(eGFR, uric acid, urinary albumin, proteinuria, 
cholesterol values or diagnosed hypercholesterolaemia, 
HbA1C, blood glucose, impaired fasting glucose, C-
reactive protein) 
X 
 
X X 
 
X X X X 
Age 
X X X X X X X X X 
Sex 
  
X 
  
X  X X 
Race, ethnicity or language 
  
X 
 
X X  X  
Material deprivation 
    
X 
 
   
Marital status 
     
X    
BMI or waist measurement 
 
X X 
 
X 
 
X  X 
Smoking status 
 
X 
  
X 
 
  X 
Comorbidity  
(CVD, heart failure, PVD, anaemia, kidney stones, 
substance abuse, major psychiatric disorder, systemic 
lupus erythematosis, rheumatoid arthritis) 
  
X 
 
X X X X  
Current drug treatment  
(antihypertensive,  lipid-lowering, NSAID)  
X 
  
X 
 
  X 
Family history (CVD, kidney disease, diabetes) 
 
X 
  
X 
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2.4.3 Mortality 
 
Six models that predicted the mortality risk in the people with diabetes are listed in table 2.2. 
(76-81) Table 2.6 provides an overview of the variables included in each model. Demographic 
variables were the most common group of risk factors included in these models: sex (6 
models); age (6); education (1); and ethnicity (1). All models include CVD as a comorbidity: 
other comorbidities were less commonly included: nephropathy (3 models); heart failure (2); 
amputation, retinopathy, history of arterial hypertension, arteriosclerosis, MI, stroke and 
revascularisation (1 model each). One model included a single covariate covering all acute 
diabetes-related complications and an overall comorbidity score (the Charlson Comorbidity 
Index). Diabetes-specific risk factors were the next most common group: HbA1C (all 6 
models); diabetes treatment type (3); diabetes duration (2); and year of diabetes diagnosis (1). 
Smoking status was the next most common single risk factor (5 models): BMI, another 
lifestyle-related risk factor, was included in just two models, and exercise and alcohol use 
were mentioned together in one further model. Cholesterol level was included in four models 
and blood pressure in two, and a history of arterial hypertension was included in one model. 
There was only one further blood result included in these models: urine albumin/creatinine 
ratio, which appeared in one model. 
  
Table 2.6 Variables included in previous all-cause mortality models (individuals with diabetes) 
 
Xu 
(76) 
Skriver  
(77) 
Andersson 
(78) 
Kerr 
(79) 
Currie 
(80) 
Clarke 
(81) 
Sex X X X X X X 
Age X X X X X X 
Education X 
     
Ethnicity 
  
X 
   
Comorbidities 
(CVD, nephropathy, heart failure, amputation, retinopathy, history of arterial 
hypertension, arteriosclerosis, MI, stroke, revascularisation, any acute 
diabetes-related comorbidity, Charlson Comorbidity Index) 
X X X 
 
X X 
HbA1C X X X X X X 
Diabetes treatment type 
  
X 
 
X X 
Diabetes duration, year of diabetes diagnosis 
 
X X X 
  
Smoking 
X 
 
X X X X 
BMI X 
 
X 
   
Exercise, alcohol use X 
     
Cholesterol level X 
 
X 
 
X X 
BP, heart rate 
  
X X 
  
Urine albumin/creatinine ratio 
  
X 
   
 27 
 
2.5 What range of risk factors should be considered for use in future models 
that predict the risk of CVD, CKD and death in people with type 2 diabetes? 
 
The three groups of models identified in tables 2.1 to 2.3 can be used to estimate the risk of 
CVD, future CKD and mortality in people with diabetes. They vary in complexity, containing 
from four to 22 covariates. (58, 60, 78) . Some include risk factors which are not routinely 
recorded in primary care, even after a diagnosis of diabetes: lipid content of diet (which is 
also difficult to measure accurately) and von Willebrand factor, for example. (60) Others 
exclude risk factors which would be routinely recorded in primary care, particularly following 
a diagnosis of diabetes, and which are known to be associated with CVD, CKD and mortality 
risk: sex; systolic blood pressure; smoking status, and BMI, for example. (54, 58, 79)   
The variables included in the models above suggest that there is a wide set of potentially 
significant predictors that should be considered for inclusion in any new predictive model for 
these outcomes. These are the demographic, lifestyle, comorbidity, biochemical, treatment, 
and clinically observed risk factors that may be associated with each outcome. The minimum 
specification for any new model should, therefore, include relevant individual predictors from 
each group in this set and should be adequately powered to detect the effect of changes in 
their level on the outcome of interest. 
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2.6 Summary 
 
This chapter introduced existing models which predicted the risk of CVD, CKD and mortality 
which can be used following a diagnosis of type 2 diabetes. The CVD models which were 
developed for use with the general population did not include HbA1C, an important risk factor 
for the outcomes of interest, and by including the presence of diabetes as a single term in their 
models, without interaction terms with other covariates, made a strong assumption that the 
effect of diabetes is independent of other risk factors such as blood pressure, cholesterol and 
comorbidities at baseline. This would tend to limit their ability to accurately estimate risk in 
type 2 diabetes and their utility in UK primary care. Many of the models specific to diabetes 
have attempted to include data which would be routinely available in UK primary care and 
could, therefore, be used in clinical practice in this setting.  However, their utility in this 
setting is limited because they: excluded cases diagnosed at older ages and were based on BP- 
and cholesterol-untreated populations; included only cases with complete risk factors; and 
may not have had the power to detect the effect of important risk factors.  
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CHAPTER 3   
REASONS WHY YOU MIGHT WANT TO USE PRIMARY CARE 
DATA AS OPPOSED TO OTHER DATA SOURCES TO DEVELOP A 
PREDICTIVE MODEL 
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3.1 Introduction 
 
The last chapter introduced previous models that predicted the risk of CVD, CKD and death 
in people with diabetes. These models were derived from a variety of data sources including 
clinical trials, single and aggregated cohort studies, disease registers, and secondary and 
primary care. These data were also from a number of countries and refer to events that 
occurred over the past three decades. Few of these studies, taken individually, would therefore 
be regarded as automatically valid for use in the current UK population without further 
evaluation in this population. A hierarchy of evidence for statistical prediction models is 
suggested below.  It emphasises the importance of the representativeness of the population 
used for development and later external validation of models, rather than the meta-analyses 
and systematic reviews used to assess other types of research question.    
The utility of the possible sources of data for the prediction models of interest are discussed: 
the strengths and weaknesses of the alternatives and the selected data source (a large primary 
care database) are then compared.  
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3.2 Hierarchy of evidence for statistical prediction models 
 
This section suggests a hierarchy of evidence which can be used to assess the utility of 
various sources of data for use in the development of the statistical prediction models of 
interest in this study. These models will predict the risk of CHD, stroke, CKD and all-cause 
mortality in people with newly diagnosed type 2 diabetes, and are intended for use in the UK 
general practice population. 
The hierarchy of evidence for models which are intended to predict clinical outcomes differs 
from that required for other types of research question (e.g. the effectiveness of an 
intervention). (82) Merlin and colleagues did not specifically include statistical prediction 
models like those developed in the current study, but did provide a hierarchy for studies 
which aim to identify prognostic factors for disease outcomes. (82) They placed systematic 
reviews of prospective cohort studies at the top of the hierarchy, followed by all-or-none 
studies (a rare situation where all or none of the people with a risk factor experience the 
outcome of interest). This was followed in their hierarchy by secondary analysis of RCT data 
to identify prognostic factors, then retrospective cohort studies (like the current study), and 
finally case series or cohort studies of people at different stages of a disease.  
This hierarchy may be appropriate for studies which aim to identify common prognostic 
factors across a range of clinical settings, countries and time periods, but not those like the 
current study which aim to combine predictive factors into a single statistical model for use in 
a specific population. A more appropriate hierarchy for a statistical prediction model (based 
on the systematic review of CKD prediction models by Collins and colleagues (50)) might be:  
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1) analysis of large population representative of the population in which the model is to be 
applied with validation (in the population in which the model is to be applied); 
2) analysis of small population representative of the population in which the model is to be 
applied (with validation); 
3) analysis of a population less representative of the population in which the model is to be 
applied (with validation); and 
4) analysis of a population different from the population in which the model is to be applied 
(with or without validation). 
The most important features in this hierarchy are the use of a population that is representative 
of the target population for model development; the inclusion (for model development) of a 
population large enough to provide precise estimates of the value of each of the predictors of 
interest; and the additional step of model validation in the target population.  
The next section describes the utility of the available sources of data for use in the 
development of predictive models which are intended for use in current UK general practice.  
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3.3 The utility of prospectively collected data compared with routine data 
 
The possible sources of data for the development of the predictive models of interest in this 
study can be divided into two broad types: prospectively collected study data from trials and 
bespoke cohorts, and routine data from primary and secondary care and from disease 
registers. (82) The utility of these sources can be assessed by the availability and accuracy of 
outcome and predictor data, the features of the population that they cover (representativeness, 
duration of follow-up) and cost. 
Outcome ascertainment: The outcomes of interest in this study were CVD (CHD and 
stroke), CKD and all-cause mortality. Studies which collect data prospectively can be 
designed to ensure that outcomes such as CVD and CKD are collected in a consistent and 
complete manner. This is unlike routine data sources which rely on these kinds of outcomes 
being ascertained and recorded in a consistent manner by a potentially large set of clinicians, 
administrators or clinical coders. Mortality (the fact and date of death, rather than cause), 
however, may be better recorded in routine data, particularly in primary care because of the 
link to payment [section 4.6]. 
Completeness and accuracy of predictor variables: The predictors of interest in this study 
were demographic (age, sex, material deprivation), comorbidities (prior CVD and CKD), 
clinical measurements (BMI, BP, cholesterol, eGFR) and drug treatments (BP-lowering and 
lipid-lowering) as the predictive models were intended for use in UK general practice where 
these data are routinely recorded for all patients or as part of clinical care following a 
diagnosis of type 2 diabetes. (39, 83, 84) Other routine data sources (secondary care and 
diabetes registers) may not collect this full range of predictors (e.g. secondary care may only 
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collect data which are relevant to the reason for referral or hospital admission: diabetes 
registers may not have data on comorbidities at diabetes diagnosis). Unlike prospective 
studies which can arrange for these predictors to be assessed at the same time points and at 
relatively fixed intervals, these same predictors may be missing (not routinely recorded or not 
measured for a particular individual), or recorded at different intervals in routine data sources 
[section 7.5].  Further, the accuracy of measurement may also be greater in prospectively 
collected study data where measurement protocols can be standardised across study sites and 
individual investigators. Routinely recorded data, like BP or weight and height, may not have 
this level of consistency [section 6.6.6]. 
Population: The target population for the clinical predictions models in this study was 
current (numbering approximately 10000) UK general practices. (85) Both prospectively 
collected study data and routine data sources may not be representative of this population: 
prospectively collected study data may not be representative if they are based on data from a 
small set of study sites and secondary care data may only reflect those who were seen in 
hospital for the management of their diabetes or complications arising from it. Given the 
number of practices in the UK, even large primary care databases comprising of hundreds of 
practices may not necessarily be representative of all types of practice (e.g. single-handed), all 
geographical regions, and deprivation. (86) 
Cost versus sample size: In principal prospective studies can recruit similar numbers of cases 
for inclusion in prediction models as studies which use routine data. (87) The limiting factor 
is cost: the cost of data collection is relatively low with routine data (THIN contributing 
practices are provided training on the use of their practice software and some feedback on 
data quality), whereas prospective studies have an ongoing cost associated with collection of 
predictor data and outcomes for the entire duration of the study. 
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The remainder of this section focuses on specific examples of each type of data (prospective 
trial/cohort study data and routine data) which could be used to develop the prediction models 
of interest in this study. Examples are used from previous prediction models to illustrate the 
strengths and weakness of each source. Lastly, the strengths and weaknesses of large primary 
care databases (the source of data selected for this study) are discussed. 
Prospectively collected trial/cohort data: The UKPDS (88) was a data source for three of 
the models identified in the previous chapter (45, 46, 81). The design of this series of studies 
demonstrates how trial and prospective cohort data in general may not be a suitable source for 
the predictive models of interest in this thesis.  
 Long interval between study start and model development/publication: Diabetic 
complications can take many years to develop (45, 89) : this can introduce a delay of 
many years before a sufficient number of outcomes to power a multivariate prediction 
model have been observed. Similarly, if the intention is to develop a model which can 
predict the 5- or 10-year risk of an outcome, then a proportion of the study participants 
must be observed for close to 5 or 10 years. 
 Representativeness: These populations are not necessarily representative of the 
population which is the target for a predictive model. These differences may include the 
duration of diabetes, age at diagnosis, health status, case definition and risk management. 
(45)  
o The UKPDS trial population was limited to people aged 25-65 at diabetes 
diagnosis: this excluded approximately half of the incident type 2 diabetic 
population who were over 65 years at diagnosis. (6)  
o It also excluded people if they had recent or multiple CHD events: data from the 
cohort included in this thesis suggests that over 20% of UK primary care patients 
 36 
 
have a history of CHD or stroke at diagnosis of type 2 diabetes (table 7.5).  The 
UKPDS prediction models could not, therefore, reliably be used to predict risk in 
this group of patients.  
o The trial also recruited participants from 1977 to 1991, before statins, which 
reduce the risk of CVD when used in primary prevention, were in widespread use 
(fewer than 7000 general practice patients in England were prescribed a statin in 
1991 (90)), and did not include any adjustment for exposure to this or other drugs 
which can reduce the risk of CVD, in particular blood-pressure lowering drugs and 
antiplatelet agents (45, 46, 81).  
Routine data:  Routine data refers to data which have been collected (prospectively) for other 
purposes (usually as part of clinical care) and which are later analysed to answer a research 
question. (91) The possible sources of data for predictive models considered here are 
secondary care data, diabetes registers and primary care data. 
 Secondary care data: Type 2 diabetes mellitus is usually diagnosed and managed in 
primary care in the UK, rather than secondary care. (92-94) Secondary care data on 
patients with diabetes is therefore likely to be restricted to patients who were referred to a 
diabetologist for a particular reason or admitted as an inpatient, and the data items 
collected in secondary care are likely to be relevant to the reason for referral or admission. 
(95) Other secondary care models, like that produced by Kerr (based on data from local 
secondary care led diabetes services data alone) may not reflect the general practice 
population which would be the target for diabetes-specific predictive models. (79) 
 Diabetes registers: Diabetes registers, an example of a disease-specific register, cover 
only relatively small geographic areas in the UK, unlike cancer registries which have 
national coverage and are relatively few in number. (96, 97) The relationship between the 
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risk factors and outcomes may differ from other areas. (86) The health services in these 
areas may also differ from those provided nationally: the presence of a register may result 
in greater contact between primary and secondary services, and the linked registry data 
may be used to improve patient outcomes as well as for research. (98) These may limit the 
representativeness of such diabetes registers as data sources for models which are 
intended for use across the national population. (59) 
 General practice data: If predictive models for CVD, CKD and mortality are to be used 
in a UK primary care setting by GPs, then there are particular advantages to using primary 
care patient records as the main or only source of data: these range from the availability of 
data on risk factors, the applicability of these data to the current population, where the 
models are most likely to be used, and the relevance of the risk factors to clinicians 
working in primary care. (38) There are also weaknesses to these data, only some of 
which can be addressed using appropriate statistical methods. (99) On balance, compared 
with the alternative sources of data and their own strengths and weaknesses, routine 
records from primary care appears to be an acceptable source of data for the prediction 
models of interest in this study. They have specific advantages over alternative sources  
Advantages:  
o Primary care is central to the management of type 2 diabetes. (92-94) 
o There is an increased level of contact and risk factor recording in primary care 
following diagnosis. (12, 13, 84) 
o This increased monitoring and management can provide suitable data for 
prognostic models. (12, 13, 37, 39, 89, 100) 
o Retrospective cohort studies can be carried out in primary care databases which 
include in excess of 500 practices from the UK. (64, 71, 101, 102) This avoids the 
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need for primary data collection from individual practices, and reduces the time 
taken to produce these models. This is particularly relevant for the current study 
which is taking place in the context of a PhD. 
o The effect of new risk factors can be explored if they are routinely recorded in 
general practice: these patient records contain a wider range of health-related 
information than that collected by disease-specific registers and hospital-based 
services. (96, 103) Primary data collected from general practices or other sources 
are usually restricted to a set of predictors identified as relevant at the outset. (104, 
105) Some primary care database owners provide researchers with the full 
electronic patient record for cases of interest (THIN and CPRD, but not 
QResearch): this allows researchers using these data sources to assess the value of 
additional predictors or explain any unexpected results using additional clinical 
data about each case. 
o The data used to develop these models can be more recent, increasing their 
applicability to the current population with diabetes. This is because the three main 
GP databases receive regular data updates from participating general practices. 
(106-108)  In the case of THIN, the gap between data extraction and data being 
ready for research use can be 5 months. (107) The data provided by the database 
owner for this study is no longer current (it dates from 2005), but the same 
modelling can be rerun in more recent data prior to publication to ensure the 
relevance of the prediction models and take advantage of linkage with secondary 
care sources and any improvements in the recording of predictors caused by the 
introduction of QOF. (63, 109) 
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o Clinicians will make decisions based on the data they have collected in routine 
primary care. (39)  
Disadvantages: 
o Large general practice databases may be representative of the wider population in 
terms of age and sex, but their representativeness may vary by region, and they 
may not reflect the full range of practices in the UK (each database contains 
approximately 500 practices (106-108): there are over 10000 practices in the UK 
(85)).  However, there are currently no other larger sources of primary care data, 
so these are the best available source of primary care data for prediction model 
development. Models derived from these sources can also be validated and revised 
using data from dissimilar sets of practices to ensure their representativeness. (64, 
71, 109, 110) 
o There can be wide variability between general practices in the coding and 
recording of the data needed to identify cases, outcomes and risk factors. (111) 
The introduction of QOF and incentives for recording the process of care after a 
diagnosis of diabetes will have led to more consistent recording of some of the 
clinical values of interest: this will benefit predictive models which use more 
recent data for development. (12) Variability in the coding of cardiovascular 
outcomes may lead to models which over or underestimate the risk of these 
outcomes. (112) 
o Clinical predictors such as cholesterol levels can be missing or not recorded for 
some cases close to the baseline (diabetes diagnosis) for the clinical prediction 
models of interest [section 6.6.6]. The exclusion of cases with incomplete risk 
factor data might lead to biased results or models which are not representative of 
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the population of interest [section 6.7.5]. (99, 113)  However there are appropriate 
statistical methods for dealing with these issues, such as the estimation of baseline 
values and multiple imputation [sections 6.6.7 and 6.7.5]. Multiple imputation of 
missing clinical measurements has been used in other clinical prediction models 
which are in current use in general practice and are therefore likely to be an 
acceptable method for dealing with missing data in this study. (64, 71) 
 
3.4 Summary 
 
Although there are alternative sources of data, routine data derived from large primary care 
databases appear to be an appropriate source of data to generate predictive models intended 
for use in UK primary care. The next chapter discusses the kind of information that UK 
primary care and large primary care databases contain with respect to diabetes and related 
outcomes. 
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CHAPTER 4   
INTRODUCTION TO PRIMARY CARE ELECTRONIC PATIENT 
RECORDS AND TO LARGE PRIMARY CARE DATABASES 
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4.1 Introduction 
 
This chapter introduces the electronic patient records held by primary care in the UK and the 
large primary care databases that are derived from them.  The purpose here is to describe how 
practices use their computer systems and the kinds of data that are entered, particularly with 
reference to the diagnosis and management of type 2 diabetes. The chapter then goes on to 
describe what data are available from the three main primary care databases currently 
operating in the UK. It ends by introducing published evidence on the validity of the 
diagnoses of interest in this thesis, namely diabetes, CVD and CKD, and their implications for 
the identification of primary care patients with these diagnoses. 
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4.2 How practices use their systems and the scope of data recorded by practices 
 
Practices with clinical computer systems typically use them in place of paper records during 
patient consultations. (12, 114) These systems allow the practice staff to review the details of 
each patient’s history and care, and to store new information on symptoms, diagnoses, test 
results, and prescribing. (103) They can also provide templates (allowing easy data entry) 
related to the periodic review of specific chronic conditions, e.g. diabetes. These serve as a 
reminder of the information that needs to be gathered during the consultation and past events 
related to that condition. (114) 
The extent to which individual practices make use of all the features of their system probably 
varies from individual clinician to individual clinician and, therefore, from practice to 
practice, depending on the level of experience of the individual members of staff. (115) It may 
not, therefore, be used to its full extent for some time after its installation in a practice.  
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4.3 What data are recorded specifically about diabetes, its management and 
diabetes-related outcomes and when are they recorded? 
 
The electronic patient records of patients with type 2 diabetes can also contain a record of the 
diagnosis and management of their diabetes, and the management of any associated risk 
factors, including relevant outcomes. (6, 12) If the diabetes is diagnosed after the patient 
registered at their practice, this can include information about the diagnosis itself: the date of 
diagnosis, blood glucose control (HbA1C) at diagnosis, and the results of any diagnostic tests. 
(6, 7) Other assessments may be carried out and recorded at this point in order to manage risk 
factors for microvascular and macrovascular complications of diabetes. (39) For CVD risk, 
for example, this would involve measuring blood pressure and BMI; identifying the patient’s 
smoking status; and requesting a blood test to measure cholesterol levels. (39) The initiation 
of drugs to manage diabetes and treat high levels of these risk factors, and subsequent 
prescriptions issued, are also recorded. (103) Blood glucose control, and the levels and 
management of other risk factors may be recorded periodically thereafter (annually or more 
frequently, if required), until the patient leaves their practice or dies. (83, 84, 89) 
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4.4 What are large primary care databases? 
 
Large GP databases are collections of electronic patient records extracted from individual 
general practices and have been used for a variety of research studies. (106, 107) The 
electronic records of individual patients consist of coded data [section 6.2 and table 6.1], and 
in the case of some databases, anonymised free-text recorded by the practice while the patient 
was registered with them. (103, 116)  The records of patients who have died or left each 
practice are also available to researchers, in addition to those who are still registered. There 
are currently three large GP databases in the UK which have been operating for a number of 
years: the General Practice Research database (GPRD), The Health Improvement Network 
(THIN), both based in London, and QResearch, based at the University of Nottingham. (106-
108) Each contains records from several hundred general practices. There are other smaller 
GP databases, such as DIN-LINK, and smaller regional databases such as the Consultations in 
Primary Care Archive (CiPCA) at the University of Keele (which is a subset of QResearch), 
but these are less widely used and are therefore not of primary concern to this thesis. (117, 
118) Any data or methodological issues arising from the use of these smaller databases are 
likely to be similar to those arising in larger databases, and so will not be addressed 
separately. 
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4.5 Which parts of the primary care electronic patient record are made 
available to researchers using large primary care databases? 
 
Typically, only data which are coded (i.e. Read coded symptom/diagnoses/process of care, 
and drugs prescribed) or are in numeric format (numeric observations, drug quantity 
prescribed) are extracted from GP systems and made available for use to researchers. (103) 
This is intended to preserve the anonymity of patients and practices, but as a consequence, 
some information which is recorded by clinical staff and available to them when they view a 
patient’s record, is not accessible to researchers.  
This includes any historical paper records received from practices where the patient was 
registered in the past, letters received from secondary care (often stored electronically as 
scanned files in the clinical computer system) and any free-text comments entered into the 
computer system during patient consultation. (103) These free-text comments can contain 
detail that is not coded by the practice (119-121) (personal experience of unanonymised free-
text while working as supplier of GPRD data). They often include additional observations or 
context explaining the significance of any diagnoses, plans for further investigations or 
treatments, and information gained from specialists, hospital discharge letters and results of 
diagnostic tests). (122-124) By its nature, free-text is a quicker and more flexible way for 
practices to enter data, and may provide more detail from consultations than is typically 
coded. (119) This can limit the ability of researchers to capture important events, like cause of 
death, and may lead to an underestimate of the frequency of important outcomes, for example 
myocardial infarction. (112) 
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4.6 The validity of primary care diagnoses and the recording of death 
 
Three systematic reviews on the validity of primary care data were identified by a literature 
search. (111, 125, 126) These reviewed studies which validated diagnoses recorded in one of 
the large UK general practice databases using: additional data recorded in the database; 
questionnaires sent to general practices; and comparisons with rates from external sources. 
With respect to the diagnoses of interest in this thesis, one of the reviews suggests that 
prevalent diabetes is well recorded (positive predictive value, PPV, over 90%), as is CVD 
(PPV > 90%). (111) None of these reviews reported finding evidence on the validity of CKD 
diagnoses [section 6.5.3]. Another of these reviews aggregated the individual study findings 
by broad disease group and found that a median 88% of cases with an endocrine, nutritional 
and metabolic diagnosis (e.g. diabetes) could be confirmed, and  85% of cardiovascular 
system diagnoses (e.g. CHD and stroke) could be confirmed. (126) The range for the 
proportion of diagnoses confirmed in the individual studies for the two groups above ranged 
from 50%-100%. (126) 
One 2005 paper reviewed the electronic patient records of 12 practices and found that less 
than 4% of patients with a recorded estimate of kidney function (eGFR) in the range for 
chronic kidney disease had a Read code that indicated that they had CKD. (122) This suggests 
that any attempt to identify CKD in primary care, especially in the period covered by the 
study (1998-2003: prior to the introduction of CKD as a QOF domain in 2006), should 
include estimated GFR in addition to Read coded records to identify patients with CKD.  
One study, based on approximately 500 general practices contributing to the QResearch 
database, estimated that about 1% of the UK population had biochemical evidence of diabetes 
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in their general practice, but were either undiagnosed or not recorded (i.e. coded) as having 
diabetes. (127) Two more recent and related studies on the validity of diabetes diagnoses 
recorded  in primary care suggest that approximately 85-90% of practice patients with one of 
a wide set of diagnostic Read codes for diabetes are true diabetes cases. (128, 129) One issue 
highlighted by them, and relevant to this thesis, is the miscoding of people with type 2 
diabetes using a code for type 1 diabetes. This suggests that any study seeking to identify 
general practice patients with type 2 diabetes should include diagnostic codes for type 1 
diabetes.  
Another study, carried out by this author, reviewed the unanonymised records of GPRD 
patients who had a diagnostic code for diabetes to develop a robust method for identifying 
cases of type 1 and type 2 diabetes. (7) We concluded that our case definition for prevalent 
diabetes mellitus should  include a wide set of codes which specified type 1 and 2 diabetes 
and unspecified diabetes mellitus, and exclude codes that specified other types of diabetes 
(gestational, drug-induced, and diabetes due to haemochromotosis). In addition we found that 
it would be necessary to exclude patients whose only mention of diabetes was within one year 
of a pregnancy in order to avoid including women with gestational diabetes only, and those 
who had a code for cystic fibrosis at any time, in order to avoid including non-type 1 and non-
type 2 cases of diabetes. This definition was validated in a subsequent study which identified 
incident cases of type 1 and type 2 diabetes, again using unanonymised GPRD records. (6) A 
stratified sample of 143 potential incident cases was reviewed by hand. Of these 12 (8%) had 
a free-text comment that indicated a new diagnosis and 115 (80%) had no evidence of 
diabetes monitoring or treatment prior to their first diagnostic code for diabetes and 13 (9%) 
were possibly or probably diagnosed in an earlier year. The remaining 3 cases (2%) had 
evidence that they were screened or had ‘borderline’ diabetes. The results of this validation 
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suggested that its method for identifying new cases of diabetes mellitus would include 89% 
who were newly diagnosed cases, 9% who were prevalent cases, and a further 2% who did 
not have diabetes. In order to decrease the risk of including patients without diabetes, we 
subsequently decided (in that study) to exclude patients with codes for other specified types of 
diabetes, e.g. diabetes due to haemochromatosis or malnutrition, and neonatal, secondary or 
‘latent’ diabetes and review by hand the records of all potential cases below the age of 25 who 
did not have evidence of diabetes-specific drug treatment. (6, 7) 
Death is an outcome of interest in this thesis and many studies, but as it is not a diagnosis was 
not included in the above systematic reviews. (111, 125, 126) A comparison of mortality in 
one large primary care database with national England & Wales data in 2001 found that 
overall GPRD mortality rates were within 5% of national rates, that cause of death could only 
be identified in 92% of their sample, and that cardiovascular deaths were probably 
underestimated in the available GP data (GPRD 33% of deaths; England & Wales 40%) 
(130). Therefore, it appears that the accuracy and completeness of cause of death available 
from these databases may not be sufficient for research use. However, the relative (all-cause) 
mortality of people with incident type 2 diabetes has specifically been addressed in a high 
impact journal, suggesting that the level of recording of this outcome in this population is 
acceptable for research use. (131) 
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4.7 Summary 
 
This chapter described the diabetes-related data that are available from primary care and large 
primary care databases. The data made available to researchers through these databases 
contain the coded portion of the full electronic patient record and typically exclude free-text 
that might confirm or refute the diagnoses and outcomes of interest in this thesis. However the 
validity of these diagnoses are likely to be sufficient to answer the research question posed in 
the next chapter, if appropriate definitions of incident diabetes are used and if mortality is 
restricted to all-cause rather than cause-specific deaths.  
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CHAPTER 5  RESEARCH QUESTION 
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5.1 Introduction 
 
This thesis will use a large UK general practice database to carry out a study on the 
epidemiology of type 2 diabetes mellitus. It will develop four separate statistical models 
which will predict the risk of coronary heart disease (CHD), stroke, chronic kidney disease 
(CKD), and all-cause mortality in the five years following diabetes diagnosis. 
 
5.2 Research question 
 
Can routinely collected primary care clinical data be used to predict future risk of CHD, 
stroke, CKD and/or all cause mortality in people with newly-diagnosed type 2 diabetes 
mellitus? 
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CHAPTER 6  METHODS 
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6.1. Introduction 
 
This chapter describes the methods used to develop the risk prediction models for CHD, 
stroke, CKD and all-cause mortality in newly diagnosed patients with type 2 diabetes. It 
begins with an introduction to the data source, the THIN primary care database. It then 
continues on to describe the criteria used to identify eligible practices and cases, the 
definitions of the outcomes of interest, and the methods used to identify baseline clinical 
characteristics and to estimate baseline clinical measurements. The development of the risk 
prediction models themselves is then described, including the approach to handling missing 
data. Finally, the methods used to assess the external and internal validity of the models are 
described. 
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6.2. Data source 
 
This study used electronic patient records from a single large UK primary care database, The 
Health Improvement Network database (THIN). (107) THIN began as a collaboration 
between In Practice Systems Ltd (InPS), the makers of Vision clinical software, and EPIC, 
the Epidemiology and Pharmacology Information Core. It began collecting data from UK 
general practices in 2002 (first collecting all available historical data from each practice and 
then by collecting periodic updates every few months). In common with similar large research 
databases (CPRD (formerly known as the GPRD) and QResearch), it maintains a database of 
anonymised patient records from about 500 voluntary participating practices which use a 
single clinical software system. (107) 
All practices that contribute to THIN use Vision which is a self contained clinical software 
system. (107) At the time of writing, approximately 1800 general practices in the UK use it to 
store and access the clinical records of their patients. It was gradually introduced from 1994 to 
replace the earlier VM practice software. In addition to storing clinical information entered by 
the practices, it is also used to manage scanned paper records from other sources such as 
letters from hospital, patient appointments, and to support clinical audit within the practices. 
Although other practices may use software from different suppliers, and patient data may be 
stored centrally by the system supplier, the use of the software, the way patient information is 
stored, and the functions provided by the systems are essentially the same whichever system 
is used. (114) 
In return for participation, all practices receive regular feedback on the quality and 
completeness of their data, summary reports which can be used for external and internal 
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audits, and free training on the use of their practice software or a payment based on their 
practice list size. (107) 
For the first ever collection, anonymised, coded clinical information is extracted from a tape 
backup of each practice system by InPS. (107) Practices then have the choice to continue with 
this extraction method, or, more recently, to install automated collection software on their 
system for each subsequent collection. These records are then passed to EPIC by InPS where 
they are checked and added to the existing THIN database. As practices do not make use of 
area-based data an additional automated matching exercise is carried out by InPS and 
participating practices periodically to link individual patients to indices of deprivation and 
environmental data such as air quality using their postcode. These data are then 
pseudoanonymised before transfer from each practice and passed to EPIC for inclusion in the 
database. Patients with invalid or missing postcodes cannot be linked to these external 
datasets, so this additional information will be missing from the THIN database. (103) 
A set of consistency checks is run by EPIC on each set of new data. (103) A flagging field is 
added to each demographic, clinical and prescribing event to indicate if it passed a check. In 
the case of demographic data, for example, the fields would show if a patient’s age lies 
outside an acceptable range, or if the recorded date for when they left the practice was before 
the date they first registered at the practice. However, as with other GP database suppliers, 
there is no attempt made to validate the clinical data in any other way that might be important 
for researchers: they do not apply any checks to ensure that clinical measurements fall within 
an acceptable range or identify implausible events for individual patients (e.g. women with a 
code for prostate cancer). (103, 106, 108) However, some clinical system suppliers do 
incorporate range checks for numerical data at the time the data are entered at the practice 
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(e.g. an attempt to enter an adult height outside the range 1-3 meters is queried before it is 
added to the patient record). (103, 106) 
Lastly, in order to ensure that no patient identifiable data is left in the record, the free-text 
comments field associated with each clinical event is filtered. (103) Only phrases which have 
been anonymised by EPIC are allowed to remain in the data that are released to researchers. 
These comments can be searched and anonymised by EPIC by hand if required for a 
particular study. 
Other than the addition of these extra flagging fields and the exclusion of patient identifiable 
comments, there are no modifications made to the data. (103) The data are provided to 
researchers as full, coded demographic, medical and prescription details at individual patient 
level (table 3.1). Within these electronic records, clinical data such as diagnoses are stored as 
5-byte Read-codes, drug prescriptions issued are stored using generic drug names, and clinical 
measurements and test results are linked to a coding system developed by InPS. 
During the period covered by this study, practices that contributed to THIN were similar to 
national practices in terms of age (table 6.2), mortality and patient turnover (table 6.3), but 
tended to be larger (table 6.4), and practices from deprived areas may have been 
underrepresented. (86) 
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Table 6.1 THIN data supplied to researchers 
 
1. Demographics (the PAT data table) 
 Dates patients registered at practices 
 Dates patients left practices 
 Patient registration status (temporary/permanent) 
 Year of birth 
 Gender 
 
THIN Data does not supply the following: name; exact address; exact date of birth; NHS number. 
 
2. Diagnoses  (the MED data table) 
 All conditions and symptoms entered on the practice computer during consultations between the 
GP and patient. Medical conditions are recorded using the Read Clinical Classification version 2. 
 Information on referrals to secondary care, including the specialty of the secondary care service. 
 Secondary care information and other related information received by the practice may be entered 
retrospectively, including: 
o Details on hospital admissions 
o Discharge medication and diagnosis 
o Outpatient consultation diagnosis 
o Investigation and treatment outcomes 
 
3. Prescribing (the THE data table) 
 The GP typically issues prescriptions to patients using their computer: prescribing is logged into 
the system automatically. The prescribing recorded in the computer logs the drug prescribed using 
the Multilex coding system, which automatically creates therapy records for THIN. 
 Acute treatments and medicines for a chronic condition can be temporally linked with a symptom 
or diagnosis although this is not comprehensive in THIN. 
 Details of prescriptions from ongoing outpatient specialist care or over-the-counter drugs may be 
summarised by the GP, but the degree of information depends on its direct relevance to the patient. 
 
4. Additional Health Information (the AHD data table) 
 Commentary from the GP entered into free text fields. This can sometimes contain confidential or 
identifying information: THIN checks and ensures these comments have been anonymised before 
release to researchers. 
 Information on lifestyle and health factors such as smoking and alcohol intake, where recorded by 
the practice. 
 Tests and laboratory results are also accessible. Currently (2011) about 75% of THIN practices are 
electronically linked to pathology laboratories and receive test results electronically.  
 
5. Socioeconomic data (the PVI data table) 
 The majority of patients are linked to postcode-based socioeconomic, ethnicity and environmental 
indicators, for example, Townsend quintile. 
 
Source: http://csdmruk.cegedim.com/our-data/data-content.shtml [accessed 6/11/2013] 
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Table 6.2 Comparison of age distribution of THIN practices with all practices in 
England, 2004 
Age group England* THIN 
   
0 – 4 5% 5% 
5 – 14 12% 12% 
15 – 44 43% 42% 
45 – 64 24% 25% 
65 – 74 8% 8% 
75 – 84 6% 6% 
85 + 2% 2% 
   
Total 100% 100% 
*Source: National data for England from NHS Executive, 2004. 
 
Table 6.3 Comparison of practices contributing to THIN and national data: death rate 
and transfer out rate 
 
THIN National 
 
   
Crude death rate
1 10.3/1000 patients 10.2/1000 persons 
Proportion of patients 
transferring out each year 
7.5% (171160/2276866) 7.7% (3.5m/45m) 2
 
1 Region: UK. Source: Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated 
database of primary care data. Informatics in Primary Care. 2004;12(3):171-7. 
2 Region: England. Note: does not include patients who were removed from their practice list following death. Source: 
http://www.connectingforhealth.nhs.uk/about/case/npfitstatus.pdf ( year not given). 
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Table 6.4 Comparison of THIN list size with QOF data for England, 2005 
 
Number of practices Median list size 
Interquartile range 
 Q1 Q3 
     
THIN 315 7185 4514 10106 
QOF* 8484 5396 3119 8259 
*Source: National data from Quality and Outcomes Framework for England, 2004/05. 
 
Table 6.5 Socioeconomic distribution of patients in THIN 
Townsend quintile 
Percentage of 
patients 
As a percentage of patients with known 
socioeconomic status 
   
1 (least deprived) 22 25 
2 19 21 
3 19 21 
4 17 19 
5 (most deprived) 12 13 
Not known 11 - 
Note: Townsend quintile is based on postcode of patient residence. Percentage of patients in each quintile would be 20% if THIN practices 
had same distribution as national practices. 
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6.3. Criteria used to identify eligible practices 
 
Individual THIN practices were eligible for inclusion in this study from one year after the date 
the Vision practice software was installed to ensure that the practice was using the system to 
its full extent. (109, 132) They were also required to have used the system for an additional 
two years following this in order to provide a total minimum duration of continuous clinical 
data of at least three years from each practice. The increased risk of death or diabetes 
complications may take several years to emerge following diagnosis, so a minimum 
observation period of two years (following the diagnosis of diabetes for each case) from each 
practice was believed to be an appropriate requirement. (133) 
Practices which were known to have gaps in their clinical data were also excluded. These 
issues were recorded by the database provider, EPIC, at the time of data collection (for 
example, the practice computer system was not functioning for a period of weeks, so patient 
care may not have been recorded electronically during this period). EPIC also supplied a date 
for each practice, before which each practice may not have routinely recorded patient deaths: 
this is known as the AMR (acceptable mortality recording) date. (132) 
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6.4. Criteria used to identify eligible cases 
 
Patients were eligible for inclusion as incident cases of type 2 diabetes if they were registered 
in their practice for at least one year prior to the first Read-coded mention of diabetes, and if 
the diagnosis took place during the study period (1998-2003). The Read codes used in this 
definition are listed in appendix 6. The code lists and case definition were originally 
developed for use in earlier studies [section 4.6]. These were updated to include more recent 
Read codes after consultation with medically qualified colleagues prior to their use in this 
study. Potential cases were excluded if they met any of the additional criteria, listed below.  
 
Exclusion criteria 
1. Diabetes Read-code with a missing date in the patient record: it is possible that the 
diagnosis occurred at some unknown time prior to the first diabetes code with a valid date. 
2. Patient’s practice had their Vision software installed less than one year before the first 
mention of diabetes: the practice may not have been using their computer system to its full 
extent and there may be missing data on other variables of interest. 
3. Women who were pregnant at the time of the diagnosis were also excluded, as they were 
likely to have gestational diabetes. Any later mention of diabetes in the same individuals, 
but not associated with a pregnancy, was included if it met the case definition. 
4. Patients who were under the age of 35 at the time of diagnosis, or who were treated with 
insulin within one year of diagnosis were excluded, as they were likely to have type 1 
diabetes.  This was based on the advice of specialist diabetes colleagues. 
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5. Patients who died or left their practice within three months of diagnosis were excluded as 
their practice would not have had sufficient opportunity to begin long-term management 
of their diabetes, and were unlikely to have recorded clinical measurements recorded 
following diagnosis. 
 
The results of this case identification process are presented in section 7.2. 
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6.5. Outcome definitions 
 
An outcome was defined as the first occurrence of any of the following conditions. The 
number and proportion of cases with each of these outcomes at and following diabetes 
diagnosis is presented in section 7.3. 
 
6.5.1 CHD 
 
The definition of CHD included MI, angina and revascularisation surgery, and any Read code 
which specified CHD without mentioning any of these subtypes or a specific surgical 
procedure (appendix 6). The date of diagnosis for CHD was the date of the first occurrence of 
any of the above Read codes [section 4.6 and table 6.1].  
 
6.5.2 Stroke 
 
The definition of stroke included Read codes for ischaemic stroke, haemorrhagic stroke, and 
codes where stroke was specified, but subtype was not (appendix 6). It did not include 
transient ischaemic attack (TIA). The date of diagnosis for stroke was the date of the first 
occurrence of any of the above Read codes  [section 4.6 and table 6.1]. 
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6.5.3 CKD 
 
Chronic kidney disease was identified using date of the earliest of the following three events: 
a single low eGFR recorded by the practice; Read-coded CKD (appendix 6); and Read-coded 
kidney dialysis (appendix 6) [section 4.6 and table 6.1]. The threshold for low eGFR was set 
at 60 ml/min/1.73m
2
, following the 2005 UK CKD guidelines (table 6.6). Cases with an 
eGFR of less than 60 ml/min/1.73m
2
 were therefore categorised as having Stage 3-5 kidney 
disease from the date of the first such record. The process for deriving eGFR from measured 
creatinine is described in the next section. 
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Table 6.6 Stages of chronic kidney disease 
   
Stage GFR range Description 
1 90+ Normal kidney function
*
 
2 60-89 Mildly reduced kidney function
*
 
3 30-59 Moderately reduced kidney function 
4 15-29 Severely reduced kidney function 
5 <15 or on dialysis Very severe, or endstage kidney failure 
Source: 2005 UK CKD Guidelines (http://www.renal.org/CKDguide/full/CKDprintedfullguide.pdf).  
* These stages are only treated as CKD in the presence of other factors, e.g. proteinuria and were not included in the definition of CKD as a 
comorbidity or an outcome in this study.  
 
6.5.4 Death 
 
The date of death for patients whose practice registration status indicated that they had died 
was identified using the date of death field provided by THIN. This field was created by the 
database suppliers to give researchers a guide to the patient's date of death. (103) The date 
was derived using an algorithm which used data from several locations in patients’ electronic 
record: the date of death recorded using a template for entering the fact and cause of death by 
practice staff; the date this template was filled out if no specific date of death was recorded; 
the date associated with a Read code which indicated that the patient had died; and lastly, if 
no other valid source can be found, the date the patient was recorded as having transferred out 
of their practice. 
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6.6. Baseline characteristics 
 
6.6.1 Demographic 
 
The age of each case at diagnosis of diabetes was estimated using their year of birth (year of 
diagnosis – year of birth) as full date of birth was not available to protect patient identity. 
Each patient was matched to a Townsend deprivation quintile (five groups, ranked from least 
deprived, quintile1, to most deprived, quintile 5) using their postcode of residence by THIN 
as part of the data collection process. (103) Some patients had multiple deprivation scores as 
they moved home while registered at their single practice. The deprivation quintile dated prior 
to their diabetes diagnosis was used as their baseline value in these instances. Broad 
geographical region was also collected by THIN as part of their data collection process. The 
exact location of practices was not made available in order to protect the identity of 
contributing practices. The last demographic factor of interest, patient sex, was recorded by 
practices at the time patients registered. The baseline demographic characteristics of eligible 
cases are presented in section 7.5. 
 
6.6.2 Comorbidities 
 
CHD, stroke and CKD at baseline were identified using the definitions described in the 
previous sections. As patients may have their creatinine estimated for the first time following 
diabetes diagnosis, restricting the definition to results recorded prior to this baseline date may 
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have resulted in an unacceptable level of missing data. Creatinine results up to three months 
after baseline were therefore included and used to estimate baseline CKD status. The 
frequency of each comorbidity at baseline among eligible cases is presented in section 7.5. 
 
6.6.3 Smoking status 
 
Each case was identified as a smoker or non-smoker on each date where their tobacco 
consumption or status was recorded, or when cessation advice or referral was offered. The 
Read and AHD codes used to identify smoking status are listed in appendix 6. The smoking 
status of each case at diabetes diagnosis (baseline) was initially identified using the last record 
of their smoking status before diagnosis, even if this was some years earlier. If the first record 
of their smoking status after diagnosis indicated that they were a smoker, then they were 
recategorised as a smoker at baseline. This was done even if their last recorded status before 
diagnosis indicated that they were a non-smoker as it was assumed that they did not begin 
smoking following their diagnosis. Cases with no smoking status recorded at any time were 
categorised as non-smokers at baseline. The baseline smoking status of eligible cases is 
presented in section 7.5, and the proportion who continued to smoke following diabetes 
diagnosis is presented in the appendix, in table A7.2. 
The effect of this method was to group ex-smokers with non-smokers, even if they had ceased 
smoking the day before diabetes diagnosis. It might have been more congruent with 
classifications used in other risk models (e.g. Framingham) to have required ex-smokers to 
have quit for at least one year prior to diabetes diagnosis, but smoking status was not recorded 
at regular intervals in the healthy population in UK general practice during the study period. 
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(134) Patients recorded as being an ex-smoker in the year prior to diabetes diagnosis may 
have quit at any time between the preceding record of smoking status and that date: this 
would make it difficult to estimate their actual quit date accurately.  
 
6.6.4 Identification of numeric values associated with clinical measurements  
 
The clinical measurements of interest were eGFR, BMI, HbA1C, total cholesterol and systolic 
blood pressure. These results were stored in the Additional Health Data (AHD) table in the 
THIN database (table 6.1). This table contained the date of the record, a Read code, an AHD 
code and a numeric value or values, along with value labels for each result (e.g. ‘mmHg’). 
The Read- and AHD-codes for the events identified for each risk factor are listed in appendix 
6. Any anonymised free text associated with one of the Read codes of interest was also 
searched for numeric results. Coded and free-text values were excluded if they lay outside a 
range of acceptable values. These ranges were set in consultation with clinical colleagues and 
are shown in table 6.7. The values associated with each label were also viewed as histograms 
as an additional data quality check (figures not shown). Results with labels other than those 
listed in table 6.7 were excluded if their distribution was not similar to results with these more 
standard value labels. The results of this search for additional clinical values in free-text are 
presented in section 7.4. 
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Table 6.7 Acceptable range for numeric values 
  
Creatinine 25-1000 micromol/L (used in eGFR calculation) 
Height 1-3m (if aged 18 years or over) 
Weight not required as BMI range applied after calculation 
BMI 10-60 kg/m2 (calculated from height and weight) 
HbA1C  2-20% 
Total cholesterol 0.5-15 mmol/L 
Systolic BP 50-300 mmHg 
  
 
 
6.6.5 Calculation of eGFR 
 
Kidney function was estimated using a formula based on measured creatinine and the age and 
sex of the case. (135) This derived value, estimated glomerular filtration rate (eGFR), is the 
recommended way to measure kidney function as creatinine level alone is affected by non-
renal influences. (100) The eGFR equation corrects for some of these influences, and is more 
sensitive for the detection of CKD than serum creatinine and may be more accurate than 
creatinine clearance. (100) eGFR was created from recorded creatinine values for each case, 
using the abbreviated MDRD equation (135) :  
eGFR = 186 x (creatinine / 88.4)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if black) ml/min/1.73m
2
  
All patients were assumed to be non-black, as individual data on ethnicity were not routinely 
available in electronic patient records from general practice at the time of the study. (136) 
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6.6.6 Calculation of BMI 
 
BMI values were automatically generated within the Vision system each time the weight of a 
patient was recorded (provided a height value was available). (103) Although there are now 
some internal checks within the Vision system which highlight unexpectedly large or small 
values, at the time of data entry (103), it was observed that automatically generated BMIs 
included in the dataset provided by THIN still contained unfeasibly large values (e.g. BMI 
141 kg/m
2
), or were missing on occasion. Further visual inspection of the data showed that 
these values were based on incorrectly entered height or weight data (e.g. weight entered as 
8684 kg instead of 86.84 kg), were based on height measurements taken when the patient was 
under 18 years, or missing if no height measurement was available at the time weight was 
measured. New BMI values were therefore calculated on each date where their weight was 
recorded. As height is not routinely measured at the time of each weight measurement, the last 
recorded height for each case was used if the measurement was taken when the case was aged 
over 18 years. (103) 
 
6.6.7 Estimation of baseline values for clinical measurements 
 
The level of each of the clinical measurements of interest was estimated at baseline for each 
case using a multilevel model which made use of all results recorded during their follow-up 
period. (137, 138) This was done because clinical risk factors such as cholesterol and blood 
pressure are a target for treatment once the initial diabetes diagnosis has been made, and 
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single measurements which are recorded in the months and years after the date of diagnosis 
may not, therefore, reflect their level at diagnosis.  
In order to validate this complex modelling approach to estimating baseline values, the 
baseline estimates obtained from the multilevel models were compared with a simpler 
method: the mean of the values recorded immediately before diabetes diagnosis and during 
follow-up. For this comparison the cohort was restricted to cases who had the risk factor of 
interest recorded within 90 days of baseline to allow the value predicted for each case by the 
simpler and more complex model to be compared directly with the observed value recorded in 
their patient record. As it was not possible to generate an overall statistic to describe the 
proportion of variation in the data explained by a multilevel model (e.g. R
2
), the residual sum 
of squares (Σ(O-E)2 : the observed minus the predicted value, squared, then summed) 
generated by each estimation method was compared using F-tests. 
The results of the modelling of baseline clinical values and the validation are presented in 
section 7.4.  
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6.7. Development of risk prediction models 
 
6.7.1 Introduction 
 
This section presents the methods used to develop the four separate risk prediction models 
(CHD, stroke, CKD and death). The relationship between the baseline characteristics and 
outcomes was assessed using survival models as cases were followed up for differing 
intervals (until they left their practice, died or the end of the study period).  
Each model excluded cases who developed the outcome of interest prior to, or in the first 
three months following diabetes diagnosis, and those who died or left their practice within 
three months of diagnosis. The remaining eligible cases were followed up from three months 
to a maximum of five years. Cases were censored at the earliest of the following dates: 
developed outcome of interest, left practice or died, last collection date from practice, and five 
years following diagnosis. Survival time, the time the case exited from the study was entered 
into each statistical model as the interval in years from the diagnosis of diabetes to the time 
they developed the outcome of interest, deregistered from their practice, or when five years 
had elapsed. 
The results of this modelling are presented in sections 7.6 and 7.7. 
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6.7.2 Choice of survival model 
 
The Weibull survival model was selected as it is frequently used to model survival data and, 
like other parametric models, makes more efficient use of data than a Cox model if its 
underlying assumption (that the fitted model follows a Weibull distribution) is met. (139) In 
particular, estimates of hazard ratios will be more precise than the equivalent Cox model if the 
survival data are observed to follow the Weibull, or other parametric distribution. (139) The 
Weibull distribution used in this study had two parameters, scale and shape, roughly 
equivalent to the intercept and slope in a linear regression. It is related to the simpler 
exponential distribution, which is also used to model survival, but can fit a wider range of 
situations. As with Cox and other survival models, the coefficient produced for each 
explanatory variable included in the Weibull model can be expressed as a hazard ratio (HR).  
The Weibull survival function, S(t), can be described as S(t) = exp(-λtγ) where λ (lambda) is 
the scale parameter, γ (gamma) is the shape parameter and t is time. (139) 
The underlying assumption, that the fitted model data followed a Weibull distribution, was 
assessed by comparing observed and expected failures using probability plots generated by 
the pweibull program within Stata. (140) The command fits a two-parameter Weibull model 
to the data and graphs the proportion of cases observed to fail at each point in time with the 
proportion predicted to fail from the model.  
It was not possible to combine the expected failure times for each case on a single probability 
plot as they follow distributions determined by their individual pattern of covariates, such as 
age and sex. Therefore, to allow them to be compared as a unit with the observed failures, 
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they were back-transformed to a common distribution using their observed failure time, and 
their shape and scale parameters from the fitted Weibull model. 
The results of this model checking are presented in section 7.8. 
 
6.7.3 How predictors were included in the survival models 
 
Continuous variables (eGFR, BMI, HbA1C, total cholesterol and systolic blood pressure) were 
entered into the model in their original metric, centred on their mean value, if they met the 
proportional hazards assumption (see below). Binary and categorical variables were also 
checked to see if they met the proportional hazards assumption. Variables which did not meet 
this assumption were transformed, combined with other variables, or included in the models 
as a set of distinct covariates.  
Comorbidities at baseline or during the first 3 months following diagnosis of diabetes were 
included as a series of binary covariates (i.e. one yes/no covariate per comorbidity). A gap of 
three months ensured that outcomes that occurred close to the diabetes diagnosis date, 
because the person was first assessed for the outcome just after they were diagnosed with 
diabetes (e.g. with CKD), were treated differently than events which may have been caused 
by diabetes itself. Each comorbidity was included as a separate predictor in each of the other 
outcome models. For example, stroke was included in the CHD outcome model as ischaemic 
stroke and CHD can share a common underlying pathology. (141, 142) 
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6.7.4 Checking of proportional hazards assumption 
 
The assumption of proportional hazards for each of the predictor variables in the survival 
models was assessed visually using log-log graphs. The intention was that predictors that 
were not observed to be proportional over time would be mathematically transformed, entered 
into the model as a set of distinct variables, or combined in order to meet this assumption. A 
separate log-log graph was generated for each outcome (CHD, stroke, CKD and death) and 
predictor as survival may have differed from model to model for a particular outcome.  
Log-log graphs compare the Kaplan-Meier (KM) estimate of the survivor function on the x-
axis against survival time in logged form, hence the name of this type of graph. They present 
the same data that you would see in a standard KM graph (the lower the line is on the graph, 
the worse the survival probability), but the KM estimate and time are presented in this 
transformed metric to ‘straighten out’ the plots, allowing the viewer to more easily assess if 
the difference in survival for each level of each covariate was constant over time, i.e. that their 
hazards were proportional.  
Hazards can be regarded as proportional if the line for each group remains roughly parallel 
with its neighbours over time, and their levels equally spaced. (139)In groups with large 
numbers of failures, the line tends to be smoother: in groups with smaller numbers of failures, 
for example in the youngest age groups, the line may be more erratic, and consequently it may 
be more difficult to make a judgment about proportionality. 
The results of this checking are presented in section 7.6.2. 
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6.7.5 Handling of missing data 
 
It is now widely accepted that complete case analyses and simple imputation of missing 
values are not appropriate methods for handling missing data especially where a significant 
proportion are missing. (50, 99, 143) Earlier studies with similar aims to the current study 
have either carried out complete case analyses, may have dropped incomplete variables from 
their analyses, or have carried forward previous or carried back later measurements for 
individuals. (55, 59, 144) The weakness of the complete case approaches is that they reduced 
the power of their study to explain their outcomes by dropping cases and variables which 
were associated with the outcomes of interest. They may also cause a systematic bias if the 
relationship between the dependent variables and the outcome for the cases that were retained 
in the analysis differed from the cases that were dropped.  
 
Table 6.8 Types of missing data 
 
Missing completely at random—There are no systematic differences between the missing values 
and the observed values. For example, blood pressure measurements may be missing because of 
breakdown of an automatic sphygmomanometer. 
Missing at random—Any systematic difference between the missing values and the observed 
values can be explained by differences in observed data. For example, missing blood pressure 
measurements may be lower than measured blood pressures but only because younger people may 
be more likely to have missing blood pressure measurements. 
Missing not at random—Even after the observed data are taken into account, systematic 
differences remain between the missing values and the observed values. For example, people with 
high blood pressure who are not adhering to treatment may be more likely to miss clinic 
appointments. 
 
Source: Adapted from: BMJ. 2009 Jun 29;338:b2393. doi: 10.1136/bmj.b2393. 
Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Sterne JA, White IR, Carlin JB, Spratt 
M, Royston P, Kenward MG, Wood AM, Carpenter JR. 
 78 
 
Statistical methods for handling missing data in health care databases have been in existence 
for some time (145), but were not available in widely used statistical software packages like 
Stata until recently. (143, 146) Multiple imputation of missing data (MI) has been used in 
other GP database studies, but is relatively complex and computationally intensive in large 
datasets: the high risk of inappropriately applying the process was demonstrated in one study 
published in the BMJ. (64, 147) 
Although the use of multiple imputation may be preferable to simpler techniques, there are 
several stages of model building and decision making for each variable with missing data 
which may result in inaccurate estimates for the missing values being generated. (147, 148) 
Important assumptions have to be met if the imputed data are to be valid; most importantly 
that the missing data are ‘missing at random’ or ‘missing completely at random’ (table 6.8). 
This assumption is not possible to test directly, but knowledge of the reasons why the data are 
missing may support the use of multiple imputation, or suggest that it is not appropriate. (113) 
Multiple imputation creates a number of imputed datasets which can contain different 
imputed values for each missing item. The individual imputed values are derived from one or 
more regression models within the imputation process: it is recommended that these should 
include all available explanatory variables to increase the plausibility of the missing at 
random assumption. (149) The main statistical analysis is then carried out on each of the 
imputed data sets in turn. The results of these analyses are then combined to produce a single 
set of results using ‘Rubin’s rules’. (150) In comparison with a single imputation process, 
multiple imputation generates larger standard errors that reflect the degree of uncertainty due 
to the use of imputation and better reflects the uncertainty due to missing values than a single 
imputed value. (151, 152) 
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Missing baseline values in this study were estimated using an imputation process known as 
multiple imputation by chained equations, implemented in Stata by Royston and colleagues. 
(146) This package (ICE) created a number of complete datasets, where missing baseline 
values were predicted using all available demographic and clinical data, and made an 
allowance for the imprecision of these predictions that was carried through to the final 
prediction models. 
The results of this multiple imputation of missing baseline clinical values and deprivation 
quintile are presented in section 7.5. 
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6.8. External and internal validation of study results 
 
This last section describes how the model results were validated. This consisted of 
comparisons with external studies and an overall statistical measure of each model’s ability to 
explain variation in the outcomes observed in the study cohort.  
 
6.8.1 Comparisons of results with other studies 
 
Each of the demographic variables, clinical values and counts of outcomes used in this study 
were compared with the UKPDS RCT (1977-1991), and studies reporting on the Tayside 
diabetes register (1995-2004), the South Tees diabetes register (1994), and the Poole Diabetes 
Study (1996-1998) where data were available. (46, 88, 153-156) The eligibility criteria for the 
study cohort were adjusted to match these studies where possible, so that comparisons could 
be made on a like-for-like basis. 
The hazard ratios for each model were also compared with the hazard ratios reported by other 
prediction models (tables 2.1 to 2.3). (44-46, 57-60) (67-81) 
External comparisons with the results of other studies are discussed in section 8.4. 
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6.8.2 Overall proportion of variation explained by each model (R2) 
 
The proportion of variation explained by each model, also known as the coefficient of 
determination, was assessed using an implementation of the R
2
 statistic called str2ph. (157) 
This was adapted from Nagelkerke's R
2
 statistic for proportional hazard models for censored 
survival data. (158) The R
2 
value can range from 0 to 1. A model with an R
2
 of 1 would 
perfectly predict the outcome for each case.  
These results are presented in section 7.7. 
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CHAPTER 7  RESULTS 
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7.1  Introduction 
 
This chapter presents the results of this study. This includes the results of the case 
identification process and the baseline characteristics of the cases included in the study, and 
comparisons with other studies where possible. The results of the final prediction models 
themselves are then presented.  
The first results presented are for the case identification process: these are presented in the 
form of a CONSORT chart (figure 7.1), The number and proportion of cases with each of the 
outcomes of interest (CHD, stroke, CKD and death) at baseline and in the first three months 
of follow-up (table 7.1), and in the period up to five years following the diagnosis of diabetes 
(table 7.2) are then presented. These data are also summarized in a single Kaplan-Meier type 
graph (figure 7.2). 
The next section presents the results of the estimation and imputation of baseline clinical 
measurements of the study population. Some of the tables and figures can be found in the 
main appendix 7, to avoid presenting too many results in the text (tables A7.1, A7.4-A7.7; 
figures A7.1-A7.11).  However, examples of each set of results are presented in the main text 
(table 7.3; figures 7.3-7.5). Table 7.5 then combines these results with the demographic, 
comorbidity and treatment data to summarise the baseline characteristics of the study 
population in a single table. 
The final section presents the development of the prediction models and the model results 
themselves (tables 7.6 to 7.12). Two examples of the log-log plots used to check the 
proportion hazards assumption for each predictor in each model can be found in figures 7.5 
and 7.6: the remainder can be found in the appendix (figures A7.4 to A7.11).  The probability 
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plot used to check that the choice of a Weibull survival model was appropriate can be found 
in figure 7.7. 
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7.2  Cases identified 
 
7.2.1 Overall results 
 
Figure 7.1 presents the results of the case identification process. Overall, a total of 149492 
potential cases were identified in the 300 general practices contributing to THIN at the time 
the study dataset was created. These practice patients had at least one of the selected Read 
codes for diabetes at some point in their record. A series of exclusions were then applied to 
these potential cases to ensure that the final set of data was as accurate and complete as 
possible (figure 7.1). Most of these exclusions (CONSORT items A-F) identify and exclude 
patients and practices (127601/149492 patients (85%)) that were never eligible for the study 
(the practices did not have research-quality data or the patients were diagnosed outside the 
study period). The remaining exclusion criteria (CONSORT item H) are more conventional 
(patients who did not have type 2 diabetes or who were not followed-up for a minimum 
period following diagnosis): these resulted in 1850/21891 patients (8.5%) being excluded 
from the study cohort. 
The CONSORT chart (figure 7.1) describes the criteria in detail, but broadly potentially 
eligible patients were excluded if they or their practice had one of the features listed below. 
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Data issues at practice and patient level [sections 6.2 and 6.3] 
 Practice had insufficient experience of clinical computer system. 
 Continuous use of system for minimum period. 
 Patient diagnosed with diabetes before practice recording mortality reliably. 
 Patient registration data inconsistent. 
 Patient not registered for minimum period at practice 
 No prescribing data for patient. 
 
Eligibility issues [sections 6.2 and 6.3] 
 Date of diabetes diagnosis not recorded. 
 Patient prescribed antidiabetic treatment before diagnosis. 
 Patient diagnosed before study period or less than one year after registration with practice. 
 Patient diagnosed after end of study period. 
 Patient likely to have type 1 diabetes. 
 Patient left practice/died within 3 months of diabetes diagnosis. 
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Figure 7.1 Case identification: CONSORT chart 
 
 
(A) Assessed for eligibility 
 (n = 149492) (300 practices) 
(B) Practice data issues  
(n = 55983) (38 practices) 
IT system (Vision) in use less than 3 years (n=11332)  
Gaps in data from practice (n=4326)  
Diabetes diagnosis occurred before practice recorded mortality 
reliably (i.e. before practice AMR date) (n=40325) 
(C) Remaining 
(n = 93509) (262 practices) 
(D) Patient data issues  
(n = 24965) 
 
Registration dates inconsistent (n=7806) 
Not registered for at least one year in study period (n=17143) 
No prescribing data (n=16) 
(E) Remaining 
(n = 68544)  
(F) Not incident diabetes within study period 
(n=46653) 
 
No date associated with diagnosis (n=4191) 
Prescribed antidiabetic before diagnosis  (n=3286) 
Diag date before study period/before pat. eligible (n=29014) 
Diagnosis date after end of study period (n=10162) 
 
(G) Remaining 
(n = 21891) 
 
(H) Not Type 2 diabetes or not observed for minimum 
period following diagnosis (n=1850) 
 
Gestational diabetes (n=91) 
Diagnosed <= 35 years old (n=1029) 
Prescribed insulin within 1 year of diagnosis (n=592) 
 
Left practice/died within 3 months of diagnosis (n=138) 
(I) Analysed 
(n = 20041) (262 practices) 
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7.2.2 Exclusions due to practice data issues (CONSORT item B) 
 
A total of 93509 patients remained after practices with specific data issues were excluded 
(37% excluded; 55983/149492). These issues were of two types: issues which affected the 
entire set of data from a practice (clinical computer systems in use less than three years and 
gaps in practice clinical data); and a single issue which depended on the apparent date of 
diagnosis of the practice patient (diabetes diagnosis before practice AMR date). The highest 
number of exclusions in this category was due to the latter issue: a total of 40325 cases were 
excluded to avoid under ascertainment of deaths.  
 
7.2.3 Exclusions due to patient data issues (CONSORT item D) 
 
The second group of exclusions (a further 17% of the original total; 24965/149492) centred 
on data issues which affected the records of individual patients, rather than the whole practice. 
A total of 24956 patients were excluded by these criteria, leaving 68544 patients (46% of the 
original total; 24956/149492). Almost all of those excluded were patients who had either 
inconsistent registration dates (a missing registration date, or a registration date which was 
later than their deregistration date), or were registered for less than one year during the study 
period. A small number of patients (n=16) were observed to have no prescriptions issued at 
any time in their record. They were excluded because they may have been training patients, 
set up by the practice to help staff to learn how to use the IT system.  
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7.2.4 Patients excluded because they were not incident diabetes within the study period 
(CONSORT item F) 
 
The next group of patients to be excluded (31% of the original total; 46653/149492) were 
those who were diagnosed outside the study period, and those where a date of diagnosis could 
not be identified. Of the 46653 patients excluded at this point, the majority (84%; 
39176/46653) were not diagnosed within the study period, and were therefore not incident 
cases of diabetes. The remainder (16%) either had no date associated with the first mention of 
diabetes) or were prescribed antidiabetic medication before the date of the first Read code for 
diabetes. As it can be several years before newly diagnosed cases of type 2 diabetes move 
from diet control to drug treatment, it was not possible to identify the true date of diagnosis of 
these patients. 
 
7.2.5 Patients excluded because they had non-type 2 diabetes or insufficient follow-up 
time (CONSORT item H) 
 
The last set of criteria applied excluded patients that were not cases of type 2 diabetes, or that 
were not followed up for a minimum period of time following diagnosis of type 2 diabetes 
(1%; 1850/149492). Of  these: 91 had gestational diabetes; 1029 were age 35 years or less at 
the time of diagnosis (and therefore likely to be type 1 rather than type 2 diabetes); and 592 
were prescribed insulin within one year of diagnosis (and also likely to have type 1 diabetes). 
At this point all remaining practice patients had incident type 2 diabetes, diagnosed within the 
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study period. The last criterion to be applied excluded 138 cases of type 2 diabetes that left 
their practice or died within three months of their diabetes diagnosis.  
 
7.2.6 Summary of cases identified 
 
Approximately 13% (20041/149492) of the potential cases assessed for eligibility were found 
to be eligible and therefore included in the analysis. Those that were excluded were excluded 
because it was not certain that the THIN database contained complete and contemporary 
records of their care at the time of diagnosis (data issues: 54% (80948/149492)), because they 
were diagnosed outside the study period (not incident diabetes: 31% (46653/149492)), or 
because they did not have type 2 diabetes mellitus or were not observed for a minimum of 
three months following diagnosis (1% (1850/149492)). 
Excluding those who could never be eligible for inclusion in the study cohort (they were 
diagnosed outside study period or their practice did not have research-quality data) 
(127601/149492 patients), a total of 20041/21891 (91.5%) of patients with type 2 diabetes 
were eligible for inclusion in the study cohort. 
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7.3  Outcomes identified 
 
7.3.1 Number of cases with CHD, stroke and CKD at diagnosis of diabetes 
 
Approximately one-third of available cases (38%; 7561/20041) had one or more of the 
morbidity outcomes of interest before diabetes diagnosis (table 7.1). The most common 
comorbidity was CKD (22%), followed by CHD (20%) and stroke (6%). 
 
7.3.2 Number of cases with CHD, stroke and CKD in first three months following 
diagnosis of diabetes 
 
A further 1% (206/20041) of available cases were diagnosed with CHD in the 3 months 
following diabetes diagnosis. Stroke was a much less common outcome in the first three 
months, affecting less than half of 1% of cases. CKD was a relatively common outcome in 
this period, with approximately 1 in 20 (4.7%) new cases of diabetes being diagnosed with 
CKD. The 133 potential cases that died in the first three months following diabetes diagnosis 
were also not eligible for inclusion in the prediction models [section 7.2].  
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Table 7.1 Number of cases with CHD, stroke and CKD at baseline and in first three 
months following diabetes diagnosis 
 
Number of cases with outcome prior 
to diagnosis 
(% of cases) 
   
At baseline   
CHD 3969 (20) 
Stroke 1240 (6) 
CKD 4376 (22) 
   
In first 3 months   
CHD 206 (1.0) 
Stroke 75 (0.4) 
CKD 950 (4.7) 
   
Note: N=20041. 
 
7.3.3 Number of cases eligible for each prediction model and number of outcomes 
observed between three months and five years following diagnosis of diabetes  
 
All 20041 cases that survived and were still registered at their practice for at least three 
months after diagnosis were included in the survival model for death (table 7.2). The 3969 
and the 206 cases who were known to have CHD in the period before or in the first three 
months following diabetes diagnosis were excluded from the survival model for CHD, 
leaving  a total of 15861 cases eligible for inclusion. The 1240 cases and the 75 cases that had 
a stroke in the period before diabetes or in the first three months following diabetes were 
excluded from the survival model for stroke, leaving a total of 18726 cases eligible for 
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inclusion. The 4376 cases and the 950 cases who were known to have CKD in the period 
before diabetes or in the first three months following diabetes were excluded from the 
survival model for CKD, leaving a total of 14704 cases eligible for inclusion in the survival 
model for CKD.  
Table 7.2 also shows that the CKD model had the greatest number of cases with an outcome 
of interest in the follow-up period, with 23% (3294/14704) of cases being diagnosed with 
CKD (stage 3+) in the 3 months to 5 years following diabetes diagnosis. The percentage of 
cases with the outcome of interest in the death, CHD and stroke models was 7.5%, 5.5% and 
1.9% respectively. 
 
Table 7.2 Number of cases eligible for inclusion in each prediction model and number of 
outcomes observed during follow-up 
Model name 
Number of 
cases 
included 
in model 
Number of 
cases with 
outcome 
following 
diagnosis 
(% of 
cases) 
Mean age 
at 
diagnosis 
of diabetes 
Years of follow-up 
Mean (SD) 
       
CHD 15861 879 (5.5) 62 3.1 (1.3) 
Stroke 18726 355 (1.9) 63 3.2 (1.3) 
CKD 14704 3294 (22.4) 61 2.8 (1.4) 
Death 20041 1502 (7.5) 64 3.2 (1.3) 
       
Note: Cases were only eligible for inclusion in each model if they did not already have the outcome of interest at diabetes diagnosis or in the 
first three months following diagnosis. 
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7.3.4 Summary of outcomes observed at diagnosis of diabetes and in the following five 
years 
 
Figure 7.2 shows the proportion of people in the full study cohort (N=20041) who were 
observed to have each of the study outcomes at diabetes diagnosis and the proportion who 
developed each outcome in the five years following diabetes diagnosis.  
CHD: After adjusting for loss of cases to follow-up, 9% of the study cohort were estimated to 
have been diagnosed with, or died from, CHD in the five-year study period. Combining the 
proportion of cases with prior CHD from the original cohort of 20041 with the results of a 
Kaplan-Meier analysis, suggests that a total of 27% of cases with type 2 diabetes died from or 
were diagnosed with CHD by five years following diabetes diagnosis. 
Stroke: A total of 355 of the 18726 cases included in the stroke outcome model were 
diagnosed with, or died from, stroke in the follow-up period. After adjusting for loss of cases 
to follow-up using the Kaplan-Meier failure function, 3% of this cohort were estimated to 
have been diagnosed with, or died from, stroke in the 5-year study period. The combined 
proportion of cases from the original cohort of 20041 who had experienced a fatal or non-fatal 
stroke by five years following diabetes diagnosis was therefore 9%. 
CKD: A total of 3294 of the 14704 cases included in the CKD prediction model were 
diagnosed with CKD (stages 3-5) in the follow-up period. After adjusting for loss of cases to 
follow-up using the Kaplan-Meier failure function, 34% of this cohort were estimated to have 
had developed chronic kidney disease by the end of the 5-year study period. The proportion of 
cases from the original cohort of 20041 who had known CKD by five years following 
diabetes diagnosis was therefore 52%. 
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Death (all-cause): A total of 1502 of the 20041 cases included in the all-cause mortality 
prediction model died in the 5-year follow-up period. After adjusting for loss of cases to 
follow-up using the Kaplan-Meier failure function, 12% of the study cohort were estimated to 
have died in the five-year study period.  
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Figure 7.2 Proportion of study cohort with each outcome of interest at diabetes diagnosis 
and in the following five years 
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7.4  Estimation and imputation of baseline clinical measurements 
 
The clinical measurements/risk factors of interest in this study were eGFR, BMI, HbA1C, total 
cholesterol, and systolic BP. Few additional results were identified by searching for values 
entered into the patient record as free text (0.02% of HbA1Cs; 0.5% of total cholesterols and 
1.7% of systolic BPs). The mean number of values recorded per case for each of the clinical 
measurements in the period between 30 days prior to diagnosis of diabetes and 5 years after 
diagnosis was as follows: HbA1C=4.9; BMI(weight)=5.3; total cholesterol=4.1; systolic 
BP=9.3; eGFR(creatinine)=4.5. The baseline values of these clinical measurements were 
estimated using a multilevel model. The multilevel model for HbA1C is shown in table 7.3. 
The remaining models (systolic BP, BMI, total cholesterol and eGFR) are shown in the 
appendix, in tables A7.4 to A7.7.  
A graphical representation of the observed and modelled trajectory (using the multilevel 
models) for HbA1C and systolic BP over time is presented in Figures 7.3 and 7.4.  The 
equivalent figures for the other clinical values of interest (BMI, total cholesterol and eGFR) 
are presented in figures A7.1 to A7.3. These trajectories for HbA1C and systolic BP are similar 
to those published as part of the UKPDS outcomes model (figure 7.5). For both studies and 
both clinical measurements, the modelled data for cases with the highest and lowest baseline 
values followed a funnel shaped path over the follow-up period, with the greatest changes in 
values in the earlier years. 
The method used to estimate baseline values was internally validated by comparison with an 
alternative, simpler approach: mean value over the follow-up period. The results table is 
presented in table A7.1, rather than here to avoid presenting too many tables in this chapter. 
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For each clinical measure, the residual sum of squares (RSS) using the more complex 
multilevel model was between 24% and 66% lower than the simpler mean of the observed 
values. The difference in the RSS was highly statistically significant for each clinical value 
(p<0.0001), indicating that the multilevel models estimated baseline clinical values better than 
the simpler mean value method. 
The mean estimated value for each of the measurements of interest is presented in table 7.4. 
HbA1C, BMI, total cholesterol and eGFR were missing in 4%-7% of cases: BP was missing 
least often, for just over 1% of cases (260/20041).  No baseline value could be estimated 
using a multilevel model for these cases. Instead, a baseline value for these measurements was 
generated for each of these cases using multiple imputation. The mean imputed value for each 
measurement is also presented in this table. The imputed data were very similar to the 
observed data for each clinical value, except for HbA1C and eGFR. These differences are 
addressed here rather than in the discussion as they relate to the internal validity of the 
imputation process.  
The mean observed and imputed baseline values for HbA1C were 8.3% and 7.8%, 
respectively. However, cases with a recorded HbA1C were twice as likely to be prescribed a 
drug to control their diabetes in the first two months following diagnosis (28% versus 12%, 
respectively). This suggests that it was reasonable to find that baseline HbA1C was higher than 
those whose HbA1C was imputed, and that the differences were not a result of any 
underestimation by the imputation process itself. 
The mean observed and imputed baseline values for eGFR were 71 and 79 ml/min/1.73m2, 
respectively. As with HbA1C, this difference may be explained in part by the characteristics of 
the cases with missing values. Although the two groups had similar baseline blood pressure 
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(144 and 146 mm/Hg), cases with no creatinine result (the basis of the eGFR calculation: if 
the creatinine level was missing, eGFR could not be calculated) present in their clinical record 
were less likely to be prescribed two blood-pressure lowering drugs recommended for use in 
chronic kidney disease. Angiotensin-converting enzyme inhibitors (ACE) were prescribed 
twice as often (53% and 27%) to cases with creatinine recorded, and angiotensin receptor 
blockers (ARB) were prescribed 11 times as often (11% and 1%) to cases with creatinine 
recorded in the follow-up period than cases with missing creatinine. This use of drug 
treatments suggests that their baseline kidney function was poorer, and therefore that their 
eGFR could reasonably be expected to be higher in those who were not treated. This assumes 
that the GP was more likely to record an abnormal eGFR, or that the first blood test was 
carried out in secondary care at the time of diagnosis. 
A summary of the combined values for all these clinical values is presented in a single table in 
the next section (table 7.5), along with other baseline characteristics of the eligible cases.  
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Table 7.3 Multilevel model used to estimate baseline HbA1C 
          
HbA1c (%) coefficient  p          95% CI 
  
   
  
    
  
year of diagnosis 1998 0.214 <0.001 0.126 0.303 
(reference year = 2000) 1999 0.015 0.700 -0.062 0.092 
(1997 and 2004 omitted due  2001 -0.140 <0.001 -0.202 -0.079 
to collinearity) 2002 -0.265 <0.001 -0.323 -0.207 
2003 -0.293 <0.001 -0.349 -0.236 
  
   
  
age at diagnosis 35-44 0.196 <0.001 0.124 0.267 
(reference age group = 55-64) 45-54 0.119 <0.001 0.067 0.170 
65-74 -0.140 <0.001 -0.185 -0.096 
75-84 -0.221 <0.001 -0.275 -0.167 
85-94 -0.259 <0.001 -0.360 -0.157 
95+ -0.358 0.155 -0.852 0.135 
  
   
  
male -0.036 0.038 -0.071 -0.002 
smoker 0.010 0.467 -0.017 0.037 
  
   
  
Townsend quintile (least deprived) 1 -0.107 <0.001 -0.146 -0.068 
(reference quintile = 3) 2 -0.069 <0.001 -0.107 -0.030 
4 -0.003 0.893 -0.041 0.035 
(most deprived) 5  0.083 <0.001 0.042 0.123 
  
   
  
region north -0.009 0.669 -0.049 0.032 
(reference = middle) south 0.066 0.001 0.026 0.107 
  
   
  
comorbidities prior chd 0.006 0.799 -0.038 0.049 
prior chd -0.075 <0.001 -0.112 -0.038 
prior stroke -0.028 0.392 -0.091 0.036 
  
   
  
drug treatments insulin -0.737 <0.001 -0.816 -0.659 
sulphonylurea -0.400 <0.001 -0.423 -0.377 
biguanide -0.427 <0.001 -0.446 -0.408 
acarbose -0.199 0.013 -0.356 -0.042 
meglitinide 0.129 0.020 0.021 0.238 
glitazone -0.485 <0.001 -0.526 -0.443 
statin 0.059 <0.001 0.039 0.078 
other lipid lowering 0.017 0.602 -0.046 0.079 
antianginal(excl. CCB) 0.012 0.546 -0.027 0.052 
aspirin -0.042 <0.001 -0.065 -0.020 
OTC aspirin -0.001 0.993 -0.249 0.247 
other antiplatelet -0.100 0.001 -0.161 -0.039 
angiotensin-II receptor antagonist 0.020 0.277 -0.016 0.057 
ACE inhibitor -0.105 <0.001 -0.128 -0.083 
alphablocker -0.108 <0.001 -0.148 -0.068 
calcium channel blocker -0.035 0.017 -0.063 -0.006 
diuretic 0.038 0.006 0.011 0.066 
  
   
  
slope(change in HbA1C per day) 0.0003 <0.001 0.0003 0.0003 
time(CDF) 3.328 <0.001 3.284 3.372 
intercept  7.520 <0.001 7.450 7.591 
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Figure 7.3 Observed and modelled HbA1C over study period 
 
Figure 7.4 Observed and modelled systolic BP over study period 
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Figure 7.5 UKPDS observed and model estimated systolic blood pressure and HbA1C 
over 15 years 
 
Source: Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR. A model to estimate the 
lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model 
(UKPDS 68) Diabetologia 2004;47:1747-1759. 
 
 
Table 7.4 Distribution of clinical measurements: estimated using multilevel modelling,  
imputed using multiple imputation, and combined 
 Cases Mean value (SD) 
    
HbA1C estimated 19017 8.3 (1.9) 
imputed 1024 7.8 (1.3) 
combined 20041 8.2 (1.9) 
    
BMI estimated 18734 30.2 (5.8) 
imputed 1307 29.4 (4.3) 
combined 20041 30.1 (5.9) 
    
Total cholesterol estimated 19020 5.6 (0.9) 
imputed 1021 5.7 (0.6) 
combined 20041 5.6 (1.0) 
    
SBP estimated 19781 146 (13) 
imputed 260 145 (11) 
combined 20041 146 (13) 
    
eGFR estimated 19193 71 (15) 
imputed 848 80 (10) 
combined 20041 71 (15) 
    
  
 103 
 
7.5  Baseline characteristics of eligible cases 
 
Table 7.5 summarises the baseline demographic and clinical characteristics of the 20041 
eligible cases included in this study in a single table for greater clarity. The demographic 
characteristics of this population and their baseline level of comorbidities were introduced 
earlier in this chapter, and are included here for completeness. 
Townsend quintile was missing for missing for a total of 7% of cases and was imputed at the 
same time as the missing clinical values. Following imputation, cases were distributed 
relatively evenly across the deprivation quintiles, with the most deprived quintile slightly 
underrepresented (16% of cases). Smoking status at baseline could not be determined for less 
than 1% of cases: these had no information on smoking present at any point in their clinical 
record. Cases with missing smoking status were assumed to be non-smokers at baseline, 
rather than estimated using the multiple imputation process. A total of 24% of cases were 
identified as smokers at baseline using this method. Blood pressure lowering drugs were the 
most commonly prescribed group of cardiovascular drugs at diagnosis of diabetes (58%). 
Aspirin, prescribed by practices or bought over the counter by patients, was the next most 
commonly used drug (23% and 2%, respectively). Lipid-lowering drugs were the least 
frequent drug group, being prescribed to 14% of cases at baseline. 
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Table 7.5 Baseline characteristics of eligible cases 
 
Cases         20041 
Male         10821  (54%) 
Mean age in years      63.9  (SD 12.4) 
Mean follow up time in years     3.2  (SD 1.5) 
 
Deprivation    Q1 (least deprived)  21% 
     Q2   20% 
     Q3   23% 
     Q4   20% 
     Q5 (most deprived)  16% 
 
Comorbidities      Cases (%) 
     CHD   3969  (20) 
     Stroke   1240  (6) 
     CKD   4376  (22) 
Current smokers      4890  (24%)  
 
Clinical measurements     Mean (SD) 
     HbA1C  %  8.2  (1.9) 
     BMI    30  (6) 
     Total cholesterol 5.6  (1.0) 
     Systolic BP  146  (13) 
     eGFR   71  (15) 
        Median (IQR) 
     HbA1C  %  7.7  (6.7 – 9.8) 
     BMI   29  (26 - 33) 
     Total cholesterol 5.6  (5.1 - 6.2) 
     Systolic BP  145  (137 - 154) 
     eGFR   72  (60 - 81) 
  
Drug treatments      Cases (%) 
     BP lowering  11624 (58) 
     Lipid lowering 2806 (14) 
     Aspirin (prescribed) 4609 (23) 
     Aspirin (OTC) 401 (2) 
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7.6  Development and checking of the statistical prediction models 
 
7.6.1 Predictors included in the models 
 
Individuals were entered into the model in their original metric where they met the 
proportional hazards assumption [section 6.6]. For example, age was entered as age at 
diagnosis of diabetes (centred on the mean age of cases), and gender was entered as one if 
male, zero if female.  
Comorbidities at baseline or during the first 3 months following diagnosis of diabetes were 
included as a series of binary covariates (i.e. one yes/no covariate per comorbidity). A gap of 
3 months ensured that outcomes that occurred close to the diabetes diagnosis date, because the 
person was first assessed for the outcome just after they were diagnosed with diabetes (e.g. 
with CKD), were treated differently than events which may have been caused by diabetes 
itself. The other outcome models (death, stroke) were treated in a similar way for simplicity. 
Each comorbidity was included as a separate covariate in each of the other outcome models. 
For example, stroke was included in the CHD outcome model as ischaemic stroke and CHD 
can share a common underlying pathology.  
In the light of the observed sharp increases in the use of BP- and cholesterol-lowering drugs 
in the period immediately following diagnosis of diabetes (table A7.3) and the limited 
precision of estimated baseline SBP (limited to broad ranges of SBP, e.g. 90-119, 120-140, 
and 140+ mmHg) (figures A7.1 and A7.2), a conservative decision was made to enter 
baseline SBP and total cholesterol into the model as binary covariates. Specifically, cases with 
high SBP (140+ mmHg) (the point at which BP-lowering treatment is likely to begin) and 
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those who were already on BP lowering treatment at baseline were merged into a single 
group: cases who had past exposure to high blood pressure (as evidenced by their current 
treatment) and those who were currently exposed to high blood pressure. The comparison 
group, therefore, was cases who had normal SBP (<140 mmHg) and were not on BP-lowering 
treatment at baseline. A similar decision was made with respect to total cholesterol: cases with 
baseline total cholesterol of 4 mmol/L (the point at which cholesterol-lowering treatment is 
likely to begin) or higher were combined into a single group with cases who were on 
cholesterol-lowering treatment at baseline. The comparison group in this instance was cases 
who had a total cholesterol of less than 4 mmol/L and were not on cholesterol-lowering 
treatment at baseline.  
Estimated GFR at baseline was not used in the all-cause mortality, CHD and stroke models as 
CKD was already entered as a binary comorbidity. Its effect on the overall R
2
 (table 7.12) for 
the CKD model was, however, assessed in an additional CKD model where it was entered as 
a set of binary covariates, with cutoffs set to reflect the stages set out in the UK CKD 
guidelines (stage1: >=90 mL/min/1.73m2; stage 2: 60-89; stage 3: 30-59; and stages 4-5: 
<=29). 
Lastly, baseline HbA1C and BMI were entered as continuous covariates, centred on their mean 
value for the cohort. Unlike SBP and cholesterol, these were not likely to be treated at 
baseline, and the estimates of baseline values produced by the multilevel models appeared to 
tally well with the observed data (figures A7.2 and A7.3), allowing their effects to be assessed 
more conventionally. 
 
 
 107 
 
7.6.2 Model checking: proportional hazards assumption for each predictor 
 
The purpose of testing the assumption of proportional hazards for each covariate included in 
each outcome model was to verify that they have been appropriately specified (parameterised) 
before being included in the survival models. The log-log plots for age and sex for each 
outcome of interest are presented in figures 7.6 and 7.7. The remaining plots are presented in 
the appendix, in figures A7.4 to A.7.11 to avoid presenting too many results in this chapter. 
Continuous covariates, such as age and BMI, were recast into distinct groups for this check, 
as the shape of each curve cannot readily be observed with a large number of closely spaced 
lines. Hazards can be regarded as proportional if the line for each group remains roughly 
parallel with its neighbours over time, and their levels equally spaced. 
Age: Figure 7.6 shows a decreasing probability of survival with increasing age for each 
outcome model (death, CHD, stroke and CKD). The curves were parallel and there was a 
constant ratio between the curves for each age group over time, except for the youngest and 
oldest age groups, who had relatively small numbers of outcomes in the follow-up period. 
Even though it only appeared to meet the proportional hazards assumption for the 
intermediate age groups, age was kept as a continuous covariate in each survival model. 
Sex: Figure 7.7 shows a similar probability of survival at each time point during follow-up for 
males and females for the death, CHD and stroke models. The survival probability differed in 
cases eligible for inclusion in the CKD model, but the groups remained parallel over time, 
suggesting that the hazard for each sex was proportional. 
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Figure 7.6 Log-log plots: age at diagnosis of diabetes 
 
Note: Both axes are on logarithmic scales. 
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Figure 7.7 Log-log plots: sex 
 
Note: Both axes are on logarithmic scales.  
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Smoking: Figure A7.4 shows that the risk of failure over time among cases who smoked at 
baseline was similar to that of non-smokers in each outcome.  The proportional hazards 
assumption was met and smoking was included in each outcome model unaltered. 
Comorbidities: Figures A7.5 to A7.7 show the plots for CHD, stroke and CKD as model 
predictors. The presence of each comorbidity was associated with a worse outcome for each 
of the outcomes of interest. There is no plot for a particular comorbidity (CHD, stroke or 
CKD) when it is the outcome of interest: these cases would not be eligible for a survival 
model where the outcome is the first ever diagnosis of CHD, stroke or CKD, respectively. 
Events in the period prior to diabetes diagnosis and in the first three months were combined as 
the study follow-up period began at three months following diagnosis. The plots for these 
comorbidities (CHD, stroke and CKD) remained roughly parallel over time. These figures 
show the proportion of cases observed to fail over time among those eligible for each outcome 
model. Each of these plots shows that the proportion surviving remains roughly parallel over 
the follow-up period. The proportional hazards assumption was, therefore, met and these 
covariates were entered into the survival models unaltered. 
Clinical measurements and drugs: Figures A7.8 to A7.11 show the plots for the clinical 
value covariates, including those which were a product of the interaction with drug treatment 
(total cholesterol and systolic BP). The plots show that the covariates are roughly proportional 
over time and that the proportional hazards assumption was met. Drug treatments for high 
blood pressure and cholesterol at baseline, but not those initiated after diabetes diagnosis were 
included in each model for the following reasons: 
 Levels of BP and lipid-lowering drug (lipid lowering) treatment were already relatively  
high at baseline (table 7.5) and treatment rates rapidly increased following diagnosis (table 
A7.3), reducing any difference in the exposure to harm in the follow-up period between 
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cases with a high but untreated baseline risk factor and those whose risk factor was low, or 
already treated.  
 Any attempt to include treatments in the period following diagnosis, including those used 
to manage blood glucose, risked including an immortal time bias, as the case had to be 
alive to be prescribed a drug. (159) 
 
7.6.3 Potential predictors considered but not included in the models  
 
Year of diagnosis, geographical area and deprivation were also considered for inclusion in the 
survival models as they may plausibly predict the risk of death or diabetic complications. 
It was decided not to include year of diagnosis in the survival analyses for the following 
reasons: 
 Baseline HbA1C was already included in the model, and the effect of lowering the 
threshold for diagnosis would be reflected in lower HbA1C at diagnosis. The inclusion of 
year of diagnosis in addition to HbA1C in survival models would, therefore, tend to lessen 
the apparent impact of HbA1C in the risk of death and other outcomes. On balance, the 
effect of HbA1C was of more interest than year of diagnosis. 
 The study period for incident cases of diabetes was relatively short (1998-2003): the 
background age-specific risk of death, CHD, stroke and CKD in the wider population was 
unlikely to have changed in such a short period, lessening the need to control for its effect. 
(160)  
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 The number of practices contributing to the study cohort varied from year to year: any 
observed year-on-year differences in the risk of death and the other study outcomes may 
be due to differences between practices, rather than year of diabetes diagnosis. 
 
On balance, as with year of diagnosis, a decision was made to drop geographical area and 
deprivation in favour of the clinically relevant variables for the reasons described below: 
 Geographical region and deprivation are proxies for other, unmeasured, health related 
variables such as lifestyle, and access to and use of health services.  
 They are both area-based measures, and do not refer to the individual case in the study 
cohort.  
 Clinically relevant variables such as BMI and smoking refer directly to the individual case 
and are known to be on the causal pathway for the outcomes of interest in this study. 
 
7.6.4 Interactions included in models 
 
Baseline systolic BP and total cholesterol were categorised into binary covariates indicating if 
a case had a high level of each risk factor at baseline.  High systolic BP and treatment with 
BP-lowering drugs were combined into a single binary covariate in order to meet the 
proportional hazards assumption, as they did not meet it individually. The rationale for this 
grouping, other than it meets the proportional hazards assumption, is that it creates two 
groups: those who were exposed to high BP in the past and the remaining cases who were not. 
The effects of high baseline cholesterol and baseline lipid-lowering (lipid lowering) 
treatments were assessed independently as they both met the proportional hazards assumption. 
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As they were closely related, their combined effect was also assessed in an interaction term in 
each model.  
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7.7  Prediction model results 
 
Tables 7.6 to 7.9 contain the results of the prediction model for each of the study outcomes: 
CHD, stroke, CKD and all-cause mortality. The first set of covariates in each table are 
demographic variables, the second are smoking/comorbidities, and the third are baseline 
clinical measurements and selected drug treatments. The hazard ratios (HRs), p-values, and 
the 95% confidence intervals for each of the HRs are displayed for each covariate included in 
each model. Table 7.11 combines these results into a single table to allow the HRs to be 
compared across models. 
 
7.6.5 CHD prediction model results 
 
Table 7.6 shows the results of the CHD model. Male sex (HR 1.36; 95% CI 1.18- 1.56) and 
higher age at diagnosis (HR 1.02 per year of age; 95% CI 1.01-1.03) were significantly 
associated with an increased risk of being diagnosed with CHD in the period from three 
months to five years following diabetes diagnosis. Smoking at diagnosis was also significant 
and increased the risk of CHD (HR 1.26; 95% CI 1.08-1.46). The effect of stroke and CKD, 
diagnosed at any time up to three months after diabetes had similar, but not statistically 
significant, HRs of 1.09 and 1.13, respectively (95% CI 0.84-1.42 and 0.97-1.33, 
respectively). Higher HbA1C, higher BMI, and high SBP/BP treatment at baseline all appeared 
to increase the risk of CHD (HRs 1.07, 1.02 and 1.41, respectively) (95% CI 1.03-1.11, 1.00-
1.03 and 1.13-1.76, respectively). High baseline cholesterol and lipid lowering treatment, 
however, were not statistically significant.  
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Table 7.6 CHD prediction model 
  Hazard ratio p 95% CI 
       
Male  1.36 *** <0.001 1.18 1.56 
Age at diagnosis of 
diabetes (per year)  
1.02 *** <0.001 1.01 1.03 
Smoker at 
diagnosis  
1.26 ** 0.002 1.08 1.46 
Comorbidities 
prior to diabetes or 
in first 3 months 
following diabetes 
Stroke 1.09  0.501 0.84 1.42 
CKD 1.13  0.117 0.97 1.33 
Clinical 
measurements and 
treatments at 
diagnosis  
HbA1C
1 
1.07 *** <0.001 1.03 1.11 
BMI
1 
1.02 * 0.015 1.00 1.03 
SBP >= 140 mmHg or 
drug treated BP 
1.41 ** 0.002 1.13 1.76 
Total cholesterol >= 4 
mmol/L  
1.38  0.530 0.50 3.83 
 Total cholesterol >= 4 
mmol/L and on lipid 
lowering drug 
0.98  0.975 0.25 3.79 
 On lipid lowering drug 1.79  0.396 0.47 6.84 
* p<.05; ** p<.01; *** p<.001 
1. Changes in hazard ratios are shown per 1% increase in HbA1C and per 1 kg/m
2 increase in BMI.   
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Table 7.7 Stroke prediction model 
  Hazard ratio p 95% CI 
       
Male  1.15  0.190 0.93 1.42 
Age at diagnosis of 
diabetes (per year)  
1.06 *** <0.001 1.05 1.07 
Smoker at 
diagnosis  
1.42 ** 0.005 1.11 1.81 
Comorbidities 
prior to diabetes or 
in first 3 months 
following diabetes 
CHD 1.50 ** 0.001 1.17 1.93 
CKD 1.17  0.152 0.94 1.48 
Clinical 
measurements and 
treatments at 
diagnosis  
HbA1C
1 1.01  0.756 0.95 1.07 
BMI
1 0.99  0.235 0.96 1.01 
SBP >= 140 mmHg or 
drug treated BP 
1.80 * 0.015 1.22 2.90 
Total cholesterol >= 4 
mmol/L  
0.90  0.855 0.29 2.83 
Total cholesterol >= 4 
mmol/L and on lipid 
lowering drug 
1.22  0.781 0.29 5.08 
On lipid lowering drug 0.63  0.521 0.16 2.57 
* p<.05; ** p<.01; *** p<.001 
1. Changes in hazard ratios are shown per 1% increase in HbA1C and per 1 kg/m
2 increase in BMI.   
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7.6.6 Stroke prediction model results 
 
Increased age at diagnosis of diabetes was significantly associated with the risk of stroke in 
the first 5 years following this index event (HR 1.06; 95% CI 1.05-1.07), and male sex 
showed a positive hazard ratio, but was not statistically significant (HR 1.15; 95% CI 0.93-
1.42) (table 7.7). Smokers at baseline also showed a significantly increased risk of stroke (HR 
1.42; 95% CI 1.11-1.81). CHD, diagnosed at any time up to three months after baseline, 
showed a significant positive association with the risk of stroke (HR 1.50; 95% CI 1.17-1.93). 
Of the clinical measurements / treatments included in the model, only high SBP/BP treatment 
at baseline was significantly associated with the risk of stroke (HR 1.80; 95% CI 1.22-2.90). 
 
7.6.7 CKD prediction model results 
 
Unlike previous outcomes, the risk of CKD was lower in males than females (HR 0.52; 95% 
CI 0.48-0.56) (table 7.8). As seen in the other survival models, older age at diagnosis of 
diabetes appeared to be significantly associated with an increased of the outcome of interest 
(HR 1.06; 95% CI 1.06-1.06). Both CHD and stroke as comorbidities significantly increased 
the risk of CKD (HRs 1.21 and 1.14, respectively) (95% CI 1.11-1.33 for CHD), although the 
estimate for stroke came very close to non-significance (95% CI 1.001-1.289 for stroke). All 
the clinical measurement covariates with the exception of high total cholesterol and lipid 
lowering treatment at baseline were significantly associated with an increased risk of CKD. 
The HRs for HbA1C, BMI, and high SBP/BP treatment at baseline were 1.03, 1.01 and 1.45, 
respectively (95% CI 1.01-1.05, 1.00-1.02 and 1.28-1.65, respectively).  
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Table 7.8 CKD prediction model 
  Hazard ratio p 95% CI 
       
Male  0.52 *** <0.001 0.48 0.56 
Age at diagnosis of 
diabetes (per year)  
1.06 *** <0.001 1.06 1.06 
Smoker at 
diagnosis  
1.10  0.019 1.02 1.19 
Comorbidities 
prior to diabetes or 
in first 3 months 
following diabetes 
CHD 1.21 *** <0.001 1.11 1.33 
Stroke 1.14 * 0.048 1.00 1.29 
Clinical 
measurements and 
treatments at 
diagnosis  
HbA1C
1 
1.03 ** 0.002 1.01 1.05 
BMI
1 
1.01 ** 0.003 1.00 1.02 
SBP >= 140 mmHg or 
drug treated BP 
1.45 *** <0.001 1.28 1.65 
Total cholesterol >= 4 
mmol/L  
1.46  0.180 0.84 2.52 
Total cholesterol >= 4 
mmol/L and on lipid 
lowering drug 
0.64  0.164 0.34 1.20 
On lipid lowering drug 1.69  0.096 0.91 3.14 
* p<.05; ** p<.01; *** p<.001 
1. Changes in hazard ratios are shown per 1%  increase in HbA1C and per 1 kg/m
2 increase in BMI. 
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7.6.8 All-cause mortality prediction model results 
 
Table 7.9 shows the results of the mortality model, that is, where the outcome of interest was 
all-cause mortality between 3 months and 5 year following a diagnosis of type 2 diabetes. Of 
the demographic covariates, male sex (HR 1.29), older age (HR 1.09), and smoking (HR 1.65) 
significantly increased the risk of death (95% CI 1.16-1.42, 1.09-1.10 and 1.46-1.87, 
respectively). All three comorbidities were significantly associated with an increased risk of 
death. In descending order of hazard ratio there were: CHD (HR 1.60), stroke (HR 1.47) and 
CKD (HR 1.33) (95% CI 1.40-1.80, 1.30-1.70 and 1.19-1.49, respectively).  Of the clinical 
measurement at baseline only HbA1C, BMI and lipid lowering treatment were significantly 
associated with the risk of death. Of these, only higher levels of HbA1C were positively 
associated with increased risk of death (HR 1.09; 95% CI 1.06-1.12). Increased BMI appeared 
to be associated with a small reduction in risk per unit BMI (HR 0.98; 95% CI 0.97-0.99) in 
this model.  
Table 7.10 shows the effect of total cholesterol and lipid-lowering treatment in more detail. 
Of these three related binary covariates (total cholesterol>=4 mmol/L, on lipid lowering drug, 
and the interaction term for these two covariates), only lipid lowering drug treatment was 
statistically significant. The relationship between total cholesterol and lipid lowering 
treatment and the risk of death was not simple or clear because of this: having either high 
cholesterol or being on lipid lowering treatment at baseline appeared to lower the risk of 
death. The effect of having both of these factors (treated but still high cholesterol), however 
was still associated with a lower risk of death than having normal and untreated cholesterol 
levels.  
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Table 7.9 All-cause mortality prediction model 
  Hazard ratio p 95% CI 
       
Male  1.29 *** <0.001 1.16 1.42 
Age at diagnosis of 
diabetes  (per year)  
1.09 *** <0.001 1.09 1.10 
Smoker at 
diagnosis  
1.65 *** <0.001 1.46 1.87 
Comorbidities 
prior to diabetes or 
in first 3 months 
following diabetes 
CHD 1.60 *** <0.001 1.40 1.80 
Stroke 1.47 *** <0.001 1.30 1.70 
CKD 1.33 *** <0.001 1.19 1.49 
Clinical 
measurements and 
treatments at 
diagnosis  
HbA1C
1 
1.09 *** <0.001 1.06 1.12 
BMI
1 
0.98 ** 0.002 0.97 0.99 
SBP >= 140 mmHg or 
drug treated BP 
1.07  0.547 0.86 1.34 
Total cholesterol >= 4 
mmol/L  
0.61  0.080 0.35 1.06 
 Total cholesterol >= 4 
mmol/L and on lipid 
lowering drug 
1.69  0.138 0.84 3.41 
 On lipid lowering drug 0.41 * 0.012 0.21 0.82 
* p<.05; ** p<.01; *** p<.001 
1. Changes in hazard ratios are shown per 1% increase in HbA1C and per 1 kg/m
2 increase in BMI.   
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Table 7.10 Combined effect of cholesterol and lipid lowering drugs on hazard ratios for 
all-cause mortality 
 
On lipid lowering treatment at diagnosis 
no yes 
    
Total 
cholesterol at 
diagnosis 
low (< 4 mmol/L) 1.00 0.41 
high (>= 4 mmol/L) 0.61 0.71 
    
Note: Numbers are hazard ratios in comparison with cases with total cholesterol < 4 mmol/L and not on lipid lowering treatment at diagnosis 
of diabetes. This comparison group has a hazard ratio of 1.00. 
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7.6.9 All prediction model results combined 
 
Table 7.11, below, presents the results of the models in a single table to facilitate later 
comparison of the results for each predictor across models.  
 
Table 7.11 Hazard ratios for all prediction models 
 CHD Stroke CKD 
All-cause 
mortality 
         
Fixed risks         
Male 1.36 *** 1.15  0.52 *** 1.29 *** 
Age 1.02 *** 1.06 *** 1.06 *** 1.10 *** 
         
CHD   1.50 ** 1.21 *** 1.58 *** 
Stroke 1.09    1.14 * 1.47 *** 
CKD 1.13  1.18    1.33 *** 
         
Modifiable risks         
Smoker 1.26 ** 1.42 ** 1.10 * 1.65 *** 
HbA1C 1.07 *** 1.01  1.03 ** 1.09 *** 
BMI 1.02 * 0.99  1.01 ** 0.98 ** 
High SBP / treated BP 1.41 ** 1.80 * 1.45 *** 1.07  
         
High total cholesterol  1.38  0.90  1.46  0.61  
Chol. high and treated 0.98  1.22  0.64  1.69  
Treated cholesterol 1.79  0.63  1.69  0.41 * 
* p<.05; ** p<.01; *** p<.001 
Note: Changes in hazard ratios are shown per 1%  increase in HbA1C and per 1 kg/m
2 increase in BMI. 
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7.7 Proportion of variation explained by each model 
 
The proportion of variation in the data explained by each complete model was summarised 
using the R
2
 statistic (table 7.12). Additional models were run for some outcomes in addition 
to the planned ones: these are shown in brackets. 
The R
2
 for each main outcome model varied between a maximum of 0.58 (all-cause mortality) 
and 0.09 (CHD). Both stroke and CKD performed similarly, with R
2
 of 0.35 and 0.34, 
respectively.  
Given the low R
2
 for CHD, additional models were run to assess if this was due to the 
outcome including both hard and soft/intermediate outcomes. The R
2
 for separate myocardial 
infarction (MI) and stable angina models performed better than the combined CHD model, 
with R
2
 of 0.20 and 0.13, respectively.  
The effect of including eGFR in the CKD outcome model was assessed separately from the 
main CKD model. The R
2
 almost doubled from 0.34 to 0.66 after its inclusion. 
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Table 7.12 Proportion of variation in the data explained by the survival models 
Model name R2 
  
CHD 0.09 
(MI only) 0.20 
(angina only) 0.13 
  
Stroke 0.35 
  
CKD 0.34 
(with eGFR) 0.66 
  
All-cause mortality 0.58 
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7.8 Model checking: goodness of fit of Weibull model 
 
The suitability of the choice of a Weibull distribution to model each of the study outcomes 
was assessed using probability plots (figure 7.8). These probability plots compared the 
proportion of observed failures (death, CHD, stroke, CKD) with those expected (fitted) using 
a separate Weibull model for each outcome of interest. The Weibull model was an appropriate 
choice of survival distribution if the plotted line (of observed versus fitted failures) lay along 
the diagonal, and did not grossly deviate from it at any point. 
Death: There were 1502 deaths observed among the 20041 cases included in the death model. 
The plotted comparison of observed and expected deaths lay along the diagonal, showing a 
small deviation to either side of it at two points, before returning to the diagonal. Overall, the 
number of deaths derived from the model closely matched that observed in the data.  
CHD: There were 879 cases of CHD diagnosed during follow-up among the 15861 people 
included in the CHD model. The plotted comparison of observed and expected occurrence of 
CHD lay along the diagonal, and did not systematically deviate from it at any point. 
Therefore, the number of expected CHD diagnoses derived from the model closely matched 
that observed in the data.  
Stroke: There were 355 strokes observed during follow-up among the 18726 people included 
in the stroke model. As with the CHD model, the plotted comparison of observed and 
expected strokes lay along the diagonal, and did not systematically deviate from it at any 
point. Therefore, the number of expected strokes derived from the model closely matched that 
observed in the data. 
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CKD: There were 3294 cases of CKD observed during follow-up among the 14704 people 
included in the CKD model.  The plotted comparison of observed and expected CKD 
occurrence lay along the diagonal, but did deviate from it at two points, before returning to 
the diagonal. At the point where 25% of the failures occurred in the data, the model predicted 
that approximately 30% of the cases would fail and at the point where 75% of failures were 
observed to occur, the model predicted about 70%. These differences are relatively small, and 
show the model both underestimating and overestimating failures at different points, but not 
grossly deviating from the centre line without returning to it. Therefore, the fitted Weibull 
model was an adequately close fit to the observed data, and accepted as a suitable choice for 
modelling CKD outcomes.  
The Weibull model was accepted as a suitable choice of distribution to model each of the 
study outcomes. On the occasions where it deviated from the observed data, the differences 
were relatively small, and the model did not consistently over- or underestimate the number of 
outcomes observed. 
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Figure 7.8 Probability plots of observed failures vs. fitted Weibull model 
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CHAPTER 8  DISCUSSION 
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8.1  Introduction 
 
This thesis concerns the development of four separate statistical models which can be used to 
predict the risk of coronary heart disease, stroke, chronic kidney disease, and all-cause 
mortality in the five years following a diagnosis of type 2 diabetes. The study used data from 
a large UK general practice database and included demographic variables, clinical predictors 
routinely recorded following diabetes diagnosis, and blood pressure and cholesterol-lowering 
treatments to populate the models. 
This chapter discusses these models, focussing on their validity in comparison with existing 
models and their clinical utility. It begins with the main findings from each model [section 
8.2] and the study’s strengths and weaknesses [section 8.3]. This is followed by: detailed 
external comparisons to establish the generalisability of the study cohort in terms of 
demography and clinical features [section 8.4.1]; detailed comparisons of the estimates 
(hazard ratios) derived for each risk factor included in the current models with existing 
prediction models [section 8.4.2]; and comparisons of the population included and statistical 
methods with existing models [section 8.5], and approaches to missing data [section 8.6].  
The last sections of this chapter discuss the implications of the results of this study. They 
identify which risk factors are most clinically important [section 8.7.1], and discuss the 
clinical utility of the models [section 8.7.2] and their implications for policy [section 8.8]. The 
very last section [section 8.9] describes the overall study conclusions.  
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8.2  Main findings 
 
Age, sex and past medical history were important but fixed predictors of future risk. The 
hazard ratios for these non modifiable risk factors were: 1.02-1.10 for age (per year); 0.52-
1.36 for male sex; 1.21-1.58 for CHD; 1.09-1.47 for stroke; and 1.13-1.33 for CKD. Key 
modifiable predictors were: smoking; weight; blood pressure; and glycaemic control. The 
hazard ratios for these risk factors were: current smoking 1.10-1.65; weight (per unit BMI) 
0.98-1.02; blood pressure high or treated 1.07-1.80; and glycaemic control (HbA1C %) 1.01-
1.09. The proportion of variation explained by each model (R
2
) was: CHD 0.09; stroke 0.35; 
CKD 0.34; and mortality 0.58.  
The most clinically useful model might be the mortality model as it accounted for a large 
proportion of the variability in outcomes (R
2
=0.58). This model found that age, sex and past 
medical history were associated with the risk of death, as were smoking, glycaemic control, 
BMI and high/treated blood pressure. The stroke and CKD models accounted for a moderate 
amount of the variation in outcomes observed (an R
2
 of 0.35 and 0.34, respectively). The 
stroke model found that age, prior CHD, smoking and high/treated blood pressure were 
significant predictors of future stroke risk. The CKD model found that male gender, age, prior 
CHD and stroke were significant predictors of future CKD risk, as were smoking, glycaemic 
control, BMI and high/treated blood pressure. The CHD model had the smallest R
2
 (0.09). 
Although it included known risk factors for CHD, the model accounted for little of the 
variation in outcomes between individuals and would not, therefore, be useful in clinical 
practice. 
These results will be discussed in more detail in the individual sections below. 
 131 
 
8.2.1 Prediction models 
 
The main outputs from this thesis were the four prediction models. This section considers the 
results of each model in turn in terms of the individual risk factors that were significant in 
each model. 
 
All-cause mortality prediction model: Perhaps the most successful of the models developed 
was that for all-cause mortality (table 7.11). This explained the majority of the variation (R
2
= 
0.58) in outcomes, more than any of the other models reported here (table 7.12). Possible 
explanations for this are discussed below [section 8.2.2]. This high R
2
 also suggests that this 
model could be used in clinical practice to predict all-cause mortality risk, after appropriate 
validation [section 8.7.2]. 
People who smoked at the time of diagnosis had an increased risk of death of almost two-
thirds (65%). Of the modifiable risk factors assessed across the four models, smoking was the 
only one to be significant in each case and had hazard ratios of sufficient size to make it 
perhaps the first target for intervention by clinicians.  
There was a 9% increase in the risk of death in the follow-up period for every 1% increase in 
baseline HbA1C. Higher HbA1C at diagnosis of diabetes implies that the case had been 
exposed to high levels of blood glucose prior to diagnosis, possibly for several years, and 
therefore was at increased risk of vascular damage. (161) This may in turn increase the risk of 
death from CHD and stroke (and the risk of renal and eye disease, and neuropathy). An RCT 
based in eastern England which carried out population-based diabetes screening among high-
risk individuals reported a lower baseline HbA1C than was observed in this study (6.8% and 
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8.2%, respectively), suggesting that population screening might detect the disease at an earlier 
stage and so allow earlier intervention (table 7.5). (162) The key clinical message is that the 
association between higher baseline HbA1C and serious outcomes observed in this study 
suggests a rationale for screening for diabetes, in that diagnosis earlier in the disease process 
could be associated with lower risk. NICE guidelines are already in place which address this. 
(163) These suggest that individuals at high risk of diabetes should have a blood test, and be 
reassessed every three years if they test negative. However a recent paper reporting 10-year 
outcomes from the ADDITION-Cambridge RCT found that a single round of screening did 
not reduce all-cause or cardiovascular mortality in the screened group. (164) Population 
screening for diabetes alone might not, therefore, be a cost-effective means to reduce these 
outcomes in the diabetic population, even if it led to a lower HbA1C at diagnosis. As the 
authors suggested, a programme which assessed cardiovascular risk in addition screening for 
diabetes might be effective at reducing serious cardiovascular outcomes. This would benefit 
both the non-diabetic and diabetic population, and is a model used by NHS Health Check 
programme. (165) 
The effect of increased BMI at baseline was also significant, but appeared to be protective: for 
every additional five units of BMI at baseline, the risk of death decreased by 10%. A similar 
protective effect of obesity on all-cause mortality was observed in a recent pooled analysis of 
five cohort studies. (166) The possible explanation for this unexpected effect given by the 
authors was that normal weight individuals with diabetes have a different genetic profile than 
overweight or obese individuals, and that these individuals are at risk of other diseases 
associated with higher mortality. (167)  The observed effect of lower BMI on mortality in the 
current study could not be explained by three major diseases associated with higher mortality: 
overt CHD, stroke and CKD, as these were adjusted for in the model. If lower BMI 
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individuals are at higher risk of diseases other than diabetes it might, therefore, be due to 
disease other than these three (cancer, for example), or diseases which were diagnosed after 
diabetes. It may also be that newly diagnosed cases of type 2 diabetes with high BMI were 
younger, or diagnosed at an earlier stage in the disease than those with lower BMI, and 
therefore at decreased risk of death in the first five years. Higher BMI is a known risk factor 
for diabetes and this is reflected in the diabetes risk scores recommended by NICE to identify 
individuals who should be tested for diabetes. (163, 168-170) Therefore clinicians may 
consider diabetes more frequently in individuals with higher BMI. (163)  Asymptomatic 
individuals may only have their diabetes diagnosed by random screening or when they are 
diagnosed with another disease. (163, 171-174) 
Of the remaining clinical measurements / treatments included in the model, only high SBP/BP 
treatment at baseline showed the positive association that might be expected with the risk of 
death, although its effect was non-significant. This is not unexpected given that even in the 
BP Lowering Treatment Trialist’ Collaborative meta-analysis of antihypertensive medication, 
the relationship between treatment and mortality (in comparison to major cardiovascular 
events) was not consistent. (175) The relationship between total cholesterol and lipid lowering 
treatment and the risk of death in the current study was not simple or clear: having either high 
cholesterol or being on lipid lowering treatment at baseline appeared to lower the risk of death 
(table 7.8). The effect of having both of these factors (treated and high cholesterol), however 
was still associated with a lower risk of death than being untreated and having a normal 
cholesterol level. Given that only one of these risk factors was statistically significant (the 
main effect for lipid lowering treatment), it is not clear if any valid inferences about their 
effect on death can be drawn from combining these results or whether these results were a 
chance effect or confounded by other factors not included in the model. If these hazard ratios 
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were an accurate reflection of reality, however, the explanation may be that patients with 
higher baseline cholesterol levels were more likely to be initiated on statins and, as a result, 
have a lower risk of future CVD, including stroke. 
Of the fixed risk factors, males were at significantly higher risk of death in the follow-up 
period than females (29% more) (table 7.9). Prior comorbidity (CHD, stroke and CKD) each 
increased the risk of death by one-third to one-half. As the effect of these is additive, a person 
with all three of these comorbidities would have a 140% increased risk of death compared to a 
person free of all three comorbidities. Both of these findings are consistent with other data 
from the literature. (79-81, 176, 177) 
 
CHD prediction model: In comparison to all cause mortality, the CHD model performed 
badly and most of the observed variability was not explained by the model (table 7.12). Of the 
modifiable risk factors, smoking was a prominent predictor of CHD risk: the risk of CHD for 
people who smoked at the time of diagnosis was 26% higher than for non-smokers, lower 
than the equivalent figure for all-cause mortality (65%) (table 7.11). As described in section 
6.7.1, the CHD cohort excluded cases from the CHD survival analysis that had prior overt 
CHD (n=3969: approximately 20% of those included in the mortality cohort). This may have 
resulted in the exclusion of many cases with the highest levels of exposure to smoking, and 
therefore the highest risk of developing CHD: these cases may have developed CHD earlier 
than those with lower or no tobacco exposure. (178) Baseline data for smoking status was 
only presented for the mortality cohort in the results chapter (table 7.5), so this possible 
explanation cannot be supported here by evidence of a higher prevalence of smoking at 
baseline for the mortality cohort, compared with the CHD cohort. 
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Higher HbA1C, higher BMI and high SBP/BP treatment at baseline were all associated with a 
significantly increased risk of CHD (a 7% and 2% increase per unit HbA1C and BMI, 
respectively, and a 41% increase for high SBP/BP treatment). The effect of HbA1C was 
similar to that for all-cause mortality (HR 1.09), and the effect of increased baseline BMI was 
positively associated with an increased risk of the outcome, unlike all-cause mortality, where 
increased BMI appeared to be protective. This suggests that HbA1C and BMI should both be 
addressed in clinical practice in order to reduce CHD risk. Higher BMI also appeared to be a 
stronger predictor of CHD than stroke (HR 1.03 and 1.01, respectively) (table 7.11): this is 
consistent with evidence from the wider population that higher BMI has a greater effect on 
CHD risk than stroke risk. (179)  
The effect of high SBP/BP treatment at baseline on risk of CHD (HR 1.41; 95% CI 1.13-1.76) 
was greater than that for mortality (HR 1.07; 95% CI 0.86-1.34), and unlike mortality, its 
effect was statistically significant. This suggests that BP is a more important target for 
treatment in order to reduce CHD risk than all-cause mortality, and fits well with trial data for 
the general population. (175) 
The effect of high cholesterol and cholesterol-lowering drugs was to increase CHD risk, but 
the effect was non-significant and opposite to that observed for mortality. Again, this apparent 
difference may be explained in part by the exclusion of cases with overt CHD prior to, or 
within 3 months of diabetes diagnosis. Most CHD diagnoses occurred prior, or very close to, 
the diabetes diagnosis, rather than in the remaining follow-up period (3969 and 879, 
respectively). The effect of BP, cholesterol and drug treatment may have differed in those 
who developed overt CHD prior to the diagnosis of diabetes, compared to those who 
developed CHD following diabetes diagnosis, and this may have led to the observed 
differences between the CHD and mortality models for these risk factors. (180) Despite this 
 136 
 
non-significant result for cholesterol on CHD risk, clinicians should not ignore this risk factor 
when attempting to reduce risk in people with Type 2 diabetes: there is ample evidence that 
cholesterol level is a risk factor from population-based trials. (41, 42) 
In terms of non-modifiable risks, males were at significantly higher risk of CHD than females 
(36%), similar to that observed for all-cause mortality (table 7.11). This was also similar to 
the risk observed in the wider Framingham population (a 44% higher lifetime risk for males at 
age 70 years). (181) However the risk of CHD increased less with increased age at diagnosis 
than was observed in the all-cause mortality model: it increased by about 20% for each 10 
year increase in age for CHD, but doubled for each 10 year increase for all-cause mortality. 
This may be due to the exclusion of cases with prior CHD from the CHD outcome model 
hence potentially resulting in a lower risk cohort. This highlights the difficulty in making 
comparisons across different models which are derived from different subsets of a larger 
cohort. It would have been possible to develop a set of models using a common cohort, 
allowing direct comparisons of hazard ratios. However, this would have resulted in the 
exclusion of at least 20% of patients (table 7.5), and produced models which could not be 
applied to a significant proportion of newly diagnosed patients with diabetes. On balance, it 
seemed better to ensure that the models were representative of the diabetic population than to 
ensure that hazard ratio estimates were directly comparable across models. 
Overall the CHD model performed the worst of the three models. The explanation for the 
relatively low R
2
 for this model was explored by running two additional sub models (table 
7.12). The definition of CHD included both the soft/intermediate outcome of stable angina – 
which mainly relies on a clinical diagnosis – and the harder outcome of myocardial infarction 
(MI): the impact of each of the risk factors may therefore have differed for each of these two 
outcomes. The two sub models showed improved R
2
 (0.20 and 0.13 for MI and stable angina, 
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respectively), suggesting that this was the case. Unfortunately, this approach could not be 
used in place of the main CHD model as only a proportion of the CHD outcomes could 
reliably be assigned to either MI or stable angina. 
It is likely that the CHD-specific model presented here (R
2
 0.09) could be improved if a 
reliable method could be found to split CHD outcomes into MI and angina. This might be 
achieved by linkage of GP and secondary care records or if there was an improvement in 
coding in general practice [section 8.3.2 weaknesses]. (112) Until such time as these can be 
achieved, this CHD model has relatively limited clinical utility [section 8.8 data issues]. 
 
Stroke prediction model: Considering modifiable risks, the effect of smoking at baseline 
was significantly associated with an increased risk of stroke, as it was with mortality and 
CHD (table 7.11). Smokers were at 42% higher risk of stroke in the period from 3 months to 5 
years following the diagnosis of diabetes, reinforcing the importance of smoking cessation as 
a key clinical intervention. 
Of the remaining modifiable risk factors included in the stroke model, only high SBP/BP 
treatment at baseline achieved statistical significance (95% CI 1.22-2.90). The effect of this 
was to increase the risk of stroke in the follow-up period by about 80%. This is almost twice 
as high as the HR observed in the CHD model (HRs 1.80 and 1.41, respectively). This is 
similar to the difference between the effect of blood pressure on CHD and stroke outcomes 
seen in studies on both non-diabetic and diabetic populations. (40, 182) The point estimate for 
the hazard ratio for blood pressure on future stroke was also the highest seen for any risk 
factor in any of the models and reinforces the importance of blood pressure control in 
preventing stroke. 
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The effect of high cholesterol, lipid lowering drugs and the interaction between the two were 
not significant, but, as with mortality, they showed a similarly counter-intuitive pattern of 
exposures that would be expected to increase risk, appearing to be protective. (41) It is not 
clear if this highlights a general issue inherent to the use of routine primary care patient data, 
or one specific to modelling chronic diseases like diabetes. It may be more likely to be the 
latter, as higher cholesterol levels predicted higher CVD risk in a study using one of the large 
GP databases in a statin-unexposed ‘healthy’ population (64, 109). In diabetes, patients with 
high cholesterol at diagnosis are likely to be treated with statins: the proportion prescribed 
lipid lowering drugs in this study rose from 19% at diagnosis to 42% at one year following 
diagnosis (table A7.3). High cholesterol at diabetes diagnosis, therefore, is likely to be 
associated with initiation of a statin in the period following diagnosis, and a subsequent 
reduction in risk. This may explain the apparent protective effect of high untreated cholesterol 
at baseline observed in this model (HR 0.90). 
Unlike all the other models (table 7.11), the effect of male sex on stroke risk was not 
statistically significant (95% CI 0.93-1.42), though the direction of the hazard ratio was 
consistent with an increased risk of stroke for males (HR 1.15). The effect of age was 
significant, however, as it was with all the other models discussed so far: it increased by 6% 
for every additional year of age at diagnosis of diabetes. 
Overall, the R
2
 for the 5-year stroke model (R
2
 0.35) was at a similar level to a 10-year CVD 
prediction model (QRISK1) developed for the wider population, which reported an R
2
 of 0.33 
and 0.36 for men and women respectively. (63) This suggests that this model could be used in 
clinical practice to predict stroke risk, after appropriate validation [section 8.7.2]. 
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CKD prediction model: Higher HbA1C, higher BMI and high SBP/BP treatment at baseline 
were all associated with a significant increased risk of CKD (a 3% and 1% increase per unit 
increase in HbA1C and BMI, respectively, and a 45% increase in risk for high SBP/BP 
treatment). This pattern of risk is similar to that observed in the CHD outcome model (7%, 
2% and 41% increases, respectively). Also, as observed in the CHD outcome model, the 
effect of high baseline cholesterol, lipid lowering treatment and their interaction was non-
significant, but followed the expected direction: exposures which implied high levels of total 
cholesterol in the past were associated with an increased risk of CKD diagnosis in the follow-
up period. 
The effect of increased age at diagnosis was significant and increased the risk of being 
diagnosed with CKD in the follow-up period by 6% for each year of age (table 7.8). This is 
similar to that observed in the earlier outcome models (table 8.6), and may not be surprising 
given that the CKD risk is strongly related to age, even in the healthy population (71, 183). 
Unlike the other models, however, the effect of male gender was protective (and significant): 
males were at 48% lower risk of CKD in the follow-up period than females.  This is 
consistent with the observed prevalence of stage 3-5 CKD in the general population, where it 
is approximately twice as common in females as males (7.3% and 3.5%, respectively). (184) 
As seen in each of the other models (table 7.11), existing comorbidities, diagnosed at any time 
up to the first 3 months following diabetes diagnosis, increased the risk of the outcome (in 
this case CKD). CHD and stroke increased the risk of CKD by 21% and 14%, respectively.  
Overall, the R
2
 for the 5-year CKD model (R
2
 0.34) was similar to that reported for a CVD 
risk model which was used in clinical practice. (63) This suggests that this model could be 
also be used in clinical practice to predict CKD risk, after appropriate validation [section 
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8.7.2] and perhaps after the inclusion of baseline eGFR as an additional predictor [section 
8.2.2].  
 
Comparison of hazard ratios between models in this study: The observed differences in 
hazard ratios for the same variables between the four models may have two explanations 
(table 7.11). Firstly, the cohorts are not directly comparable, as they each excluded cases with 
the outcome of interest. Also, as CHD, stroke and CKD can have a similar underlying disease 
process, atherosclerosis, the effect of excluding cases with an overt outcome of interest, may 
also exclude cases at risk of the other outcomes in this study. Secondly, other than differences 
caused by case selection, there are likely to be real differences in the effect of covariates, such 
as blood pressure levels at baseline, on each outcome. (40) Lastly, it is important to keep in 
mind when interpreting the hazard ratios for individual covariates, that it is the hazard ratio 
for that variable after all the other covariates have been taken into account. So, for example, 
the hazard ratio for smoking already takes into account the impact of sex and vice versa. 
These models, however, do demonstrate that there are a set of known fixed and modifiable 
risk factors which predict future CVD and CKD risk, and risk of death, within 5 years 
following diabetes diagnosis. Age, gender and comorbid CHD, stroke and CKD predicted 
risk: where their hazard ratios were not statistically significant, they were in the expected 
direction. Smoking, higher HbA1C and high/treated SBP were positively associated with 
increased risk of each outcome, though not always statistically significant. The effect of 
higher BMI predicted an increased risk of CHD and CKD outcomes, but was protective for 
stroke (but not statistically significant) and mortality. The clinical importance of each of these 
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risk factors is discussed below [section 8.7.1 what risk factors make most difference?; section 
8.8 policy implications: clinical issues].    
 
8.2.2 Differences in proportion of variation in outcomes explained by the models 
 
The proportion of variation explained by each of the survival models (the R
2
) varied widely, 
from a maximum of 0.58 for all-cause mortality, to a minimum of 0.09 for the CHD outcome 
model (table 7.12). For clinical populations like the study cohort, with wide age ranges and 
outcomes which are strongly age related, much of the explanatory power of the model will 
reside in the age and age-related variables (e.g. comorbidities present at diabetes diagnosis). 
Age at diagnosis was, therefore, probably the biggest contributor to the proportion of 
variation explained by each of the models. 
A likely explanation for the relative success of the mortality model compared with the other 
outcomes, and CHD in particular, is the completeness and accuracy of recording of each 
outcome in primary care electronic patient records [section 4.6]. Morality in another UK 
primary care database was within 5% of national rates suggesting that the fact of death is well 
recorded in primary care. (130) The definition of CHD used in this thesis, however, was a 
composite outcome which included myocardial infarction (MI) and angina. A sensitivity 
analysis which developed separate models for these outcomes showed that the separate 
models predicted a much greater proportion of variation when separated (R
2
: MI 0.20; angina 
0.13) than when combined (R
2
 0.09) (table 7.12), suggesting that the risk factors had a 
different effect on MI and angina. Even as separate models, they explained one-third or less of 
the variation in outcomes when compared with the mortality model. A recent paper on MI 
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which linked GP, secondary care and disease registry data found that 18% of the MIs 
recorded in the patients’ primary care records could not be validated in the other data sources, 
and a similar proportion of MIs found in the secondary care and registry data could not be 
matched to events recorded in the primary care data. (112) This suggests that there is a 
substantial amount of underrecording and misrecording of MIs and, potentially, other acute 
events such as stroke in primary care electronic patient records. This is likely to have reduced 
the ability of the CHD and stroke models to accurately predict CHD and stroke outcomes, and 
led to the observed low R
2
 observed for the CHD model. The CKD model explained a similar 
proportion of variation as the stroke model (stroke 0.35; CKD 0.34), but would have been 
substantially improved by the inclusion of eGFR at baseline (R
2
=0.66) (table 7.12). This was 
greater than the R
2
 for the mortality model, suggesting that any future versions of the model 
should include baseline eGFR as a predictor. 
 
8.2.3 Clinical characteristics of people newly diagnosed with type 2 diabetes 
 
A byproduct of the decision to develop risk models from the point of diagnosis of diabetes 
was that it also provided estimates of their clinical characteristics at this point (table 7.5). 
These results included comorbidities already present at diabetes diagnosis, clinical 
measurements and current drug treatments. As such it provides a snapshot of the 
characteristics of people diagnosed in the UK in the study period, 1998-2003, and can serve as 
a baseline for comparisons with more recent periods. As the outcomes of interest for the 
prediction models are mainly vascular-related, it is worth noting that one in five already had 
overt vascular-related disease at diabetes diagnosis (mainly CHD and CKD), and that some 
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drug treatments for primary or secondary prevention of CVD were already used by many 
practice patients by the time their diabetes was diagnosed (table 7.5). Of these the most 
common was BP lowering, with 6 in 10 cases already being treated at diagnosis. Patients 
already treated at baseline and those who began BP lowering treatment after diagnosis were 
likely to experience improved outcomes, as shown in previous studies in the diabetic and 
general population. (185, 186) Aspirin was also being used, but was less common at 1 in 4 
cases, perhaps reflecting its use in secondary rather than primary prevention. Given the 
disagreement reported between systematic reviews of aspirin use in primary prevention in 
people with diabetes, it is uncertain if initiation for primary prevention prior to diabetes 
diagnosis would have any benefit over initiation after diagnosis. (24, 187) Lipid lowering 
treatments were the least commonly used CVD prevention drugs at baseline, used by just over 
1 in 8 cases. Given that prolonged statin use is likely to produce larger absolute reductions in 
vascular events, patients initiated on a statin prior to diabetes diagnosis may have seen more 
reduction in outcomes than those who were initiated after diabetes diagnosis. (188) 
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8.3  Study strengths and weaknesses 
 
8.3.1 Strengths 
 
The study cohort was drawn from practices that were representative of the UK population 
and, therefore, was likely to be representative of patients with newly diagnosed diabetes. 
(189-192) Further, a minimal number of potential cases were excluded from the study cohort, 
increasing the likelihood that it was representative of the wider population of patients with 
type 2 diabetes. Only 8.5% of potentially eligible patients were excluded from the study 
cohort: where patients were excluded it was because they did not appear to have type 2 
diabetes or were not followed-up for a minimum of three months following diabetes 
diagnosis.  
The prediction models included risk factors which are known to predict the outcomes of 
interest and which are routinely recorded in general practice. This should ensure that the 
models are applicable to current UK general practice and that the data required to calculate 
these risks are available to practice staff. Some risk factors which may have predicted risk but 
were not routinely recorded in general practice during the period covered by this study were 
HDL cholesterol, waist:hip ratio and ethnicity. The lack of completeness in the recording of 
these risk factors prevented their inclusion in these models. The completeness of recording of 
HDL, and other laboratory results, will have improved since the introduction of electronic 
links with laboratories. (103) The recording of ethnicity for newly registered patients was 
incentivised in QOF, and has led to an improvement in the completeness of recording of 
ethnicity since the end of the period covered by this study. (193, 194) The recording of waist: 
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hip ratio in UK general practice for people with type 2 diabetes, however, is still not high: in a 
currently unpublished study using the THIN primary care database only 18% of patients with 
type 2 diabetes had a waist:hip ratio recorded at any time in their electronic patient record. 
The models presented here are, therefore, as complete as possible, although future updates, 
using more recent clinical data may allow the inclusion of HDL cholesterol and ethnicity as 
predictors. 
The case definition was developed in earlier primary care database studies published by this 
author. (6, 7) The principal authors of that study had full access to the unanonymised free-text 
comments of practice staff. This allowed them to identify a set of Read codes with high 
sensitivity and specificity. This should have ensured that important groups of cases were not 
systematically excluded from the study cohort and have minimised the risk of including 
practice patients who did not have diabetes mellitus. 
The prediction models developed in this study are likely to predict risk more accurately in 
patients with newly diagnosed (incident) type 2 diabetes than other models which were 
developed using prevalent diabetes cases. (44-46, 52-60, 76-81) This study showed that some 
risk factor levels, particularly HbA1C, total cholesterol and systolic BP show steep declines in 
the first years after diagnosis, and that cases became more homogenous over time (figures 7.3, 
A7.2 and 7.4). Previous models which used risk factor data from the years following 
diagnosis are likely to systematically underestimate the level of these risk factors at diabetes 
diagnosis and will, therefore, overestimate the effect of these risk factors on outcomes 
[section 8.9.1 paragraph 4]. This implies that the models presented here could provide a more 
accurate estimate of risk in people with newly diagnosed diabetes than these other models, 
and would, therefore, be more useful in a clinical setting as they would help target treatment 
to those at highest risk. 
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8.3.2 Weaknesses 
 
The time period covered by this study predates the introduction of the Quality and Outcomes 
Framework. Since the mid-2000s general practices in the UK have been financially 
incentivised to meet targets for the monitoring and treatment of patients with diabetes and 
other diseases which are associated with increased cardiovascular risk. This is reported to 
have improved the management of type 2 diabetes compared with the period before its 
introduction (although the initial rate of improvement was not sustained). (16) The clinical 
areas that were incentivised included the control of blood pressure, cholesterol, and HbA1C. 
These three areas saw improvements in risk factor control from 1998 (pre-QOF) compared 
with 2005: a more than doubling in the proportion of patients meeting their target in the case 
of blood pressure and cholesterol. The prediction models developed in this study may 
therefore overestimate the underlying risk of outcomes in people diagnosed with diabetes in 
recent years: patients diagnosed in the post-QOF period will have achieved better control of 
risk factors, and therefore better outcomes following diagnosis than the patients who were 
included in this study. 
The median follow-up period following diagnosis was relatively short at three years: this led 
to a decision to limit the prediction models to five years, to avoid making predictions past five 
years using data from relatively few patients. This may reduce the utility of the prediction 
models in clinical practice as many, though not all, clinical guidelines focus on the level of 
risk over 10 years. (195) Despite this, a five-year period for people in their 60s (the mean age 
at diabetes diagnosis) may be an appropriate time period over which to report results, and five 
year risk is used in the New Zealand risk guidelines. (195) The distinction between five and 
ten year risk may be less important than the distinction between short-term and lifetime risk, 
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and how risk is communicated to patients. (196-199) Short-term risk equations may also 
preferentially identify people who have already accrued substantial risk and miss others who 
might benefit from early preventative treatment, and risk estimates need to be understood by 
patients. (200-205) Identifying the most appropriate risk tools and methods for risk 
communication in patients with type 2 diabetes is beyond the scope of this thesis, but these 
papers suggest that the restriction of the risk models presented here to five years rather than 
ten is less important clinically than how and when the risks are presented, and how patients 
are engaged in their own care. 
Patient turnover may have influenced the results reported in this thesis.  In general practice 
turnover is around 7% per annum on average, though it can be as high as 25% in some areas. 
(206) Also, over half of all home moves in people aged 80 years or over between the 1991 
and 2001 Censuses were from private to communal establishments and were often associated 
with the onset of a chronic illness. (207) Prediction models based on general practice data, 
where cases are censored when they leave their practice, rely on the assumption that the rate 
of failures (e.g. death) is the same in those who are censored as those who remain at their 
current practice until the end of the study period. The above national data suggests that this 
may not be a safe assumption, especially for the oldest age groups, and that the models 
developed in this study may have underestimated the risk of death and the association 
between baseline cardiovascular disease and death. Despite this potential weakness, however, 
the 5-year risk of death in the presence of baseline CVD was very high: 58% higher in 
patients with CHD than without, and 47% higher in patients with stroke than without (table 
7.11). Work is currently in progress to link the THIN database to national death records on 
cause of death and hospital records, including events that occur after patient deregistration. It 
will, therefore, be possible in the future to ascertain if patients who are censored when they 
 148 
 
deregister experience outcomes at a different rate than those who remain registered, and the 
extent of any systematic bias that this might have caused in prediction models developed 
using GP data. 
Relatively few (18%, 3643/20041) of the cases in the study cohort had all their clinical 
measurements recorded (that is, coded in their electronic patient record) within 90 days of 
diabetes diagnosis [section 7.4]. The extent of this missing data meant that additional 
computationally intensive and time-consuming steps had to be taken in selecting appropriate 
methods for dealing with these missing values, increasing the time taken to develop the 
models and decreasing the precision of the estimates (HRs) reported [sections 6.6.3 to 6.6.7]. 
The prediction models presented in this study were developed in parallel for convenience. 
Separate models with their own sets of covariates and interactions may have better predicted 
the individual outcomes, but this would have increased the amount of time taken to build 
these models. As the main aim of the study was to demonstrate that risk factors routinely 
recorded in general practice predict risk in this clinical group, it was decided that a common 
set of predictors would be sufficient to achieve this.  The CHD prediction model would also 
have been improved if it had been possible to separate all CHD outcomes into MI and angina 
subtypes (including those who had both subtypes), as would the CKD model if baseline eGFR 
had been included (table 7.12). Linked primary care and hospital inpatient and outpatient data 
has recently (2013) been made available to researchers using THIN. (107) These might allow 
researchers to distinguish between angina and MI in future models using this linked data 
source. 
The direction of some hazard ratios in some of the prediction models has not been fully 
explained. Higher BMI appeared to be protective for all-cause mortality but increased both 
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CHD and CKD risk: further development of these risk models individually would allow non-
linear effects of BMI to be tested (e.g. using fractional polynomials), though this might be a 
non-trivial task as missing BMI data was multiply imputed for some cases. (208) It may also 
be that this association is clinically plausible: this was discussed earlier in this chapter 
[section 8.2 all-cause mortality prediction model]. The effects of high baseline total 
cholesterol and cholesterol treatment were not statistically significant in three of the four 
models: the point estimates appeared to show increased CHD and CKD risk and a protective 
effect for stroke and all-cause mortality. Further development of these models separately, as 
with BMI, could include a non-linear effect of total cholesterol on each outcome if, like BMI, 
a way to include the multiply imputed missing data can be found. (208) 
Although published after the literature searches carried out as part of this thesis, a recent BMJ 
paper on the validity of acute MI diagnoses recorded in primary care suggests that these 
diagnoses have a positive predictive value of only 92% when compared with a disease 
registry data. (112) Given its relevance to this thesis, it was decided to include it here as it has 
implications for the ascertainment of CHD as a comorbidity and outcome in studies using 
primary care data such as this. The authors conclude that linked primary care, death 
certification, hospital and disease registry data are required to avoid biased ascertainment of 
acute MI outcomes. These kinds of external data were not available at the time the models in 
this thesis were developed, but, as mentioned above, linked data is being introduced for use 
with THIN primary care records. Future studies could make use of some of these data sources 
to validate existing GP data or identify additional outcomes.  
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8.4  Comparison with other cohorts, models and study designs 
 
This section compares the results of and methods used in the current study with previous 
studies with respect to the generalisability of its results to other UK patients with newly 
diagnosed type 2 diabetes and the external validity of the results.  
The first set of comparisons are intended to establish the generalisability of the current study 
cohort to other patients with newly diagnosed Type 2 diabetes in terms of demography, 
comorbidity and frequency of outcomes. The studies used in these comparisons were UK-
based where possible.  
The next set of comparisons was intended to externally validate each prediction model, that is, 
the hazard ratios for the demographic and clinical predictors included in each model. The 
models used for comparison were based on cohorts of cases with newly diagnosed type 2 
diabetes where possible. 
The last part of this section addresses two major methodological differences between the 
current study and the other prediction model studies identified from the literature. The first of 
these differences was the decision to restrict the cohort to cases who were observed from the 
point of diabetes diagnosis. The second was the method for dealing with missing data adopted 
in the current study. 
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8.4.1 Cohort comparisons: baseline levels of risk factors and frequency of outcomes 
 
In order to understand whether or not the results in this thesis are generalisable, baseline 
levels of risk factors and subsequent frequency of outcomes were compared to the literature. 
Tables 8.1 to 8.3 provide comparisons between the current study cohort and previous studies. 
These comparisons consist of the baseline demographic and clinical characteristics of people 
with newly diagnosed type 2 diabetes, and the frequency of selected outcomes at and 
following diabetes diagnosis. The present study cohort was restricted to specific subgroups 
where required to provide like-for-like comparisons between the published results and the 
other studies. Some external studies reported results for type 1 and type 2 diabetes combined, 
or data for prevalent rather than newly diagnosed diabetes cases. These are indicated in the 
tables, where applicable. 
Demography - age and gender of cases: As can be seen from the hazard ratios in the 
models, age and sex are amongst the most important risk factors found. Table 8.1 compares 
the age and sex of the study cohort with results from external studies in order to judge 
generalisability and comparability of results. The mean age at diagnosis of diabetes in the 
current study cohort was the same as that for the Poole study (both were 64 years), and higher 
than that for the South Tees study (58 years). (153, 209) The younger age of the South Tees 
cohort is likely to be explained by the inclusion of cases with type 1 diabetes. The mean age at 
diagnosis in the current study was also similar or the same as that found in the UKPDS (55 
and 53, respectively) and Tayside studies (63 and 62, respectively), once the current study 
cohort was restricted to match the external studies. (59, 133) 
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The proportion of cases that were male in the study cohort was similar to that found in the 
South Tees study (54% and 56%, respectively). (153) The proportion of cases that were male 
in the UKPDS and Tayside studies were also similar to that found in the current study, once 
the study cohort was restricted to match the external studies’ inclusion criteria. (59, 133) 
The similar results reported for this and other cohorts of patients with diabetes suggest that 
the study cohort was representative of the wider population of patients with type 2 diabetes in 
terms of age and gender. Given the limited age range included in the UKPDS, it is also likely 
that the current study cohort was in fact more representative of the wider population of people 
with type 2 diabetes. These imply that the models developed in this study would be useful in 
clinical practice: they would accurately estimate the risk at diabetes diagnosis of these 
outcomes in the wider population of people with type 2 diabetes.  
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Table 8.1 Comparisons with previous studies: age and gender of cases 
 Study Note 
Study 
period 
  
      
    Mean (SD) 
Age Current study  (all ages) 1998-2003 64 (12) 
 South Tees (153) * 1994 58  
 Poole (209)  (all ages) 1996-1998 64 (13) 
      
 Current study  (ages 35-65) 1998-2003 54.5 (8) 
 UKPDS (133) (ages 25-65) 1977-1991 53.3 (9) 
      
 Current study (excl. prior CHD) 1998-2003 62.6 (13) 
 Tayside (59) (excl. prior CHD) 1995-2004 61.7 (12) 
      
 
   
Percentage 
of cases 
 
Male Current study (all cases) 1998-2003 54  
 South Tees (153) * 1994 56  
      
 Current study  (ages 35-65) 1998-2003 59  
 UKPDS (133) (ages 25-65) 1977-1991 61  
      
 Current study (excl. prior CHD) 1998-2003 52  
 Tayside (59) (excl. prior CHD) 1995-2004 52  
      
* Included type 1 diabetes. Included prevalent cases of diabetes.  
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Prevalence of comorbidities at diagnosis of diabetes: Co-morbidities had a large influence 
on prognosis in the models developed in this thesis, particularly in the mortality model. Table 
8.2 compares the prevalence of CHD, stroke and CKD at diabetes diagnosis in the current 
study cohort with external studies. 
The prevalence of CHD in the current study cohort (19.8%) was much higher than that 
reported for the DAI study in Italy (3.3%) and the study by Uusitupa in Finland (38%), but 
was very similar to the Ruigomez GPRD study, once the age range of the current study was 
restricted to match that used in the GPRD study (17.3% and 17.0%, respectively). (210-212) 
The prevalence of stroke found in the French drug trial reported by Cathelineau was 
substantially lower than that found in the current study (1.6% and 6.2%, respectively). (213) 
After the restriction of the current study to the age range, the prevalence of stroke in the 
UKPDS was lower than that that found in the current study (0.8% and 3.0%, respectively). 
(46) However, it is not clear from the report if the 37 UKPDS stroke cases were the complete 
prevalent stroke population, or if others had been excluded at an earlier point. This may be 
likely as the original UKPDS study excluded cases with more than one previous major 
vascular event. (88) Lastly, the Ruigomez GPRD study reported a similar prevalence of prior 
stroke after restriction of the current cohort (4.7% and 4.4%, respectively). (212)  
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Table 8.2 Comparisons with previous studies: prevalence of comorbidities at diagnosis 
of diabetes 
 Study Note 
Study 
period 
Percentage 
of cases 
     
CHD Current study  (all ages) 1998-2003 19.8 
 DAI, Italy (210)  1998-1999 3.3 
 Uusitupa, Finland (211)  1979-1981 38 
     
 Current study (ages 30-74) 1998-2003 17.0 
 Ruigomez, GPRD (212) (ages 30-74) 1990-1992 17.3 
     
Stroke Current study  (all ages) 1998-2003 6.2 
 Cathelineau, Fra.  (213)  1992-1995 1.6 
     
 Current study (ages 35-65) 1998-2003 3.0 
 UKPDS (46)  (ages 25-65) 1977-1991 0.8 
     
 Current study (ages 30-74) 1998-2003 4.4 
 Ruigomez, GPRD (212) (ages 30-74) 1990-1992 4.7 
     
CKD Current study  (all ages) 1998-2003 22 
 South Tees (153) * 1994 32 
 Wolverhampton (214) ** 2002-2003 30 
 Israel (215) ** 1999-2003 29 
     
 Current study (ages 30-74) 1998-2003 16 
 Ruigomez, GPRD (212) (ages 30-74) 1990-1992 1.3 
     
* Included type 1 diabetes. Included prevalent cases of diabetes. 
** Included prevalent cases of diabetes.  
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The prevalence of CKD at diagnosis of diabetes was 22% in the study cohort. The South Tees 
study reported a higher CKD prevalence (32%) in a cross-sectional cohort which included all 
diabetes cases in a region (both newly diagnosed (incident) diabetes cases and prevalent cases 
which had been diagnosed in previous years). (153) A similar CKD prevalence was reported 
in a study that used a regional diabetes register in Wolverhampton (30%), and among 269 
prevalent diabetes cases in Israel (29%). (214, 215) These higher figures are consistent with 
the expected decrease in eGFR within individuals over time following a diagnosis of diabetes. 
The Ruigomez GPRD study reported a substantially lower prevalence of CKD than the 
current study, even after restriction of the current cohort (1.3% and 16%, respectively). (212) 
However, its definition of CKD required a diagnosis of albuminuria, proteinuria, renal failure, 
diabetic nephropathy or metabolic disorder, which will have only included cases where there 
was evidence of significant chronic kidney damage or established renal failure. 
Although there were differences between the prevalence of comorbidities with non-UK 
studies, the prevalence of CHD, stroke and CKD was similar to that reported in more recent 
UK data. The strength of this evidence is weakened, however, for CHD and stroke, as both 
sets of results came from the GPRD: there was an overlap of approximately 50% in the 
practices contributing to that database and THIN. 
Comorbidities were found to be highly predictive of each outcome in this study and were 
common at diabetes diagnosis. Unlike the clinical trials and observational studies from the 
UK and other countries, the models developed in this study included patients regardless of 
their health status and age, and provide UK-wide coverage. The current study models are 
more likely to be representative of patients seen in UK clinical practice in terms of 
comorbidity and age than these other studies, and more likely to accurately estimate baseline 
risk in the UK, resulting in models which can better predict risk in clinical practice. 
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Proportion of cases with outcomes in follow-up period: Table 8.3 compares the proportion 
of cases with each outcome in the current study with results reported for similar studies. A 
total of 5.5% of cases were diagnosed with or died from CHD during the follow up period in 
the current study (mean follow-up: 3.0 years). One study using the Tayside diabetes register 
reported that 5.3% of their incident cases of diabetes developed CHD during their 4.1 year 
follow-up period. (155) This is roughly equivalent to 3.6% over the period observed in the 
current study. This lower figure may be explained in part or in full by the younger age of the 
Tayside cohort (64 years and 55 years at diagnosis). 
A total of 1.9% of cases were diagnosed or died from a stroke during the follow-up period 
(mean follow-up: 3 years). The estimated percentage of stroke outcomes in the UKPDS 
cohort was 1.2% over the first three years. (46) The equivalent percentage for the current 
study was close to this, once it was restricted to match the UKPDS age range (0.9%). The 
incidence of stroke also fell in the wider population between the period covered by the 
UKPDS and the current study (from 1981-84 to 2002-04). (216) This 29% decrease in 
incident stroke in the wider population is very similar to the difference between stroke 
occurrence in the UKPDS cohort and the current study (25%). 
There was one non-UK study that reported changes in eGFR over time, but no studies 
reported the proportion of cases developing CKD after diagnosis of diabetes, so it was not 
possible to externally validate these particular results from the current study. (217)  
A total of 7.5% of current study cases died during the follow-up period (mean follow-up: 3 
years) (table 7.5). The Poole Diabetes Study reported that 20% of their incident cases of 
diabetes died during their 7.5 year follow-up period. (156) This is roughly equivalent to 8% of 
cases dying over a three year period, close to that observed in the current study. 
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The number of outcomes observed in the study cohort for CHD, stroke and all-cause mortality 
was similar to other published studies that used UK data: where differences were observed, 
they could be accounted for by differences in the age of each study population (CHD), or by 
differing study periods (stroke). This suggests that the study cohort was representative of the 
wider population of people with type 2 diabetes and, therefore, appropriate to use to assess 
prognosis. 
  
 159 
 
Table 8.3 Comparisons with previous studies: proportion of cases with outcomes in 
follow-up period 
 Study Note Study period 
Percentage of 
cases 
     
CHD Current study  (all ages) 1998-2003 5.5  
 Tayside (155)   3.6 * 
      
Stroke Current study  (all ages) 1998-2003 1.9  
      
 Current study (ages 35-65) 1998-2003 0.9  
 UKPDS (46) (ages 25-65) 1977-1991 1.2 ** 
      
CKD (No external comparisons available) 
      
Death Current study  (all ages) 1998-2003 7.5  
 Poole (156)   8.0 *** 
     
* Percentage estimated at 2.8 years based on percentage reported by study at 4.1 years (5.3%). 
** Percentage estimated at 3 years based on percentage reported by study at 10.5 years (4.2%). 
*** Percentage estimated at 3 years based on percentage reported by study at 7.5 years (20%). 
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8.4.2 Model comparisons: comparison of hazard ratios with other diabetes-specific and 
non-diabetes specific risk models  
 
Introduction: This section attempts to externally validate the estimates of individual model 
predictors in the current study using comparisons with the estimates reported for earlier 
models. The hazard ratios for each of the current study models are listed in tables 8.4 to 8.7, 
along with equivalent results from other study models. The features of the comparison study 
populations are also listed where they differed from the current study in important ways, and a 
full list of the predictors included in each external model is provided as these also differed 
from study to study. It would have also been useful to compare the proportion of variation 
explained by each model (the R
2
), but these data were only reported in the current study. 
It should be noted that where a predictor reported by the external models does overlap with 
one from the current study, any dissimilarity in their values could be due to a number of 
factors. Each model is multivariate and includes a distinct set of predictors, spans different 
time periods, national populations and can be restricted to specific age-ranges. They also 
differ in terms of the target population: some are aimed at the wider population and include 
non-diabetics, and others include cases with type 1 diabetes or prevalent cases of type 2 
diabetes. Therefore, unless those differences are repeated across a set of external models, it is 
unlikely that robust explanations for these differences can be identified. Despite this 
limitation, these external comparisons may provide general confirmatory or contradictory 
evidence about the expected importance or strength of specific predictors, and may also serve 
to highlight strengths or weaknesses of the current and external models in terms of 
generalisability to current clinical settings.  
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Three models derived from the UKPDS feature in the hazard ratio comparisons below. (45, 
46, 81) They provide concrete examples of the difference between the current study cohort 
and external study cohorts. The UKPDS included cases diagnosed with diabetes between 
1977 and 1991: the equivalent period for the current study was 1998-2003. The UKPDS was 
also restricted to cases aged 25 to 65 years at diabetes diagnosis: over half the incident cases 
of diabetes included in the current study cohort were aged over 65 years. The UKPDS models 
predict outcomes between 4 and up to 15 years following diabetes diagnosis: the current study 
was developed on outcomes observed between three months and five years following 
diagnosis.  
In summary, the current study models for CHD, stroke and all-cause mortality included 
calendar periods, follow-up periods and age ranges not included in the UKPDS models: it is 
quite possible that estimates for an individual predictor may differ, yet both accurately 
described the effect of the predictor on the types of cases included in their respective cohort. It 
also indicates that the current study models for these outcomes are likely to be representative 
of the current UK population with type 2 diabetes, and, in particular, are valid for estimating 
risk in the years immediately following diabetes diagnosis, unlike the equivalent UKPDS risk 
models. It could, therefore, be argued that the models derived in this thesis are more pertinent 
to current clinical practice than other models including those from UKPDS. 
CHD: Five CHD risk prediction models specific to people with diabetes were identified from 
the literature (table 8.4). (44, 45, 57, 59, 60) None of these models used the full set of 
covariates included in the current study model. All but one (45) included prevalent diabetes 
cases, and two included younger cases only (aged 45-64 and 25-65 years, respectively). (45, 
60) Comparisons were, therefore, restricted to studies which reported hazard ratios for one or 
more overlapping predictors.  
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Three studies reported hazard ratios for age, male sex and current smoking. (45, 57, 59) One 
of these studies also reported a hazard ratio for HbA1C. (45) A further one reported hazard 
ratios for current smoking and BMI. (60) The values reported by the Donnan model (59) for 
this and all common predictors were opposite to that reported by all other studies, including 
the current study.  It may be that this is related to their reporting model coefficients rather 
than more readily interpretable estimates such as hazard ratios. No further comparisons with 
this study will be made in this text to avoid unnecessary repetition of its counterintuitive 
results. 
The hazard ratio for male sex in the current study was 1.36 (95% CI 1.18-1.56): this was in 
the same direction but differed in level from the results reported for the two other studies: 
Yang (HR 2.01; 95% CI 1.66-2.63) and Stevens (HR 1.69; 95% CI 1.52-1.88). (45, 57) This 
was lower than the hazard ratio reported by both studies. However the Yang model was 
developed with a Hong Kong population which may not be directly comparable with the UK 
population and the 95% CI estimated by the current study overlapped with that of the model 
reported by Stevens suggesting that the observed differences were not statistically significant. 
The hazard ratio for each additional year of age in the current study was 1.02: this was similar 
to the results reported by both studies that reported comparable data. (45, 57) The Yang model 
(57) reported a hazard ratio of 1.03 (95% CI 1.01-1.04) for age and the Stevens model 
reported a hazard ratio of 1.06 (95% CI 1.05-1.07). The estimate for the current study did not 
lie within the 95% confidence interval reported by the Stevens model.  The inclusion of stroke 
as a predictor in the current model, but not in the Stevens model may account for some of this 
difference: the risk of stroke increases with age, and it’s inclusion in a multivariate model 
with age would tend to reduce the hazard ratio for age itself.  
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The hazard ratio for smokers in the current study was 1.26. The hazard ratio for the other 
models also indicated that smoking increased the risk of CHD (45, 57, 60). The estimate 
reported by Yang was 1.55 (96% CI 1.08-2.22), by Folsom was 1.05 for males and 1.57 for 
females (95%CIs nor reported); and by Stevens was 1.35 (95% CI 1.11-1.59), respectively. In 
each case the estimate reported by the current study lies within the 95% confidence interval 
reported by the comparison studies or the gender-specific estimates that they reported. 
Comparable results for HbA1C and BMI were reported by a single study each. (45, 60) The 
hazard ratio for a 1% increase in HbA1C in the current study was 1.07. This is close to, but still 
outside, the lower boundary of the 95% confidence interval for the estimate reported by 
Stevens (HR 1.18; 95% CI 1.11-1.25). (45) The hazard ratio for a 1 kg/m
2
 unit increase in 
BMI was 1.02 in the current study. Folsom (60) reported a hazard ratio of 0.95 for BMI for 
both men and women, but their model included waist to hip ratio which may have led to a 
lower hazard ratio for BMI than would have been produced by a model with BMI alone. 
There were few prior CHD models which produced comparable hazard ratios. Where they did 
there were some differences which could not be directly accounted for (age, HbA1C): both of 
these were from the UKPDS model reported by Stevens. (45) However, overall, these 
comparisons suggest that the CHD prediction model created as part of the current study 
produced equivalent results to other prediction models based on UK data  
Stroke: Two stroke risk prediction models specific to people with diabetes were identified 
from the literature (table 8.5). (46, 58) As with CHD no other model used the full set of 
covariates included in the current study model. The inclusion of CHD and CKD (outcomes 
which increase with age) as predictors, therefore, might tend to result in a lower hazard ratio 
for age itself in the current model compared with models which did not include them.  
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Yang (58) reported comparable results for age, prior CHD and HbA1C, while Kothari (46) 
reported age, male gender and current smoking. The hazard ratio for male gender was positive 
(HR 1.15) but not statistically significant in the current study. Yang (58) did not report an 
estimate for the effect of gender indicating that it, like the current study, was not statistically 
significant. The equivalent result for Kothari (46) was 1.42 (95% CI 1.09-2.06). This 95% 
confidence interval was relatively wide and overlapped with the estimate from the current 
study, suggesting that the observed difference was non-significant.  
The hazard ratio for age in the current study was 1.06. The equivalent result from the Yang 
model (58) was 1.07 (95% CI 1.06-1.08), and the result from the Kothari (46) model was 1.09 
(95% CI 1.07-1.12). The estimate for the current study lay within the 95% confidence 
intervals reported by both Yang and Kothari.  
The current study and the Kothari (46) stroke model produced similar estimates of the effect 
of current smoking. The hazard ratio for smoking in the current study was 1.42. This was 
within the 95% confidence intervals reported by the Kothari model (HR 1.55; 95% CI 1.08-
2.01). The hazard ratio for prior CHD in the current study (HR 1.50) was also within the wide 
95% confidence intervals reported by Yang (58) (HR 1.76; 95% CI 1.15-2.69).  
A 1% increase in HbA1C did appear to increase the risk of stroke to a small extent (HR 1.01) 
in the current study, but was not statistically significant. HbA1C did not achieve statistical 
significance in the stepwise selection method used to develop the model reported by Kothari 
(46) either, but was significant and positive in the model reported by Yang  (HR 1.09; 95% CI 
1.02-1.08), although the lower boundary of the 95% confidence interval indicated that its 
importance may be small in clinical practice (a 2% increase in the risk of stroke for each 
additional unit increase in HbA1C). 
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Overall, gender did not seem to influence the risk of stroke in the current study model: the 
results of the two other comparable models did not contradict this. (46, 58) A similar pattern 
was seen for age, smoking and HbA1C: the effect of each of these was to increase risk and 
there was an overlap between the confidence intervals for the current and comparison studies 
suggesting that any observed differences were non-significant. This suggests that the current 
study model for stroke has face validity, at least for the set of predictors that could be 
compared. 
CKD: Only three of the nine CKD prediction models identified in the literature search 
analysed their data as a time-to-event/ survival model (table 8.6). (67-75) The remaining six 
used a logistic model which does not produce directly comparable results. (67, 68, 70, 72, 74, 
75) Of the three models which reported their results as hazard ratios (69, 71, 73), two reported 
at least one predictor which overlapped with the current study. (69, 73).  
Male gender was associated with an increased risk of CKD in the current study and the 
prediction model published by Hanratty. (69) The hazard ratio was higher in the current study 
(HR 0.52) than in the Hanratty model (HR 0.63; 95% CI 0.59-0.66) and did not overlap with 
its 95% confidence interval. The effect of age was published by both remaining studies: the 
hazard ratio for each year increase in age in the current study was 1.06. This is the same as 
that reported by Hanratty (HR 1.06; 95% CI 1.05-1.07), and was slightly lower but 
overlapped the 95% confidence interval reported by Chien (HR 1.08; 95% CI 1.07-1.10). (73) 
The effect of prior CHD was similar in both the current study (HR 1.21) and Hanratty (HR 
1.24; 95% CI 1.15-1.33). The effect of prior stroke in the current study (HR 1.14) was also 
similar to that reported by Hanratty (HR 1.08; 95% CI 0.95-1.22), and substantially lower 
than, but within the wide 95% confidence intervals reported by Chien (HR 3.46; 95% CI 1.27-
9.38). The effect of the last common predictor, increasing BMI in the current study, like age, 
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was the same as that reported by Hanratty (HR 1.01 for both), and within the 95% confidence 
intervals reported by Chien (HR 1.12; 95% CI 1.01-1.12).  
Despite the differences in the populations used in the current study and in the models used in 
these comparisons, similar results were seen for age, prior CHD and BMI. The sole study 
which produced comparable results for male gender was in the same direction but 
approximately 20% higher than the current study. This level of difference may be accounted 
for by other differences between the study populations and the predictors included in each 
model. Overall, this suggests that the current study model for CKD has face validity, at least 
for the set of predictors that could be compared. 
All-cause mortality: As previously discussed, the results from the current study for mortality 
appeared to be the most robust. Six other all-cause mortality prediction models intended for 
use in the diabetic population were identified from the literature (table 8.7). (76-81) Two of 
these models had two predictors in common with the current study (79, 80), and a further two 
had just one predictor in common (HbA1C). (76, 78) The Skriver model (77) reported results 
for HbA1C as a set of categorical predictors rather than a single continuous one, and the Clarke 
model (81) published a logistic model for mortality, and so were not comparable with the 
current study. 
Male gender was associated with a similar increased risk of death in the current study (HR 
1.29) and the prediction models published by Kerr (HR 1.20; 95% CI 1.0-1.5) and Currie (HR 
1.34; 95% CI 1.26-1.43), and lay between the 95% confidence intervals for each of these 
studies. (79, 80) The hazard ratio for each additional year of age in the current study was 1.09: 
this was very close to the ratio of 1.08 (95% CI 1.08-1.09) published by Currie.  
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The impact of smoking on the risk of death in the current study (HR 1.65) was lower than that 
reported by the Kerr model (HR 2.1; 95% CI 1.5-2.8) which, like the current study, included 
incident cases of type 2 diabetes. (79) The comparison group in the Kerr model was never-
smokers, unlike the current study, where it was with ex- and current smokers. This and the 
overlap of the confidence intervals from the Kerr study with the current study estimate 
probably go some way to explaining differences in the hazard ratio estimate between the two 
studies.  
The hazard ratio for a one unit increase in HbA1C on the risk of death in the current study was 
1.09, less than that reported for the Xu (HR 1.13; 95% CI 1.06-1.20) (76) and Andersson (HR 
1.16; 95% CI 1.09-1.23) (78) models, but overlapped with their 95% confidence intervals. 
Overall, the estimates reported for the current study model for all-cause mortality were 
equivalent to the other similar models for comparable predictors. (76-81) The one instance 
where they were dissimilar (smoking), may be explained by differences in the way smoking 
status was categorised.  This suggests that this prediction model has face validity when 
compared with equivalent models, at least for this common set of predictors. 
Summary: A total of 16 comparable models were identified from the literature: between two 
and six external models for each of the current study models. (44-46, 57-60, 69, 71, 73, 76-
81) Only four of the 16 external model cohorts consisted of newly diagnosed cases of type 2 
diabetes (45, 46, 79, 81); six used prevalent cases of type 2 diabetes (57-60, 77, 78, 80), two 
used prevalent type 1 and type 2 cases (44, 76), and three included people without diabetes 
(69, 71, 73).  
The most commonly reported comparable predictors from these earlier studies were age, 
gender and smoking status. (45, 46, 57, 59, 60, 69, 73, 79, 80) Comorbidities at baseline 
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(CHD and stroke, but not CKD), HbA1C, and BMI were reported for between three and six 
external models. (45, 58, 60, 69, 73, 76, 78, 81) No other studies reported results for the effect 
of systolic BP, cholesterol or drugs used in their treatment in a form which could be compared 
with the current study models, and none included the level and treatment of all these risk 
factors. Given the importance of blood pressure and cholesterol as risk predictors (table 7.11) 
and the prevalence of these treatments at diagnosis of diabetes (table 7.5), this suggests that 
the current models would also be more useful in clinical practice. 
The results for the effect of age, gender and current smoking at baseline in the current study 
models were in the same direction and on a similar scale to the estimates published in earlier 
models. The effect of CHD and stroke as comorbidities was also similar to that reported by 
other models. The estimate for HbA1C on the risk of CHD, stroke and all-cause mortality was 
lower than that reported by other studies: it lay within the reported confidence intervals in the 
comparison studies for all-cause mortality, but just outside those for CHD and stroke. 
Comparisons of the effect of BMI on risk were not as consistent as for other predictors:  it 
was higher than the sole external model for CHD that reported a hazard ratio for BMI 
(Folsom) (60), but the same as or within confidence intervals of the two external models for 
CKD prediction. However this difference may be explained by the predictors included in each 
model: in addition to BMI, the Folsom model included waist to hip ratio. This may have led 
to a lower hazard ratio for BMI than would have been produced by a model with BMI alone 
and explain the difference between the results of the two models. 
Overall, despite the many sources of variation between the models generated in the current 
study and external models, the effect of age, gender, smoking, prior CHD and stroke did not 
differ consistently. However, where they did differ, the size of the difference was relatively 
small and may plausibly be due to differences in the membership of their respective cohorts. 
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It was, unfortunately, not possible, however, to externally validate the current study hazard 
ratios for CKD as a comorbidity or the blood pressure and cholesterol-related predictors.  
These predictors (systolic BP, total cholesterol and their respective drug treatments) were 
entered into their respective models as categorical terms with treatment interaction. It would 
have been useful to validate these estimates as many are relatively large (a 7%-69% change in 
risk over 5 years) but were not statistically significant. It remains unclear, as a result, if they 
are likely to be useful predictors of future risk and it is unlikely that a future study could 
achieve substantially greater power to give a clinically useful, suitably precise, estimate for 
these predictors (as the current study used one of the UK’s three large GP databases as the 
data source). 
Although the four prediction models produced by the current study appear to have face 
validity following comparisons with prior prediction models, their external validity hasn’t 
been established. It would be necessary to go beyond the scope of the current study to validate 
it using a second set of primary care data or by using it prospectively in clinical practice 
[section 8.7.2]. 
  
Table 8.4 Comparison of hazard ratios with other CHD prediction models specific to people with diabetes 
Lead author 
(reference) 
Study population Hazard ratios Predictors in model 
Male Age Smoker Stroke CKD HbA1C BMI SBP 
>= 140 
mmHg 
or drug 
trt. BP 
Total chol. 
>= 4 mmol/L 
Total chol. 
>=4 
mmol/L 
and on lipid 
lower.drug 
On lipid 
lowering 
drug 
 
              
Current 
study 
Incident type 2 diabetes 
(age 35+) 
1.36 1.02 1.26 1.09 1.13 1.07 1.02 1.41 1.38 0.98 1.79 (see column titles) 
Yang (57) Prevalent type 2 diabetes  
(free of heart failure) 
2.01 1.03 1.55 - - - - - - - - Age, diabetes duration, sex, 
smoking, eGFR, albumin:creatinine 
ratio, non-HDL cholesterol, 
total:HDL cholesterol ratio, HbA1C, 
Systolic BP 
Donnan  (59) Prevalent type 2 diabetes 
with complete risk factor 
data 
0.73 0.97 0.76 - - - - - - - - Age at diagnosis, duration of 
diabetes, HbA1C, smoking, sex, 
systolic BP, treated hypertension, 
total cholesterol, height 
Folsom (60) Prevalent type 2 diabetes,  
(aged 45-64 years) 
(men and women modelled 
separately) 
- - 1.05(m) 
1.57(f) 
- - - 0.95(m) 
0.95(f) 
- - - - Age, age-squared, race, smoking, 
total cholesterol, HDL cholesterol, 
systolic BP, use of 
antihypertensives, smoking status. 
BMI, waist:hip ratio, heart rate, 
physical activity, FEV, Keys score, 
tobacco pack-years, creatinine, 
albumin, factor VII, WBC, LVH, 
carotid IMT factor VIII, von 
Willebrand factor 
Stevens (45) Incident type 2 diabetes  
(aged 25-65, no recent 
history of CHD)  
(model data was from 4 
years post diagnosis) 
1.69 1.06 1.35 - - 1.18 - - - - - Age at diagnosis, sex, ethnicity, 
smoking, HbA1C, systolic BP, 
total:HDL cholesterol ratio, duration 
of diabetes 
Yudkin (44) Prevalent type 1, type 2 
diabetes 
(model coefficients/ hazard 
ratios not published) 
- - - - - - - - - - - Age, sex, smoking, 
microalbuminuria, total:HDL 
cholesterol ratio 
  
Table 8.5 Comparison of hazard ratios with other stroke prediction models specific to people with diabetes 
Lead author 
(reference) 
Study population Hazard ratios Predictors in model 
Male Age Smoker CHD CKD HbA1C BMI SBP 
>= 140 
mmHg 
or drug 
treated 
BP 
Total chol. 
>=4 
mmol/L 
Total 
cholesterol 
>= 4 mmol/L 
and on lipid 
lowering drug 
On lipid 
lowering 
drug 
 
              
Current study Incident type 2 diabetes 
(age 35+) 
(1.15) 1.06 1.42 1.50 (1.17) (1.01) (0.99) 1.80 (0.90) (1.22) (0.63) (see column titles) 
Yang  (58) Prevalent type 2 diabetes 
 
n/s 1.07 n/s 1.76 - 1.09 - - - - - Age, HbA1C,  albumin:creatinine 
ratio, CHD, sex, smoking, SBP, 
total:HDL cholesterol ratio 
Kothari (46) Incident type 2 diabetes  
(aged 25-65, no recent or 
multiple CHD events, 
followed-up from 4 years 
after diabetes diagnosis) 
1.42 1.09 1.55 - - - - - - - - Age at diagnosis, duration of 
diabetes, sex, smoking, systolic BP, 
total:HDL cholesterol ratio, atrial 
fibrilation 
 
  
  
Table 8.6 Comparison of hazard ratios with other CKD prediction models for wider population 
Lead author 
(reference) 
Study population Hazard ratios Predictors in model 
Male Age Smoker CHD Stroke HbA1C BMI SBP 
>= 140 
mmHg 
or drug 
trt. BP 
Total 
chol. >= 
4 
mmol/L 
Total 
chol. >= 
4 mmol/L 
and on 
LLD 
On 
lipid 
low. 
drug 
(LLD) 
 
              
Current study Incident type 2 
diabetes (age 35+) 
0.52 1.06 (1.10) 1.21 1.14 1.03 1.01 1.45 (1.46) (0.64) (1.69) (see column titles) 
Hanratty (69) Hypertensive adults 0.63 1.06 - 1.24 1.08 - 1.01 - - - - Age, gender, race/ethnicity, baseline eGFR, 
SBP, HDL cholesterol, BMI, diabetes, CHD, 
CVD, heart failure, PVD 
Chien (73) Wider population - 1.08 - - 3.46 - 1.06 - - - - Age, BMI, diastolic BP, type 2 diabetes, stroke 
Hippisley-Cox (71) Wider population 
(ages 35-74) 
(fractional polynom. 
or categorised 
values reported) 
- - - - - - - - - - - Age, ethnicity, deprivation, smoking, BMI, 
SBP, diabetes type, rheumatoid arthritis, CVD, 
treated hypertension, congestive cardiac failure, 
PVD, NSAID use, FH of kidney disease, 
systemic lupus erythematosis, kidney stones 
 
Studies where a logistic model was used to predict future risk (no direct comparisons with hazard ratios from current study possible) 
Lead author (ref) Study population Predictors in model 
   
O'Seaghdha (67) Wider population (ages 30-62) Age, diabetes, hypertension, baseline estimated glomerular filtration rate, albuminuria 
Alssema (68) No type 2 diabetes, no CVD (ages 25-85) Age, smoking, use of antihypertensives, use of lipid-lowering drugs, BMI, waist circ., FH <65 years of MI/stroke, FH diabetes, hist. of gest. 
diabetes 
Halbesma (70) Wider population (ages 28-75) 
 
Baseline eGFR, age, urinary albumin excretion, systolic BP, C-reactive protein, and known hypertension 
Hanratty (72) Hypertensive adults (age 21+) Age, sex, race/ethnicity, marital status, language, diabetes, vascular disease, heart failure, dyslipidaemia, major psychiatric diag., substance abuse, 
baseline eGFR 
Kshirsagar (74) Wider population (ages 45+) Age, sex, race/ethnicity, anaemia, CVD, diabetes, heart failure, PVD, HDL cholesterol 
Fox (75) Wider population (ages 30-62) Age, sex, baseline eGFR, BMI, smoking, diabetes, systolic BP, hypertension, hypert. treatment, total chol., HDL, impaired fasting glucose 
  
Table 8.7 Comparison of hazard ratios with other all-cause mortality prediction models specific to people with diabetes 
Lead author 
(reference) 
Study population Hazard ratios Predictors in model 
Male Age Smoker CHD Stroke CKD HbA1C BMI SBP >= 
140 
mmHg or 
treat. BP 
Total 
chol. >= 
4 
mmol/L 
Tot. chol. 
>= 4 &  
on LLD 
On 
lipid 
low. 
drug  
 
               
Current study Incident type 2 
diabetes 
(age 35+) 
1.29 1.09 1.65 1.60 1.47 1.33 1.09 0.98 (1.07) (0.61) (1.69) 0.41 (see column titles) 
Kerr (79) Incident type 2 
diabetes 
1.20 - 2.10 - - - - - - - - - Age group, sex, year of diagnosis, HbA1C 
category at 3 months, systolic BP, smoking 
Currie (80) Prevalent type 2 
diabetes, on 
combination oral 
antidiabetic treatment 
or insulin 
(aged 50+) 
1.34 1.08 - - - - - - - - - - Age, sex, smoking status, cohort (combination 
therapy or insulin initiated), HbA1C, mean total 
cholesterol, LVD, Charlson Index 
Xu,(76) Prevalent type 1 and 
type 2 DM (age 65+) 
- - - - - - 1.13 - - - - - Age, sex, education, smoking, alcohol use, 
exercise, CVD, BMI, total cholesterol, HbA1C 
Andersson (78) Prevalent type 2 
diabetes, high BMI 
and high CVD risk 
 
- - - - - - 1.16 - - - - - Age, sex, randomised treatment assignment 
(sibutramine), diabetes duration, history of: 
arterial hypertension/congestive heart 
failure/CVD/revascularisation, ethnicity, 
tobacco use, SBP, DBP, heart rate, HbA1C, 
BMI, HDL chol., LDL chol., urine 
albumin/creatinine ratio and use of insulin, 
metformin, thiazolidinediones and 
sulfonylureas 
Skriver (77) Prevalent type 2 
diabetes (HR for 
HbA1C categories 
reported only) 
- - - - - - - - - - - - Age, sex, diabetes duration, mean annual 
HbA1C at baseline, CVD, arteriosclerosis, acute 
complication of diabetes, retinopathy, 
nephropathy, MI, stroke, neuropathy 
               
Study where a logistic model was used to predict future risk (no direct comparisons with hazard ratios from current study possible) 
Lead author (ref) Study population Predictors in model 
Clarke (81) Incident type 2 diabetes (aged 25-65) Age, sex, smoking status (ever vs never), HbA1C, total:HDL cholesterol ratio, MI, renal failure, amputation 
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8.5 Other analysis methods 
 
Understanding the relevance of the present study requires comparison to the methods used 
elsewhere as well as the comparative results. Sixteen of the 23 studies identified from the 
literature used time-to-event statistical models like the current study. (44-46, 57-60, 69, 71, 
73, 76-81) The remaining seven used logistic models. (67, 68, 70, 72, 74, 75, 81) The use of 
time-to-event models for the current study was appropriate for the source data, and better than 
the use of logistic models, given the censoring of outcomes when patients move practice. 
(103) It allowed patients who left their practice before the end of the five-year follow-up to be 
included in the analyses, and the observed survival time to be used in place of a simpler, less 
informative, binary outcome. As a result the time-to-event models made better use of the 
available data, and were powered to estimate the effect of each predictor with greater 
precision than their logistic counterparts in the literature. 
Only four of the 13 previous prediction models, which were specific to diabetes, modelled 
risk from the point of diabetes diagnosis (incident cases). (45, 46, 79, 81) The remaining nine 
included cases who had been diagnosed at some time in the past (prevalent cases): the level of 
their risk factors were estimated at the time of their entry into follow-up, rather than at the 
diagnosis of diabetes. (44, 57-60, 76-78, 80) Where diabetes duration was included as a 
predictor in four of these nine models, it was entered as a single covariate, with no 
interactions between it and other covariates. (57, 59, 77, 78) Data from the current study show 
how high levels of HbA1C (figure 7.3) and cholesterol (figure A7.2) at diagnosis of diabetes 
declined substantially in the first few years as treatment was initiated. Models that derived 
their HbA1C and cholesterol data from prevalent cases of diabetes did not make any allowance 
for this feature of the data (at a minimum by including an interaction term for HbA1C 
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/cholesterol and time since diagnosis). (44, 57-60, 76-78, 80) If used with newly diagnosed 
case of diabetes, these models are likely to overestimate the effect of HbA1C and total 
cholesterol on outcomes [section 8.3.1, paragraph 4 and section 8.9.1 paragraph 4]. This is 
consistent with the somewhat higher hazard ratios for HbA1C reported by these studies and 
reinforces the clinical utility of the current study (tables 8.5 and 8.7). (58, 73, 76)  
A similar effect may also be present in the UKPDS-derived CHD prediction model which 
used incident cases of diabetes and the average of HbA1C at one and two years following 
diabetes diagnosis (table 8.4) (45):  they also reported higher hazard ratios for HbA1C than 
were estimated in the current study CHD model. This implies that the current study models, 
with their inclusion of clinical values at diagnosis of diabetes, would be more accurate 
estimates of future risk when used with patients with newly diagnosed diabetes than previous 
models. It could be a useful tool for use with patients with newly diagnosed diabetes to 
identify and target preventative treatment at those with highest risk, and to advise these 
patients of their likely prognosis.  
The use of risk factor levels at baseline to predict future risk over relatively short periods (five 
years) may be appropriate for predictors which are subject to treatment (HbA1C), or more 
intensive treatment (cholesterol and blood pressure). However, if the follow-up period was to 
be extended to more than 10 years in future models, account would need to be taken of 
regression dilution, where exposure levels at baseline do not reflect the relationship between 
exposure levels in later periods and subsequent risk. (218) For shorter follow-up periods 
baseline risk levels may accurately reflect the accumulated exposure to the risk factor, than 
measurements from later periods. Future models that follow cases from the point of diagnosis 
for periods of 10 years or more may, therefore, benefit from the use of multiple measurements 
for each of these risk factors: a single measurement at diabetes diagnosis which reflects past 
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(untreated or less aggressively treated) exposure, and one or more additional measurements 
separated by several years to identify and account for any regression dilution effect. (218) 
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8.6 Other approaches to missing data 
 
8.6.1 The strengths and weakness of the approach used in the current study 
 
The extent of missing data in this study meant that care had to be taken in selecting 
appropriate methods for dealing with it. Relatively few (18%, 3643/20041) of the cases in the 
study cohort had all their clinical measurements recorded (that is, coded in their electronic 
patient record) within 90 days of diabetes diagnosis (table A7.1). After modelling their level 
using later values, baseline clinical measurement data was still missing for between 1% and 
7% of cases [section 7.4]. The current study used two methods in combination to deal with 
missing baseline clinical measurements (HbA1C, systolic BP, total cholesterol, BMI, 
eGFR/creatinine) and Townsend deprivation quintile. This involved estimating the baseline 
level of clinical measurements for cases using data from later time periods using a set of 
multilevel models [section 6.6.7] and using multiple imputation to estimate  the level of the 
missing data where it could not be estimated using these multilevel models [section 6.7.5]. It 
had the following strengths and weaknesses. 
Strengths: (a) The proportion of cases with missing clinical values was minimised by 
thorough data cleaning and inclusion of data recorded as free text. (b) Patients’ own data were 
used to estimate their baseline clinical value levels, rather than treating it as missing and 
imputing from the values recorded from complete cases.  (c) The multiple imputation process 
made an allowance for the imprecision of its estimates which was reflected in the confidence 
intervals for the hazard ratios for clinical values in the final prediction models. 
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Weaknesses: (a) The free text search (looking for clinical values added as text) was time-
consuming and did not identify a significant number of new values [section 7.4]. (b) The 
model to estimate baseline systolic BP did not produce very accurate estimates of baseline 
values (figure 7.4): systolic BP had to be entered into the survival models as a binary rather 
than a continuous predictor as a consequence of this [section 7.6.1]. This reduced the ability 
of the outcome models to identify the relationship between this predictor and each of the 
outcomes of interest.  
Only 18% of patients with newly diagnosed type 2 diabetes between 1998 and 2003 had all 
their clinical measurements recorded within 90 days of diagnosis (table A7.1) It is possible 
that the recording of these values in electronic patient records close to the time of diagnosis 
has improved following the introduction of electronic linkages to laboratories and QOF, 
although it appears that recording did not improve for newly diagnosed cases as much as for 
prevalent diabetes cases in the period up to 2007. (12, 103) This suggests that missing 
baseline data would still be an issue if the models presented here were used in current clinical 
practice. Practices would have to either impute missing values or measure them directly when 
using these models to estimate risk for an individual. This would be possible in an individual 
patient setting, where BP could be measured during the consultation, but it might require a 
new blood test to estimate total cholesterol or eGFR, increasing the burden on practice staff 
and delaying the risk assessment. Alternatively, these data may already be to hand in the form 
of a scanned hospital letter, in which case they would only need to be entered by hand into the 
appropriate section of the electronic patient record.  
An alternative to using actual measured values from an individual would be to impute missing 
values using estimates from the wider population or from the cohort used to derive the 
prediction models. (219, 220) This would also be required if estimating risk for a large group 
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of individuals simultaneously. The current models do not yet provide a means of doing this, 
but one could be incorporated in the software used to estimate risk at a later stage. Whatever 
the final source of data for these imputations, it would be valuable if the uncertainty 
surrounding the precision of a risk estimate derived for an individual patient using imputed 
data could be reported by the clinical software. This could be reported as an upper and lower 
estimate of risk which would be wider for a patient where one or more values were imputed, 
and narrower where none were missing.  
 
8.6.2  The approach used in earlier prediction models  
 
Ten of the 23 prediction models reported using at least one method for dealing with missing 
predictor data. (45, 46, 59, 60, 71, 72, 78-81) One of them reported using three separate 
methods for handling missing data. (71) The most common method used was complete-case 
analysis. (45, 46, 59, 60, 78, 79, 81) Aside from reducing the power of a prediction model, 
this approach may cause bias and is not recommended unless the proportion of missing data is 
low [section 6.7.5]. (99, 221)  
Single imputation: Single imputation (using a population mean value or a default category) 
was used in two studies.(71, 72). The multilevel models used in this study estimated baseline 
values more accurately than the mean of the observed values for each case [section 7.4], 
suggesting that this method was preferable to mean imputation. It would not have been 
appropriate to use the alternative single imputation method (a default category) (71) in this 
study as it would have assumed that all cases from the current study with missing Townsend 
deprivation quintile could safely be assigned to a single default quintile as the population as a 
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whole was relatively evenly distribution across deprivation levels.  This approach would have 
assigned cases with missing Townsend to the quintile with the greatest number of cases, and 
led to an systematic underestimation of the effect of deprivation on outcomes, and 
overestimated the precision of these estimates. 
Last value carried forward / last value carried back: Last value carried forward was used 
in one (80) and the closest in time to baseline of last value carried forward and last value 
carried back was used in a second prediction model identified from the literature. (71)  It may 
be unsafe to use these simple approaches as they treat risk factors recorded at different times, 
perhaps years apart, as if they were all recorded on the same date and not correlated with one 
another. It also assumes that there was no risk of recording bias. For example, some risk 
factors may be first recorded as part of the investigation of an outcome of interest, for 
example a family history of gastrointestinal cancer or higher levels of alcohol use may be first 
recorded when cancer is suspected. (101) The inclusion of these records, close to the cancer 
diagnosis, would tend to overestimate the relationship between family history/alcohol use and 
the risk of that cancer. 
The multilevel models used in this study were more likely to produce accurate estimates than 
these two other simple methods as: (i) they took into account the relatively large changes in 
the levels of some risk factors following diabetes diagnosis (figures 7.3, 7.4 and A7.2; and (ii) 
the level of some risk factors would not have been routinely measured prior to diabetes 
diagnosis (HbA1C, creatinine) and were not part of routine screening in the healthy population 
(total cholesterol). The implication of the approach to missing baseline values adopted in this 
study is that the values entered into the analyses used to produce the prediction models were 
more likely to represent their true value at baseline than other approaches. These values are 
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more likely to be close to the actual baseline levels experienced by patients at diagnosis, and 
therefore produce more accurate estimates of future risk in clinical practice. 
Multiple imputation: Multiple imputation, as used in the current study and one of the other 
models (71) is currently regarded as an appropriate approach to missing covariate data in 
predictive models. (50, 99, 143) It does rely on the assumption that data are missing at 
random: this may hold for risk factors where practice patients would be expected to have this 
recorded routinely (e.g. total cholesterol in patients with type 2 diabetes), but may not hold for 
the healthy population (i.e. where cholesterol screening is not routine). However, the use of 
multiple imputation in the latter situation did not appear to have systematically under- or 
overestimated total cholesterol levels in those with missing data in one CVD prediction model 
based on the healthy population. (64) 
 
8.6.3 Approaches which may be available for future studies 
 
More efficient approaches to missing baseline data would remove the need to fill them in 
using two separate processes, but none have yet emerged. Standard multiple imputation, as 
used in this study, uses non-missing observations from others to impute an individual’s 
missing data, and does not make use of that individual’s non-missing observations in other 
time periods. The two-fold fully conditional specification algorithm appears to offer a partial 
answer to the need to estimate baseline levels of risk factors, but requires that individuals 
have a recorded value before and after baseline. (222) These will not always be available, 
particularly for risk factors which are recorded more frequently following diagnosis of 
diabetes (e.g. HbA1C, total cholesterol), and so only provides a partial solution. Ongoing 
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work, led by University College London, to develop imputation models for missing data in 
primary care databases may provide a more comprehensive approach like that outlined above. 
(223) This could be used in future prediction models like those in this study.  
 183 
 
8.7 Clinical implications 
 
8.7.1 What risk factors make most difference and what opportunities are there for  
risk to be reduced? 
 
The results presented in table 7.11 show the relationship between each of the risk factors and 
the risk of CHD, stroke, CKD and all-cause mortality. Modifiable risk factors are considered 
here first. 
Smoking: Smoking was common and had a significant influence in all of the models: one-
quarter of patients were smokers at baseline (table 7.5), and half of these still smoked at five 
years following diagnosis (table A7.2). The risk of all four outcomes was higher in smokers 
(65% higher in for all-cause mortality) (table 7.11), suggesting that intensive smoking 
cessation interventions would be appropriate in aiming to reduce the risk of all four outcomes 
in individual patients.   
BMI: BMI at diagnosis was high for a large proportion of cases (median BMI=29 kg/m
2
) 
(table 7.5) and did not change substantially over the five years following diagnosis (figure 
A7.1). Higher baseline BMI increased the risk of CHD and CKD significantly: a 3.18kg (7lbs/ 
half-stone) increase in weight was associated with a relatively modest 3% and 1.5% increase 
in the 5-year risk of CHD and CKD, respectively (table 7.11). The greatest reductions in risk 
may, therefore be obtained by the 25% of patients whose baseline BMI was in excess of 33 
kg/m
2
. Given that weight loss is associated with a lowering of CVD risk and better glucose 
control (26, 29), this suggests that there are significant further opportunities to reduce risk by 
interventions aimed at weight loss, for example early referral to patient education 
programmes. (224) 
 184 
 
HbA1C: Higher HbA1C at diagnosis of diabetes was a statistically significant predictor for 
CHD and CKD, and highest for all-cause mortality (9% risk increase for each 1% HbA1C 
increase) (table 7.11). Following diagnosis, mean HbA1C decreased significantly in the 
subsequent six months among the groups with the highest levels at diagnosis (HbA1C 9.5%+ 
and HbA1C 7.5%-9.4%) (figure 7.3). A similar pattern was seen in the UKPDS (figure 7.5), 
though their data were reported from one year following diagnosis rather than diabetes 
diagnosis itself. (81) These early reductions in the current study were maintained in the 
following five years, but there was a small and observable annual increase in all HbA1C 
groups from one year following diagnosis (figure 7.3). By five years, only the group with the 
lowest initial HbA1C (baseline HbA1C of under 6%) remained under the current NICE target of 
6.5%. (43)  This indicates that initial improvements in HbA1C control were not followed up by 
further successful attempts at control after the first year and that more aggressive and 
sustained blood glucose control may be indicated for those with higher baseline HbA1C (i.e. 
those with HbA1C>6%: the majority of cases). Further reductions in HbA1C in the period after 
the first year following diagnosis should lead to reductions in the risk of major outcomes. (28)  
Systolic BP:  Hypertension at diagnosis (high systolic BP or treated BP) was associated with 
an increased risk of CKD and CHD and was highest for stroke (an 80% increase in risk) (table 
7.11). This was similar to that observed in the literature, where BP was a more important risk 
factor for stroke than CHD. (40) More than half of patients had a high SBP (>=140 mmHg) at 
baseline (table 7.5). Average systolic BP slowly declined in this group over the follow up 
period but was still high at the end of the fifth year (figure 7.4). A similar progression can be 
seen in data reported by the UKPDS (figure 7.5). This indicates that there is opportunity for 
improved management of this risk factor from diabetes diagnosis to at least five years, which 
should have the effect of reducing the risk of the above diabetic complications. (27, 29, 32, 
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34) Such reductions would also impact on microvascular disease and hence are doubly 
important. (225) 
Total cholesterol: High total cholesterol at diagnosis (>=4 mmol/L) was associated with an 
increased risk of CHD and CKD, but was not statistically significant (table 7.11). More than 
three-quarters of patients had high total cholesterol at baseline (25
th
 percentile 5.1 mmol/L) 
(table 7.5). Average total cholesterol levels did decline over the five-year follow-up for 
patients with a baseline cholesterol of 5 mmol/L or higher, but did not fall below the cutoff of 
4.5 mmol/L by the end of this period (figure A7.2). Table A7.3 also shows that the prevalence 
of lipid-lowering drug use increased from 19% of patients at baseline to 42% at one year 
following diagnosis, but does not provide any data past this point. However, the high total 
cholesterol observed at five years in those with the highest baseline levels (figure A7.2) 
indicates that there was scope for further reductions in cholesterol levels and, therefore, risk 
of diabetic complications from improved drug and lifestyle changes. (27, 29, 32, 34) 
Prior comorbidity: Prior comorbidity (CHD, stroke or CKD) at diagnosis of diabetes was 
relatively common: more than one in five patients had at least one comorbid condition (table 
7.5). These also had a large effect on the risk of death in the first five years (table 7.11). 
Patients with two of these comorbidities had approximately twice the risk of death as patients 
free from them. Although not modifiable, the increased risk of major outcomes following 
diabetes diagnosis should be recognised in this group: these patients could be flagged for 
intensive treatment to reduce risk. (38, 39) In addition to this, a substantial number of 
additional patients (5%) were found to have CKD in the three months following diabetes 
diagnosis (table 7.1), presumably when their creatinine level was first measured as part of 
routine diabetes care. (39) This suggests that there may be a benefit in checking creatinine 
earlier, possibly when patients are being assessed for diabetes or in patients with pre-diabetes, 
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as it would allow treatment to preserve kidney function to be initiated at an earlier stage in the 
disease. 
Given the high risk of CVD, CKD and death in patients with prior comorbidity, an argument 
can also be made in favour of routinely screening these patients for diabetes [section 8.8  
policy implications: clinical issues]. 
 
8.7.2 What is the clinical utility of the risk prediction models developed in this study?  
 
The clinical utility of the models presented in this thesis is assessed here in terms of how they 
could be used in clinical practice to improve health outcomes. The final part of this section 
describes a possible use of the models in a likely clinical setting, once they were validated and 
improved in the manner suggested below. 
Broadly, a clinically useful model should: predict the risk of an important health outcome; 
provide thresholds for action; trigger the use of available and safe interventions to reduce risk; 
and be cost-effective. (226) In addition to helping clinicians make treatment decisions about 
individual patients, risk models may help patients understand their risk of disease and 
motivate them to initiate behavioural change or improve adherence to prescribed treatments. 
(227) Risk prediction models may also be used at a population level, to allocate resources to 
those at highest risk [section 1.3]. (38, 105, 228, 229) 
The models presented in this thesis predicted the risk of three important outcomes, namely 
CVD, CKD and death. Clinically- and cost-effective interventions to reduce these risks are 
available in UK general practice - the likely setting where these models would be used 
[section 1.2]. The risk of these outcomes is higher in people with type 2 diabetes [section 1.4] 
 187 
 
but could be reduced by lifestyle changes and medical management [section 1.2] which are 
relatively cheap (as generically prescribed drugs) and available (e.g. the DESMOND patient 
education programme) to patients in the UK. (230) It is also possible that better understanding 
of prognosis on the patients’ part might lead to more effective implementation of such 
interventions. (200-202, 204, 231) 
However, the models presented here do not currently have thresholds for action (e.g. prescribe 
statin/ BP lowering drugs to all patients with greater than 20% 5-year risk of CVD or death), 
and their cost-effectiveness, if they were used in UK general practice, is not known. Further 
work, beyond the scope of this thesis, would be required to validate their clinical utility and 
impact in these particular respects. (232-235) 
Simply reporting the limitations of previous attempts to predict risk in people with type 2 
diabetes and the potential superiority of the new models, described earlier [sections 1.4, 2.3, 
2.4, 3.3], is insufficient to recommend their adoption at this stage. The models do provide 
estimates of absolute risk, and the calibration plots presented in section 7.8 and the proportion 
of variation (R
2
) statistics [section 7.7] suggest that the models may perform at least as well as 
other risk models currently used in UK clinical practice. (234) Additional research would also 
be required to quantify (e.g. measures of discrimination, calibration, and (re)classification) 
and externally validate their performance prior to adoption for use in clinical practice. (232-
234, 236, 237) 
An early use of the models in general practice might be to rank newly diagnosed type 2 
diabetes patients by risk of CVD/CKD and death so that those at the highest risk could be 
allocated early assessment or additional interventions to manage their risk factors. This would 
be an alternative approach to the current incentives to general practices which focus on 
 188 
 
individual risk factors. (84) The risk models would be relatively straightforward to implement 
in current clinical systems by third parties or the system suppliers, using the coded clinical 
data that they contain to populate the risk equations: this has been done elsewhere. (104, 238) 
The cost of making these models available in all UK practices using each clinical system 
would, therefore, not be significantly higher than installing it in a single practice. In such an 
application, the models would only to be required to discriminate between low and high risk 
patients. (239) The risk of misclassification for any individual patient (a high risk individual 
being misclassified as low risk or vice versa) would also be minimised in this application, as 
individual risks factors would eventually be addressed in routine care, probably at the time of 
their diabetes annual review. CVD and CKD risk are known to increase with age: older 
patients with newly diagnosed type 2 diabetes may already be on appropriate treatments to 
reduce these risks, or may be initiated on treatment without having their individual risk 
calculated. These models may, therefore, be most useful in younger patients to stratify and 
treat them according to their overall risk, rather than the level of their individual risk factors. 
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8.8 Policy implications 
 
The previous section indicated that there were additional clinical opportunities available to 
reduce the level of modifiable risk factors in the years following diabetes diagnosis [section 
8.7.1] and discussed their clinical utility [section 8.7.2]. The identification of future CVD, 
CKD and mortality risk among patients with newly diagnosed diabetes, and more aggressive 
management of risk factors in the years immediately following diagnosis should result in 
improved health outcomes [sections 1.3, 1.4]. The prediction models created in this study may 
prove particularly useful for this task as they were developed for this specific patient group 
[section 2.5], use risk factors which should be routinely available at diabetes diagnosis 
[section 4.3], and predict the risk of important clinical outcomes [section 1.2]. This section 
describes the implications of these and the other results presented in this thesis for policy 
makers. These are separated into two subsections: clinical issues and data issues. 
 
Clinical issues: In addition to the opportunities available to reduce the level of modifiable 
risk factors in clinical practice in the years following diabetes diagnosis [section 8.7.1], there 
was also a high level of co-morbidity at diabetes diagnosis: unrecognised CKD along with 
previous stroke and CHD were frequently present at baseline (table 8.2). Assuming that these 
trends continued past the end of the study period (circa 2004) and are still common among 
patients diagnosed in more recent periods, approximately 10 years since the introduction of 
QOF, then there may be scope for additional national guidelines or incentives specific to 
patients newly diagnosed with Type 2 diabetes. This may be true even if the management of 
prevalent Type 2 diabetes appears to have improved since the introduction of QOF as the 
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management of this subgroup of newly diagnosed patients may not have improved to the 
same extent. (12, 13, 240) 
The high levels (5%) of previously unrecognised CKD found in the first three months 
following a diagnosis of type 2 diabetes (table 7.1), and the fact that progression to CKD 
stages 3-5 occurred in one-third of patients overall, may suggest that targeted routine 
screening for CKD should be carried out at an earlier point, for example in patients with 
impaired glucose tolerance/impaired fasting glucose.  Earlier identification of patients at risk 
of CKD and CKD itself could lead to earlier treatment initiation, delay further decline in 
kidney function, and reduce the risk of end-stage renal failure. (100) 
A comparison of the trends in HbA1C following diagnosis between the UKPDS (1977-1991) 
and the current study (1998-2003) for the first five years following diabetes diagnosis appears 
to show that blood glucose management had improved greatly, even before the introduction of 
financial incentives for diabetes management as part of QOF in 2004 (figures 7.3, 7.5). (13) 
There was little change in BMI in the five years following diagnosis, irrespective of baseline 
BMI (figure A7.1) [section 8.7]. This suggests that there are significant further opportunities 
to reduce risk by weight reduction, for example utilizing early referral to patient education 
programmes such as DESMOND which can offer support and advice on weight loss and other 
diabetes-relates issues to newly diagnosed patients. (230) 
Pre-existing CHD and stroke were relatively common at diabetes diagnosis and were strong 
predictors of future stroke, CKD and mortality (table 7.11). Given the existence of effective 
treatments, this suggests that these patients should be targeted for intensive treatment, 
irrespective of the level of their other clinical risk factors. (39) An argument can also be made 
in favour of routinely screening these patients for diabetes. This would allow their diabetes to 
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be identified at an earlier stage and damage associated with prolonged exposure to high blood 
glucose levels to be prevented through earlier intervention. 
 
Data issues: The current study shows the importance of reporting a full set of covariates. Of 
the six previous all-cause mortality prediction models identified in this thesis (table 2.3), three 
carried out multivariate prediction models but only two reported results for the effect of 
HbA1C on mortality (table8.6). A further single model to predict CHD risk reported its results 
as coefficients, rather than more easy to interpret hazard ratios (table 8.4). (59)  When 
transformed into hazard ratios, male sex, increasing age and smoking could be seen to reduce 
the risk of future CHD, rather than to increase the risk as was observed by all the other models 
reviewed. (current study) (45, 57, 60) The reporting of full model results in a transparent 
format can allow flawed data or analyses to be identified and corrected. (64, 147) Reporting 
recommendations for predictive models should include reporting of model results for the full 
set of covariates and reporting those results in a transparent form (e.g. HRs not coefficients)  
in order to  avoid selective non-reporting of results which do not fit previously published 
results. 
Complex prediction models with a wide range of clinical predictors, which may include some 
with missing data, do not necessarily result in better or more useful models than simpler 
alternatives. The inclusion of predictors with missing data in this study led to complex data 
preparation and analysis (baseline prediction models and multiple imputation), that may not 
have been radically better than simpler demographic models.  The availability of existing 
large UK primary care databases models makes the development of predictive models easier 
as they contain sufficient patients and outcomes to power a wide range of models. However, 
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they may appear to produce models which predict risk in UK populations better than models 
that are based on old or foreign data. This improved performance may only be because they 
have up to date data on the underlying risk in the population than the alternative sources. 
Reporting recommendations for predictive models should therefore report a summary statistic 
like R
2
 or similar statistics for a basic and full model to allow the absolute value of the 
additional predictors derived from clinical data to be assessed. 
A recent BMJ paper on the validity of acute MI diagnoses recorded in primary care suggests 
that these diagnoses have a positive predictive value of only 92% when compared with a 
disease registry data and that perhaps 25% of diagnoses were missing from primary care. 
(112) The authors conclude that linked primary care, death certification, hospital and disease 
registry data are required to avoid biased ascertainment of acute MI outcomes. These kinds of 
external data were not available at the time the models in this thesis were developed, but, as 
mentioned above, linked data is being introduced for use with THIN primary care records. 
(107) Future studies could make use of these data to validate existing GP data or identify 
additional outcomes [section 8.2.2].  
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8.9 Overall conclusions 
 
Routinely collected primary care data can be used to predict future risk of coronary heart 
disease, stroke, chronic kidney disease, and all-cause mortality in people with newly-
diagnosed type 2 diabetes mellitus. This last section of the discussion summarises the 
information that supports this main conclusion.  It highlights the reasons why the current 
models may be more valid and clinically useful than previous models in a UK general practice 
setting. This includes their applicability to newly diagnosed patients with type 2 diabetes, the 
inclusion of predictors routinely available in general practice, the ease with which they can be 
updated in the future, and their management of missing baseline data. The section continues 
with a description of what might be usefully be communicated to patients, based on the study 
results, and ends with a summary of the study’s scope, key findings, clinical utility, and 
recommends  appropriate next steps in model development and validation. 
 
8.9.1 How the prediction models developed in this study differ from past models 
 
They are more applicable to newly diagnosed cases of type 2 diabetes: More than 20 
models, identified from the literature, can be used to predict the risk of future CVD, CKD and 
death in people with type 2 diabetes (tables 2.2 to 2.3). Prediction models for CVD and all-
cause mortality specific to people with diabetes which were developed using prevalent cases 
of diabetes are likely to overestimate risk when used with newly diagnosed cases of type 2 
diabetes as the levels of HbA1C, systolic blood pressure and total cholesterol decline in the 
years immediately following diagnosis [section 7.4]. Other models, developed using incident 
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(newly diagnosed) cases of diabetes were either derived from the UKPDS cohort and can only 
be used from four years following diabetes diagnosis (45, 46), or included year of diagnosis 
as a predictor and, therefore, can only be used with cases diagnosed between 1999 and 2007 
(79). Some (for CKD risk) were intended for use with the general population (table 2.2): 
where these included diabetes as a predictor, they assumed that the effect of diabetes did not 
depend on the level of other risk factors, that duration of diabetes did not influence risk, and 
that diabetes control (HbA1C) did not influence risk. (67, 69, 71-75) 
This implies that the current study models, with their inclusion of clinical values at diagnosis 
of diabetes could provide more accurate estimates of future risk when used with patients with 
newly diagnosed diabetes than previous models. Of the four models presented, the most 
useful might be the all-cause mortality prediction model which appeared to explain a large 
proportion of the variability in clinical outcomes (R
2
=0.58) This model, and the stroke and 
CKD prediction models, could be useful tools for use with patients newly diagnosed with 
diabetes: to identify and target preventative treatment at those with highest risk; and to advise 
patients of their likely prognosis. 
They include a set of predictors available in general practice and can be easily updated: 
This study developed four separate prediction models which can be used with recently 
diagnosed cases of type 2 diabetes. These models predict the risk of CHD, stroke, CVD and 
all-cause mortality up to five years following diabetes diagnosis. They include a range of 
demographic and clinical predictors including some clinical measurements which are 
routinely assessed in patient with type 2 diabetes (HbA1C, eGFR). These models can be easily 
updated to include cases diagnosed since 2004 (the end of the study period) using more recent 
primary care data, as has been done for the QRISK model. (109) This would allow the models 
to be extended to predict outcomes up to 10 years following diagnosis, and would provide 
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more precise estimates of risk in the first five years. Updates to these models could also 
include additional predictors not included in this study. 
They handled missing data better than existing prediction models: The prediction models 
identified from the literature used a variety of approaches to handling missing baseline 
clinical measurements [section 8.6.2]. This included methods which may have introduced 
bias: complete-case analysis, single imputation using population mean values, and last value 
carried forward or back. (50, 145, 149, 221) One model which predicted risk in the general 
population did use a recommended approach, multiple imputation, but it was used in 
conjunction with last value carried forward/back. If this approach was used to develop a risk 
prediction model using data from patients with newly diagnosed type 2 diabetes it would 
systematically underestimate baseline risk levels:  most of these values would be carried back 
from periods months after the diagnosis of diabetes, after lifestyle changes or new drug 
treatments had been initiated [section 6.6.7, table 7.4, table A7.1].  
The approach adopted in this study was to estimate these baseline clinical measurements 
using multivariate models and then to use multiple imputation to fill in baseline values which 
could not be estimated [section 7.4]. This avoided introducing bias from the use of complete 
case, single imputation and last value carried forward/back approaches, and provided more 
accurate baseline estimates than single imputation and last value carried forward/back (table 
A7.1). The values that were multiply imputed at the next step in the process were probably 
also more accurate as a result. This process can be used in other studies where accurate 
baseline values need to be estimated, and can be used with longitudinal records where there 
are no data available prior to baseline, unlike more recent approaches such as the two-fold 
fully conditional specification algorithm. (241) 
 196 
 
8.9.2 What to tell patients 
 
Some of the risk of these major complications of diabetes cannot be altered (e.g. prior 
comorbidities), but their impact can be lessened by early interventions which reduce risk, such 
as drug treatments and lifestyle changes. (23-35) For all patients at high risk, there may be 
initial reductions in important risk factors such as HbA1C, cholesterol and blood pressure once 
treatment is started, but they may well need to be followed up by further aggressive treatment 
to achieve and sustain treatment targets and reduce the risk of complications. Lastly, smoking 
is known to be associated with an increased risk of CVD and death among people with and 
without diabetes. (34, 35, 81) Because people with diabetes are at a higher risk of these and 
other significant outcomes, it is important to reduce as many risk factors as possible at the 
same time: this includes smoking. However, over half of people who smoked at diagnosis are 
still smoking five years later, so they may need increased support to quit and remain non-
smokers.  
 
8.9.3 Study summary 
 
Routinely collected primary care data can be used to predict future risk of coronary heart 
disease, stroke, chronic kidney disease, and all-cause mortality in people with newly-
diagnosed type 2 diabetes mellitus. This thesis developed four models which could be used to 
predict the risk of these outcomes in the five years following a diagnosis of type 2 diabetes.  
They may predict risk more accurately in the years following diabetes diagnosis than existing 
models: these were either developed using risk factors recorded some years after diagnosis, 
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included risk factors not routinely recorded in general practice or excluded important risk 
factors which are routinely recorded, or were developed for use in the wider population. 
This study used data from a large UK general practice database and included risk factors 
which are known to predict these outcomes to populate the models: demographic variables, 
clinical predictors routinely recorded following diabetes diagnosis, and blood pressure and 
cholesterol-lowering treatment. Some of these models could, therefore, be used in a general 
practice setting to identify and target preventative treatment, and as educational tools to 
advise people newly diagnosed with type 2 diabetes of their likely prognosis. 
Across models, the key modifiable predictors identified were: smoking; weight; blood 
pressure; and glycaemic control. The most clinically useful model might be the mortality 
model as it accounted for a large proportion of the variability in outcomes (R
2
=0.58). This 
model found that age, sex and past medical history were associated with the risk of death, as 
were smoking, glycaemic control, BMI and high/treated blood pressure. The stroke and CKD 
models accounted for a moderate amount of the variation in outcomes observed (an R
2
 of 0.35 
and 0.34, respectively). The stroke model found that age, prior CHD, smoking and 
high/treated blood pressure were significant predictors of future stroke risk. The CKD model 
found that male gender, age, prior CHD and stroke were significant predictors of future CKD 
risk, as were smoking, glycaemic control, BMI and high/treated blood pressure. The CHD 
model had the smallest R
2
 (0.09). Although it included known risk factors for CHD, the 
model accounted for little of the variation in outcomes between individuals and would not, 
therefore, be useful in clinical practice. 
The cohort of patients used to populate the models appear to be representative of the wider 
UK population of people with type 2 diabetes, and unlike some previous models included 
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patients of all ages and health statuses. However incentives introduced as part of QOF since 
the end of the study period (1998-2003) may have improved the management of newly 
diagnosed diabetes in the years following diagnosis and may have resulted in improved 
outcomes in more recent years. It would therefore be prudent to update and extend these 
models using more recent clinical data and to assess their predictive validity in one or more 
external populations, particularly in comparison with existing risk models available in clinical 
practice.  
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Appendix 2    
 
Rapid review methods 
 
Appendix 2.1 Methods and search terms used to identify previous CVD, CKD and all-
cause mortality prediction models 
 
Aim 
To identify all papers presenting a CVD or CKD prediction model developed in patients with diabetes or that can 
be applied to individuals with type 2 diabetes. 
 
CVD 
1. Use van Dieren’s existing systematic review. 
2. Run van Dieren’s search again in PubMed to identify any additional studies published in period 2011-2012. 
3. Check PubMed suggested papers for papers identified in steps 1 & 2. 
 
CKD and all-cause mortality 
1. Run PubMed search to identify studies published in period 1991-2012. 
2. Check PubMed suggested papers for papers identified in step 1. 
 
 
Eligibility criteria 
1. The prediction model was either developed in people with diabetes or included diabetes as a predictor.  
2. The outcome of the prediction model was CVD or CKD or a CVD/CKD component (i.e., CHD, stroke, end 
stage renal failure, kidney dialysis, kidney transplant).  
3. It presented a specific prediction rule/model with sufficient information on all variables to calculate the 
CVD CKD risk in a different population (beta coefficients of the model or otherwise a scoring 
system/graph/score card/nomogram was provided). 
 
Exclusion criteria 
1. Non-human studies. 
2. Articles in languages other than English. 
3. Studies presenting a prediction model developed in patients with previous CVD/CKD. 
4. Studies focusing on the added predictive value of new risk factors to an existing prediction model. 
5. Studies where full text was not available. These could not have presented sufficient information on all 
variables to calculate CKD risk. 
 
Screening process 
1. Screen on title. 
2. Screen on abstract. 
3. Screen on full text. 
 
 201 
 
 
 
Search terms for CVD 
 
(( 
Validat$ OR Predict$.ti. OR Rule$)  
OR  
(Predict$ AND (Outcome$ OR Risk$ OR Model$))  
OR  
(Decision$ AND (Model$ OR Clinical$ OR Logistic Models/))  
OR  
(Prognostic AND (History OR Variable$ OR Criteria OR Scor$ OR Characteristic$ OR Finding$ OR 
Factor$ OR Model$))  
OR  
(“risk score”[All fields] OR "prediction model"[All fields] OR "prediction rule"[All fields] OR "risk 
assessment" [All fields] OR "algorithm"[All fields] 
))  
 
AND 
(cardiovascular OR coronary OR cerebrovascular OR heart OR stroke)  
AND  
(diabetes OR "diabetes mellitus" OR "type 2 diabetes")  
NOT  
(Animals[MeSH] NOT Humans[MeSH]) 
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Search terms for CKD 
 
(( 
Validat$ OR Predict$.ti. OR Rule$)  
OR  
(Predict$ AND (Outcome$ OR Risk$ OR Model$))  
OR  
(Decision$ AND (Model$ OR Clinical$ OR Logistic Models/))  
OR  
(Prognostic AND (History OR Variable$ OR Criteria OR Scor$ OR Characteristic$ OR Finding$ OR 
Factor$ OR Model$))  
OR  
(“risk score”[All fields] OR "prediction model"[All fields] OR "prediction rule"[All fields] OR "risk 
assessment" [All fields] OR "algorithm"[All fields] 
))  
 
AND 
(CKD OR kidney OR nephr OR dialysis OR transplant OR replacement OR "end stage") 
AND  
(diabetes OR "diabetes mellitus" OR "type 2 diabetes")  
NOT  
(Animals[MeSH] NOT Humans[MeSH]) 
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Search terms for all-cause mortality 
 
 
(( 
Validat$ OR Predict$.ti. OR Rule$)  
OR  
(Predict$ AND (Outcome$ OR Risk$ OR Model$))  
OR  
(Decision$ AND (Model$ OR Clinical$ OR Logistic Models/))  
OR  
(Prognostic AND (History OR Variable$ OR Criteria OR Scor$ OR Characteristic$ OR Finding$ OR 
Factor$ OR Model$))  
OR  
(“risk score”[All fields] OR "prediction model"[All fields] OR "prediction rule"[All fields] OR "risk 
assessment" [All fields] OR "algorithm"[All fields] 
))  
 
AND 
(death  OR mortality) 
AND  
(diabetes OR "diabetes mellitus" OR "type 2 diabetes")  
NOT  
(Animals[MeSH] NOT Humans[MeSH]) 
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Appendix 6   
 
Read codes used to identify cases of Type 2 diabetes mellitus 
 
Note: This list includes codes specific to Type 2 diabetes, codes which do not specify 
diabetes type, and codes for Type 1 diabetes. These are used in combination with other 
criteria to identify cases of Type 2 diabetes: age at diagnosis >= 35 years and no insulin 
treatment within one year of diagnosis.  
 
Read code Description 
  
13AB.00 Diabetic lipid lowering diet 
13AC.00 Diabetic weight reducing diet 
13B1.00 Diabetic diet 
1434.00 H/O: diabetes mellitus 
14F4.00 H/O: Admission in last year for diabetes foot problem 
2BBF.00 Retinal abnormality - diabetes related 
2BBL.00 O/E - diabetic maculopathy present both eyes 
2BBP.00 O/E - right eye background diabetic retinopathy 
2BBQ.00 O/E - left eye background diabetic retinopathy 
2BBR.00 O/E - right eye preproliferative diabetic retinopathy 
2BBS.00 O/E - left eye preproliferative diabetic retinopathy 
2BBT.00 O/E - right eye proliferative diabetic retinopathy 
2BBV.00 O/E - left eye proliferative diabetic retinopathy 
2BBW.00 O/E - right eye diabetic maculopathy 
2BBX.00 O/E - left eye diabetic maculopathy 
2G51000 Foot abnormality - diabetes related 
2G5A.00 O/E - Right diabetic foot at risk 
2G5B.00 O/E - Left diabetic foot at risk 
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2G5C.00 Foot abnormality - diabetes related 
2G5E.00 O/E - Right diabetic foot at low risk 
2G5F.00 O/E - Right diabetic foot at moderate risk 
2G5G.00 O/E - Right diabetic foot at high risk 
2G5H.00 O/E - Right diabetic foot - ulcerated 
2G5I.00 O/E - Left diabetic foot at low risk 
2G5J.00 O/E - Left diabetic foot at moderate risk 
2G5K.00 O/E - Left diabetic foot at high risk 
2G5L.00 O/E - Left diabetic foot - ulcerated 
3881.00 Education score - diabetes 
3882.00 Diabetes well being questionnaire 
3883.00 Diabetes treatment satisfaction questionnaire 
42W..00 Hb. A1C - diabetic control 
42W..11 Glycosylated Hb 
42W..12 Glycated haemoglobin 
42W1.00 Hb. A1C < 7% - good control 
42W2.00 Hb. A1C 7-10% - borderline 
42W3.00 Hb. A1C > 10% - bad control 
42WZ.00 Hb. A1C - diabetic control NOS 
42c..00 HbA1 - diabetic control 
66A..00 Diabetic monitoring 
66A1.00 Initial diabetic assessment 
66A2.00 Follow-up diabetic assessment 
66A3.00 Diabetic on diet only 
66A4.00 Diabetic on oral treatment 
66A5.00 Diabetic on insulin 
66A8.00 Has seen dietician - diabetes 
66A9.00 Understands diet - diabetes 
66AA.11 Injection sites - diabetic 
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66AD.00 Fundoscopy - diabetic check 
66AG.00 Diabetic drug side effects 
66AH.00 Diabetic treatment changed 
66AI.00 Diabetic - good control 
66AJ.00 Diabetic - poor control 
66AJ.11 Unstable diabetes 
66AJ100 Brittle diabetes 
66AJz00 Diabetic - poor control NOS 
66AK.00 Diabetic - cooperative patient 
66AL.00 Diabetic-uncooperative patient 
66AM.00 Diabetic - follow-up default 
66AN.00 Date diabetic treatment start 
66AO.00 Date diabetic treatment stopp. 
66AP.00 Diabetes: practice programme 
66AQ.00 Diabetes: shared care programme 
66AR.00 Diabetes management plan given 
66AS.00 Diabetic annual review 
66AT.00 Annual diabetic blood test 
66AU.00 Diabetes care by hospital only 
66AV.00 Diabetic on insulin and oral treatment 
66AW.00 Diabetic foot risk assessment 
66AX.00 Diabetes: shared care in pregnancy - diabetol and obstet 
66AY.00 Diabetic diet - good compliance 
66AZ.00 Diabetic monitoring NOS 
66Aa.00 Diabetic diet - poor compliance 
66Ab.00 Diabetic foot examination 
66Ac.00 Diabetic peripheral neuropathy screening 
8A12.00 Diabetic crisis monitoring 
8A13.00 Diabetic stabilisation 
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8CA4100 Pt advised re diabetic diet 
8H2J.00 Admit diabetic emergency 
8H3O.00 Non-urgent diabetic admission 
8H4F.00 Referral to diabetologist 
8H7C.00 Refer, diabetic liaison nurse 
8H7f.00 Referral to diabetes nurse 
8HKE.00 Diabetology D.V. requested 
8HLE.00 Diabetology D.V. done 
8HME.00 Listed for Diabetology admissn 
8HVU.00 Private referral to diabetologist 
9N1v.00 Seen in diabetic eye clinic 
9NM0.00 Attending diabetes clinic 
9OL..00 Diabetes monitoring admin. 
9OL..11 Diabetes clinic administration 
9OL1.00 Attends diabetes monitoring 
9OL2.00 Refuses diabetes monitoring 
9OL3.00 Diabetes monitoring default 
9OL4.00 Diabetes monitoring 1st letter 
9OL5.00 Diabetes monitoring 2nd letter 
9OL6.00 Diabetes monitoring 3rd letter 
9OL7.00 Diabetes monitor.verbal invite 
9OL8.00 Diabetes monitor.phone invite 
9OL9.00 Diabetes monitoring deleted 
9OLA.00 Diabetes monitor. check done 
9OLA.11 Diabetes monitored 
9OLZ.00 Diabetes monitoring admin.NOS 
C10..00 Diabetes mellitus 
C100.00 Diabetes mellitus with no mention of complication 
C100000 Diabetes mellitus, juvenile type, no mention of complication 
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C100011 Insulin dependent diabetes mellitus 
C100100 Diabetes mellitus, adult onset, no mention of complication 
C100111 Maturity onset diabetes 
C100112 Non-insulin dependent diabetes mellitus 
C100z00 Diabetes mellitus NOS with no mention of complication 
C101.00 Diabetes mellitus with ketoacidosis 
C101000 Diabetes mellitus, juvenile type, with ketoacidosis 
C101100 Diabetes mellitus, adult onset, with ketoacidosis 
C101y00 Other specified diabetes mellitus with ketoacidosis 
C101z00 Diabetes mellitus NOS with ketoacidosis 
C102.00 Diabetes mellitus with hyperosmolar coma 
C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma 
C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
C102z00 Diabetes mellitus NOS with hyperosmolar coma 
C103.00 Diabetes mellitus with ketoacidotic coma 
C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma 
C103100 Diabetes mellitus, adult onset, with ketoacidotic coma 
C103y00 Other specified diabetes mellitus with coma 
C103z00 Diabetes mellitus NOS with ketoacidotic coma 
C104.00 Diabetes mellitus with renal manifestation 
C104.11 Diabetic nephropathy 
C104000 Diabetes mellitus, juvenile type, with renal manifestation 
C104100 Diabetes mellitus, adult onset, with renal manifestation 
C104y00 Other specified diabetes mellitus with renal complications 
C104z00 Diabetes mellitus with nephropathy NOS 
C105.00 Diabetes mellitus with ophthalmic manifestation 
C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation 
C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation 
C105y00 Other specified diabetes mellitus with ophthalmic complicatn 
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C105z00 Diabetes mellitus NOS with ophthalmic manifestation 
C106.00 Diabetes mellitus with neurological manifestation 
C106.11 Diabetic amyotrophy 
C106.12 Diabetes mellitus with neuropathy 
C106.13 Diabetes mellitus with polyneuropathy 
C106000 Diabetes mellitus, juvenile, + neurological manifestation 
C106100 Diabetes mellitus, adult onset, + neurological manifestation 
C106y00 Other specified diabetes mellitus with neurological comps 
C106z00 Diabetes mellitus NOS with neurological manifestation 
C107.00 Diabetes mellitus with peripheral circulatory disorder 
C107.11 Diabetes mellitus with gangrene 
C107.12 Diabetes with gangrene 
C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder 
C107100 Diabetes mellitus, adult, + peripheral circulatory disorder 
C107200 Diabetes mellitus, adult with gangrene 
C107300 IDDM with peripheral circulatory disorder 
C107400 NIDDM with peripheral circulatory disorder 
C107y00 Other specified diabetes mellitus with periph circ comps 
C107z00 Diabetes mellitus NOS with peripheral circulatory disorder 
C108.00 Insulin dependent diabetes mellitus 
C108.11 IDDM-Insulin dependent diabetes mellitus 
C108.12 Type 1 diabetes mellitus 
C108.13 Type I diabetes mellitus 
C108000 Insulin-dependent diabetes mellitus with renal complications 
C108011 Type I diabetes mellitus with renal complications 
C108012 Type 1 diabetes mellitus with renal complications 
C108100 Insulin-dependent diabetes mellitus with ophthalmic comps 
C108111 Type I diabetes mellitus with ophthalmic complications 
C108112 Type 1 diabetes mellitus with ophthalmic complications 
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C108200 Insulin-dependent diabetes mellitus with neurological comps 
C108211 Type I diabetes mellitus with neurological complications 
C108212 Type 1 diabetes mellitus with neurological complications 
C108300 Insulin dependent diabetes mellitus with multiple complicatn 
C108311 Type I diabetes mellitus with multiple complications 
C108312 Type 1 diabetes mellitus with multiple complications 
C108400 Unstable insulin dependent diabetes mellitus 
C108411 Unstable type I diabetes mellitus 
C108412 Unstable type 1 diabetes mellitus 
C108500 Insulin dependent diabetes mellitus with ulcer 
C108511 Type I diabetes mellitus with ulcer 
C108512 Type 1 diabetes mellitus with ulcer 
C108600 Insulin dependent diabetes mellitus with gangrene 
C108611 Type I diabetes mellitus with gangrene 
C108612 Type 1 diabetes mellitus with gangrene 
C108700 Insulin dependent diabetes mellitus with retinopathy 
C108711 Type I diabetes mellitus with retinopathy 
C108712 Type 1 diabetes mellitus with retinopathy 
C108800 Insulin dependent diabetes mellitus - poor control 
C108811 Type I diabetes mellitus - poor control 
C108812 Type 1 diabetes mellitus - poor control 
C108900 Insulin dependent diabetes maturity onset 
C108911 Type I diabetes mellitus maturity onset 
C108912 Type 1 diabetes mellitus maturity onset 
C108A00 Insulin-dependent diabetes without complication 
C108A11 Type I diabetes mellitus without complication 
C108A12 Type 1 diabetes mellitus without complication 
C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
C108B11 Type I diabetes mellitus with mononeuropathy 
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C108B12 Type 1 diabetes mellitus with mononeuropathy 
C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
C108C11 Type I diabetes mellitus with polyneuropathy 
C108C12 Type 1 diabetes mellitus with polyneuropathy 
C108D00 Insulin dependent diabetes mellitus with nephropathy 
C108D11 Type I diabetes mellitus with nephropathy 
C108D12 Type 1 diabetes mellitus with nephropathy 
C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C108E11 Type I diabetes mellitus with hypoglycaemic coma 
C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
C108F00 Insulin dependent diabetes mellitus with diabetic cataract 
C108F11 Type I diabetes mellitus with diabetic cataract 
C108F12 Type 1 diabetes mellitus with diabetic cataract 
C108G00 Insulin dependent diab mell with peripheral angiopathy 
C108G11 Type I diabetes mellitus with peripheral angiopathy 
C108G12 Type 1 diabetes mellitus with peripheral angiopathy 
C108H00 Insulin dependent diabetes mellitus with arthropathy 
C108H11 Type I diabetes mellitus with arthropathy 
C108H12 Type 1 diabetes mellitus with arthropathy 
C108J00 Insulin dependent diab mell with neuropathic arthropathy 
C108J11 Type I diabetes mellitus with neuropathic arthropathy 
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy 
C108y00 Other specified diabetes mellitus with multiple comps 
C108z00 Unspecified diabetes mellitus with multiple complications 
C109.00 Non-insulin dependent diabetes mellitus 
C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
C109.12 Type 2 diabetes mellitus 
C109.13 Type II diabetes mellitus 
C109000 Non-insulin-dependent diabetes mellitus with renal comps 
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C109011 Type II diabetes mellitus with renal complications 
C109012 Type 2 diabetes mellitus with renal complications 
C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps 
C109111 Type II diabetes mellitus with ophthalmic complications 
C109112 Type 2 diabetes mellitus with ophthalmic complications 
C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
C109211 Type II diabetes mellitus with neurological complications 
C109212 Type 2 diabetes mellitus with neurological complications 
C109300 Non-insulin-dependent diabetes mellitus with multiple comps 
C109311 Type II diabetes mellitus with multiple complications 
C109312 Type 2 diabetes mellitus with multiple complications 
C109400 Non-insulin dependent diabetes mellitus with ulcer 
C109411 Type II diabetes mellitus with ulcer 
C109412 Type 2 diabetes mellitus with ulcer 
C109500 Non-insulin dependent diabetes mellitus with gangrene 
C109511 Type II diabetes mellitus with gangrene 
C109512 Type 2 diabetes mellitus with gangrene 
C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
C109611 Type II diabetes mellitus with retinopathy 
C109612 Type 2 diabetes mellitus with retinopathy 
C109700 Non-insulin dependent diabetes mellitus - poor control 
C109711 Type II diabetes mellitus - poor control 
C109712 Type 2 diabetes mellitus - poor control 
C109800 Reaven's syndrome 
C109900 Non-insulin-dependent diabetes mellitus without complication 
C109911 Type II diabetes mellitus without complication 
C109912 Type 2 diabetes mellitus without complication 
C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy 
C109A11 Type II diabetes mellitus with mononeuropathy 
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C109A12 Type 2 diabetes mellitus with mononeuropathy 
C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
C109B11 Type II diabetes mellitus with polyneuropathy 
C109B12 Type 2 diabetes mellitus with polyneuropathy 
C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
C109C11 Type II diabetes mellitus with nephropathy 
C109C12 Type 2 diabetes mellitus with nephropathy 
C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma 
C109D11 Type II diabetes mellitus with hypoglycaemic coma 
C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
C109E11 Type II diabetes mellitus with diabetic cataract 
C109E12 Type 2 diabetes mellitus with diabetic cataract 
C109F00 Non-insulin-dependent d m with peripheral angiopath 
C109F11 Type II diabetes mellitus with peripheral angiopathy 
C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
C109G11 Type II diabetes mellitus with arthropathy 
C109G12 Type 2 diabetes mellitus with arthropathy 
C109H00 Non-insulin dependent d m with neuropathic arthropathy 
C109H11 Type II diabetes mellitus with neuropathic arthropathy 
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
C109J00 Insulin treated Type 2 diabetes mellitus 
C109J11 Insulin treated non-insulin dependent diabetes mellitus 
C109J12 Insulin treated Type II diabetes mellitus 
C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10E.00 Type 1 diabetes mellitus 
C10E.11 Type I diabetes mellitus 
C10E.12 Insulin dependent diabetes mellitus 
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C10E000 Type 1 diabetes mellitus with renal complications 
C10E011 Type I diabetes mellitus with renal complications 
C10E012 Insulin-dependent diabetes mellitus with renal complications 
C10E100 Type 1 diabetes mellitus with ophthalmic complications 
C10E111 Type I diabetes mellitus with ophthalmic complications 
C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps 
C10E200 Type 1 diabetes mellitus with neurological complications 
C10E211 Type I diabetes mellitus with neurological complications 
C10E212 Insulin-dependent diabetes mellitus with neurological comps 
C10E400 Unstable type 1 diabetes mellitus 
C10E411 Unstable type I diabetes mellitus 
C10E412 Unstable insulin dependent diabetes mellitus 
C10E500 Type 1 diabetes mellitus with ulcer 
C10E511 Type I diabetes mellitus with ulcer 
C10E512 Insulin dependent diabetes mellitus with ulcer 
C10E600 Type 1 diabetes mellitus with gangrene 
C10E611 Type I diabetes mellitus with gangrene 
C10E612 Insulin dependent diabetes mellitus with gangrene 
C10E700 Type 1 diabetes mellitus with retinopathy 
C10E711 Type I diabetes mellitus with retinopathy 
C10E712 Insulin dependent diabetes mellitus with retinopathy 
C10E800 Type 1 diabetes mellitus - poor control 
C10E811 Type I diabetes mellitus - poor control 
C10E812 Insulin dependent diabetes mellitus - poor control 
C10E900 Type 1 diabetes mellitus maturity onset 
C10E911 Type I diabetes mellitus maturity onset 
C10E912 Insulin dependent diabetes maturity onset 
C10EC00 Type 1 diabetes mellitus with polyneuropathy 
C10EC11 Type I diabetes mellitus with polyneuropathy 
 215 
 
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy 
C10ED00 Type 1 diabetes mellitus with nephropathy 
C10ED11 Type I diabetes mellitus with nephropathy 
C10ED12 Insulin dependent diabetes mellitus with nephropathy 
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
C10EE11 Type I diabetes mellitus with hypoglycaemic coma 
C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C10EF00 Type 1 diabetes mellitus with diabetic cataract 
C10EF11 Type I diabetes mellitus with diabetic cataract 
C10EF12 Insulin dependent diabetes mellitus with diabetic cataract 
C10EH00 Type 1 diabetes mellitus with arthropathy 
C10EH11 Type I diabetes mellitus with arthropathy 
C10EH12 Insulin dependent diabetes mellitus with arthropathy 
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy 
C10EJ11 Type I diabetes mellitus with neuropathic arthropathy 
C10EJ12 Insulin dependent diab mell with neuropathic arthropathy 
C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
C10EK11 Type I diabetes mellitus with persistent proteinuria 
C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
C10EL11 Type I diabetes mellitus with persistent microalbuminuria 
C10EM00 Type 1 diabetes mellitus with ketoacidosis 
C10EM11 Type I diabetes mellitus with ketoacidosis 
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
C10EN11 Type I diabetes mellitus with ketoacidotic coma 
C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
C10EP11 Type I diabetes mellitus with exudative maculopathy 
C10F.00 Type 2 diabetes mellitus 
C10F.11 Type II diabetes mellitus 
C10F000 Type 2 diabetes mellitus with renal complications 
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C10F011 Type II diabetes mellitus with renal complications 
C10F100 Type 2 diabetes mellitus with ophthalmic complications 
C10F111 Type II diabetes mellitus with ophthalmic complications 
C10F200 Type 2 diabetes mellitus with neurological complications 
C10F211 Type II diabetes mellitus with neurological complications 
C10F300 Type 2 diabetes mellitus with multiple complications 
C10F311 Type II diabetes mellitus with multiple complications 
C10F400 Type 2 diabetes mellitus with ulcer 
C10F411 Type II diabetes mellitus with ulcer 
C10F500 Type 2 diabetes mellitus with gangrene 
C10F511 Type II diabetes mellitus with gangrene 
C10F600 Type 2 diabetes mellitus with retinopathy 
C10F611 Type II diabetes mellitus with retinopathy 
C10F700 Type 2 diabetes mellitus - poor control 
C10F711 Type II diabetes mellitus - poor control 
C10F800 Reaven's syndrome 
C10F811 Metabolic syndrome X 
C10F900 Type 2 diabetes mellitus without complication 
C10F911 Type II diabetes mellitus without complication 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10FA11 Type II diabetes mellitus with mononeuropathy 
C10FB00 Type 2 diabetes mellitus with polyneuropathy 
C10FB11 Type II diabetes mellitus with polyneuropathy 
C10FC00 Type 2 diabetes mellitus with nephropathy 
C10FC11 Type II diabetes mellitus with nephropathy 
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
C10FE00 Type 2 diabetes mellitus with diabetic cataract 
C10FE11 Type II diabetes mellitus with diabetic cataract 
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C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
C10FF11 Type II diabetes mellitus with peripheral angiopathy 
C10FG00 Type 2 diabetes mellitus with arthropathy 
C10FG11 Type II diabetes mellitus with arthropathy 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
C10FJ00 Insulin treated Type 2 diabetes mellitus 
C10FJ11 Insulin treated Type II diabetes mellitus 
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
C10FL11 Type II diabetes mellitus with persistent proteinuria 
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
C10FN00 Type 2 diabetes mellitus with ketoacidosis 
C10FN11 Type II diabetes mellitus with ketoacidosis 
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
C10FP11 Type II diabetes mellitus with ketoacidotic coma 
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
C10FQ11 Type II diabetes mellitus with exudative maculopathy 
C10G.00 Secondary pancreatic diabetes mellitus 
C10K.00 Type A insulin resistance 
C10M.00 Lipoatrophic diabetes mellitus 
C10y.00 Diabetes mellitus with other specified manifestation 
C10y000 Diabetes mellitus, juvenile, + other specified manifestation 
C10y100 Diabetes mellitus, adult, + other specified manifestation 
C10yy00 Other specified diabetes mellitus with other spec comps 
C10yz00 Diabetes mellitus NOS with other specified manifestation 
C10z.00 Diabetes mellitus with unspecified complication 
C10z000 Diabetes mellitus, juvenile type, + unspecified complication 
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C10z100 Diabetes mellitus, adult onset, + unspecified complication 
C10zy00 Other specified diabetes mellitus with unspecified comps 
C10zz00 Diabetes mellitus NOS with unspecified complication 
Cyu2.00 [X]Diabetes mellitus 
Cyu2300 [X]Unspecified diabetes mellitus with renal complications 
F171100 Autonomic neuropathy due to diabetes 
F345000 Diabetic mononeuritis multiplex 
F35z000 Diabetic mononeuritis NOS 
F372.00 Polyneuropathy in diabetes 
F372.11 Diabetic polyneuropathy 
F372.12 Diabetic neuropathy 
F372000 Acute painful diabetic neuropathy 
F372100 Chronic painful diabetic neuropathy 
F372200 Asymptomatic diabetic neuropathy 
F381300 Myasthenic syndrome due to diabetic amyotrophy 
F381311 Diabetic amyotrophy 
F3y0.00 Diabetic mononeuropathy 
F420.00 Diabetic retinopathy 
F420000 Background diabetic retinopathy 
F420100 Proliferative diabetic retinopathy 
F420200 Preproliferative diabetic retinopathy 
F420300 Advanced diabetic maculopathy 
F420400 Diabetic maculopathy 
F420500 Advanced diabetic retinal disease 
F420600 Non proliferative diabetic retinopathy 
F420700 High risk proliferative diabetic retinopathy 
F420800 High risk non proliferative diabetic retinopathy 
F420z00 Diabetic retinopathy NOS 
F440700 Diabetic iritis 
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F464000 Diabetic cataract 
G73y000 Diabetic peripheral angiopathy 
K01x100 Nephrotic syndrome in diabetes mellitus 
K01x111 Kimmelstiel - Wilson disease 
Kyu0300 [X]Glomerular disorders in diabetes mellitus 
L180500 Pre-existing diabetes mellitus, insulin-dependent 
L180600 Pre-existing diabetes mellitus, non-insulin-dependent 
L180700 Pre-existing malnutrition-related diabetes mellitus 
L180X00 Pre-existing diabetes mellitus, unspecified 
Lyu2900 [X]Pre-existing diabetes mellitus, unspecified 
M037200 Cellulitis in diabetic foot 
M271000 Ischaemic ulcer diabetic foot 
M271100 Neuropathic diabetic ulcer - foot 
M271200 Mixed diabetic ulcer - foot 
N030000 Diabetic cheiroarthropathy 
N030011 Diabetic cheiropathy 
N030100 Diabetic Charcot arthropathy 
R054200 [D]Gangrene of toe in diabetic 
R054300 [D]Widespread diabetic foot gangrene 
ZV65312 [V]Dietary counselling in diabetes mellitus 
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Read codes used to identify pregnancy 
 
Note: First 100 codes from list of 3154 presented here to demonstrate range of codes in full 
table. 
 
Read code Description 
  
13H7.00 Unwanted pregnancy 
13H7.11 Unwanted child 
13H8.00 Illegitimate pregnancy 
13S..00 Pregnancy benefits 
13S..11 Maternity allowances 
13SZ.00 Pregnancy benefit NOS 
1514.00 Estimated date of confinement 
1514.11 Due to deliver - EDC 
1514.12 Estimated date of delivery 
27...00 Obstetric examination 
271..00 O/E - gravid uterus size 
271..11 O/E - fundus size - obstetric 
271..12 O/E - uterus size - obstetric 
272..00 O/E - fetal presentation 
272..11 O/E - lie of fetus 
272..12 O/E - presenting part 
2726.00 O/E -fetal presentation unsure 
272Z.00 O/E - fetal presentation NOS 
274Z.00 O/E - fetal station NOS 
275..00 O/E - fetal movements 
2751.00 O/E - no fetal movements 
2752.00 O/E - fetal movements seen 
 221 
 
2753.00 O/E - fetal movements felt 
2754.00 O/E - fetus very active 
2755.00 O/E - fetal movemnt.diminished 
275Z.00 O/E - fetal movements NOS 
276..00 O/E - fetal heart heard 
2761.00 O/E - fetal heart not heard 
2762.00 O/E - fetal heart < 40 
2763.00 O/E - fetal heart 40-80 
2764.00 O/E - fetal heart 80-100 
2765.00 O/E - fetal heart 100-120 
2766.00 O/E - fetal heart 120-160 
2767.00 O/E - fetal heart 160-180 
2768.00 O/E - fetal heart 180-200 
2769.00 O/E - fetal heart > 200 
276A.00 O/E - fetal heart -type 1 dips 
276B.00 O/E - fetal heart -type 2 dips 
276Z.00 O/E - fetal heart NOS 
27A..00 O/E - VE - descent of P. part 
27A..11 O/E - VE - descent of fetus 
27A..12 O/E - VE - presenting part 
27B..00 O/E - viable fetus 
27Z..00 Obstetric examination NOS 
3188.00 Placental localisation 
3885.00 Edinburgh postnatal depression scale 
444..00 Feto/placental hormones 
4441.00 Feto/placent. hormones abnorm. 
4442.00 Feto/placen. hormones normal 
4443.00 Placental lactogen - HPL 
4443.11 HPL - Human placental lactogen level 
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4443000 Human placental lactogen level normal 
4443100 HPL - Human placental lactogen abnormal 
4444.00 Serum oestriol level 
4444.11 Human placental lactogen 
4444.12 Placental lactogen 
4445.00 Placental function test 
4445000 Placental function test normal 
4445100 Placental function test abnormal 
444Z.00 Feto/placental hormones NOS 
4453.00 Serum pregnancy test positive 
4654.00 Urine pregnancy test positive 
4H...00 Amniotic fluid examination 
4H...11 Liquor examination 
4H1..00 Amniotic fluid exam. - general 
4H11.00 Amniotic fluid sent for exam. 
4H12.00 Amniotic fluid - nil abnormal 
4H13.00 Amniotic fluid - abnormality 
4H1Z.00 Amniotic fluid exam. gen. NOS 
4H2..00 Amniotic fluid appearance 
4H21.00 Amniotic fluid - clear 
4H22.00 Amniotic fluid - blood stained 
4H23.00 Amniotic fluid -meconium stain 
4H2Z.00 Amniotic fluid appearance NOS 
4H3..00 Amniotic fluid microscopy 
4H31.00 Amniotic fluid microscopy -NAD 
4H32.00 Amniotic fluid microsc. - abn. 
4H33.00 Amniotic fluid cell content OK 
4H3Z.00 Amniotic fluid microscopy NOS 
4H4..00 Amniotic fluid chemistry 
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4H41.00 Amniotic fluid chemistry: NAD 
4H42.00 Amniotic fluid chemistry: abn. 
4H43.00 Amniotic fluid L/S ratio 
4H43.11 Lecithin - amniotic 
4H43.12 Sphingomyelin -amniotic 
4H44.00 Amniotic fluid palmitic acid 
4H45.00 Amniotic fluid cholinesterase 
4H4Z.00 Amniotic fluid chemistry NOS 
4H5..00 Amniotic fluid AFP 
4H51.00 Amniotic fluid AFP normal 
4H52.00 Amniotic fluid AFP equivocal 
4H53.00 Amniotic fluid AFP abnormal 
4H5Z.00 Amniotic fluid AFP NOS 
4H7..00 Amniotic fetal cell study 
4H71.00 Amniotic fetal cell study: NAD 
4H72.00 Amniotic fetal cell abnormal 
4H73.00 Amniotic fetal cell: mongol 
4H7Z.00 Amniotic fetal cell study NOS 
4HZ..00 Amniotic fluid exam. NOS 
4JL3.00 Amniotic fluid for organism 
  
 
  
 224 
 
Read codes used to identify cases of CHD 
 
Read code Description 
  14A3.00 H/O: myocardial infarct <60 
14A4.00 H/O: myocardial infarct >60 
14A5.00 H/O: angina pectoris 
14AH.00 H/O: Myocardial infarction in last year 
14AJ.00 H/O: Angina in last year 
14AL.00 H/O: Treatment for ischaemic heart disease 
322..00 ECG: myocardial ischaemia 
3222.00 ECG:shows myocardial ischaemia 
322Z.00 ECG: myocardial ischaemia NOS 
323..00 ECG: myocardial infarction 
3232.00 ECG: old myocardial infarction 
3233.00 ECG: antero-septal infarct. 
3234.00 ECG:posterior/inferior infarct 
3235.00 ECG: subendocardial infarct 
3236.00 ECG: lateral infarction 
323Z.00 ECG: myocardial infarct NOS 
44H3.00 Cardiac enzymes abnormal 
44H3000 Cardiac enzymes abnormal - first set 
5543.00 Coronary arteriograph.abnormal 
662K.00 Angina control 
662K000 Angina control - good 
662K100 Angina control - poor 
662K200 Angina control - improving 
662K300 Angina control - worsening 
662Kz00 Angina control NOS 
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790H300 Revascularisation of wall of heart 
792..00 Coronary artery operations 
792..11 Coronary artery bypass graft operations 
7920.00 Saphenous vein graft replacement of coronary artery 
7920.11 Saphenous vein graft bypass of coronary artery 
7920000 Saphenous vein graft replacement of one coronary artery 
7920100 Saphenous vein graft replacement of two coronary arteries 
7920200 Saphenous vein graft replacement of three coronary arteries 
7920300 Saphenous vein graft replacement of four+ coronary arteries 
7920y00 Saphenous vein graft replacement of coronary artery OS 
7920z00 Saphenous vein graft replacement coronary artery NOS 
7921.00 Other autograft replacement of coronary artery 
7921.11 Other autograft bypass of coronary artery 
7921000 Autograft replacement of one coronary artery NEC 
7921100 Autograft replacement of two coronary arteries NEC 
7921200 Autograft replacement of three coronary arteries NEC 
7921300 Autograft replacement of four of more coronary arteries NEC 
7921y00 Other autograft replacement of coronary artery OS 
7921z00 Other autograft replacement of coronary artery NOS 
7922.00 Allograft replacement of coronary artery 
7922.11 Allograft bypass of coronary artery 
7922000 Allograft replacement of one coronary artery 
7922100 Allograft replacement of two coronary arteries 
7922200 Allograft replacement of three coronary arteries 
7922300 Allograft replacement of four or more coronary arteries 
7922y00 Other specified allograft replacement of coronary artery 
7922z00 Allograft replacement of coronary artery NOS 
7923.00 Prosthetic replacement of coronary artery 
7923.11 Prosthetic bypass of coronary artery 
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7923000 Prosthetic replacement of one coronary artery 
7923100 Prosthetic replacement of two coronary arteries 
7923200 Prosthetic replacement of three coronary arteries 
7923300 Prosthetic replacement of four or more coronary arteries 
7923y00 Other specified prosthetic replacement of coronary artery 
7923z00 Prosthetic replacement of coronary artery NOS 
7924.00 Revision of bypass for coronary artery 
7924000 Revision of bypass for one coronary artery 
7924100 Revision of bypass for two coronary arteries 
7924200 Revision of bypass for three coronary arteries 
7924300 Revision of bypass for four or more coronary arteries 
7924400 Revision of connection of thoracic artery to coronary artery 
7924500 Revision of implantation of thoracic artery into heart 
7924y00 Other specified revision of bypass for coronary artery 
7924z00 Revision of bypass for coronary artery NOS 
7925.00 Connection of mammary artery to coronary artery 
7925.11 Creation of bypass from mammary artery to coronary artery 
7925000 Double anastomosis of mammary arteries to coronary arteries 
7925011 LIMA sequential anastomosis 
7925012 RIMA sequential anastomosis 
7925100 Double implant of mammary arteries into coronary arteries 
7925200 Single anast mammary art to left ant descend coronary art 
7925300 Single anastomosis of mammary artery to coronary artery NEC 
7925311 LIMA single anastomosis 
7925312 RIMA single anastomosis 
7925400 Single implantation of mammary artery into coronary artery 
7925y00 Connection of mammary artery to coronary artery OS 
7925z00 Connection of mammary artery to coronary artery NOS 
7926.00 Connection of other thoracic artery to coronary artery 
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7926000 Double anastom thoracic arteries to coronary arteries NEC 
7926100 Double implant thoracic arteries into coronary arteries NEC 
7926200 Single anastomosis of thoracic artery to coronary artery NEC 
7926300 Single implantation thoracic artery into coronary artery NEC 
7926y00 Connection of other thoracic artery to coronary artery OS 
7926z00 Connection of other thoracic artery to coronary artery NOS 
7927.00 Other open operations on coronary artery 
7927500 Open angioplasty of coronary artery 
7928.00 Transluminal balloon angioplasty of coronary artery 
7928.11 Percutaneous balloon coronary angioplasty 
7928000 Percut transluminal balloon angioplasty one coronary artery 
7928100 Percut translum balloon angioplasty mult coronary arteries 
7928200 Percut translum balloon angioplasty bypass graft coronary a 
7928y00 Transluminal balloon angioplasty of coronary artery OS 
7928z00 Transluminal balloon angioplasty of coronary artery NOS 
7929.00 Other therapeutic transluminal operations on coronary artery 
7929000 Percutaneous transluminal laser coronary angioplasty 
7929100 Percut transluminal coronary thrombolysis with streptokinase 
7929111 Percut translum coronary thrombolytic therapy- streptokinase 
7929200 Percut translum inject therap subst to coronary artery NEC 
7929300 Rotary blade coronary angioplasty 
7929400 Insertion of coronary artery stent 
7929y00 Other therapeutic transluminal op on coronary artery OS 
7929z00 Other therapeutic transluminal op on coronary artery NOS 
792B.00 Repair of coronary artery NEC 
792B000 Endarterectomy of coronary artery NEC 
792By00 Other specified repair of coronary artery 
792Bz00 Repair of coronary artery NOS 
792C.00 Other replacement of coronary artery 
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792C000 Replacement of coronary arteries using multiple methods 
792Cy00 Other specified replacement of coronary artery 
792Cz00 Replacement of coronary artery NOS 
792D.00 Other bypass of coronary artery 
792Dy00 Other specified other bypass of coronary artery 
792Dz00 Other bypass of coronary artery NOS 
792y.00 Other specified operations on coronary artery 
792z.00 Coronary artery operations NOS 
88A8.00 Thrombolytic therapy 
88A8.11 Fibrinolysis 
8B27.00 Antianginal therapy 
8B3k.00 Coronary heart disease medication review 
8B63.11 Aspirin prophylaxis - IHD 
G3...00 Ischaemic heart disease 
G3...11 Arteriosclerotic heart disease 
G3...12 Atherosclerotic heart disease 
G3...13 IHD - Ischaemic heart disease 
G30..00 Acute myocardial infarction 
G30..11 Attack - heart 
G30..12 Coronary thrombosis 
G30..13 Cardiac rupture following myocardial infarction (MI) 
G30..14 Heart attack 
G30..15 MI - acute myocardial infarction 
G30..16 Thrombosis - coronary 
G30..17 Silent myocardial infarction 
G300.00 Acute anterolateral infarction 
G301.00 Other specified anterior myocardial infarction 
G301000 Acute anteroapical infarction 
G301100 Acute anteroseptal infarction 
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G301z00 Anterior myocardial infarction NOS 
G302.00 Acute inferolateral infarction 
G303.00 Acute inferoposterior infarction 
G304.00 Posterior myocardial infarction NOS 
G305.00 Lateral myocardial infarction NOS 
G306.00 True posterior myocardial infarction 
G307.00 Acute subendocardial infarction 
G307000 Acute non-Q wave infarction 
G307100 Acute non-ST segment elevation myocardial infarction 
G308.00 Inferior myocardial infarction NOS 
G309.00 Acute Q-wave infarct 
G30A.00 Mural thrombosis 
G30B.00 Acute posterolateral myocardial infarction 
G30X.00 Acute transmural myocardial infarction of unspecif site 
G30X000 Acute ST segment elevation myocardial infarction 
G30y.00 Other acute myocardial infarction 
G30y000 Acute atrial infarction 
G30y100 Acute papillary muscle infarction 
G30y200 Acute septal infarction 
G30yz00 Other acute myocardial infarction NOS 
G30z.00 Acute myocardial infarction NOS 
G31..00 Other acute and subacute ischaemic heart disease 
G310.00 Postmyocardial infarction syndrome 
G310.11 Dressler's syndrome 
G311.00 Preinfarction syndrome 
G311.11 Crescendo angina 
G311.12 Impending infarction 
G311.13 Unstable angina 
G311.14 Angina at rest 
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G311000 Myocardial infarction aborted 
G311011 MI - myocardial infarction aborted 
G311100 Unstable angina 
G311200 Angina at rest 
G311300 Refractory angina 
G311400 Worsening angina 
G311500 Acute coronary syndrome 
G311z00 Preinfarction syndrome NOS 
G312.00 Coronary thrombosis not resulting in myocardial infarction 
G31y.00 Other acute and subacute ischaemic heart disease 
G31y000 Acute coronary insufficiency 
G31y100 Microinfarction of heart 
G31y200 Subendocardial ischaemia 
G31y300 Transient myocardial ischaemia 
G31yz00 Other acute and subacute ischaemic heart disease NOS 
G32..00 Old myocardial infarction 
G32..11 Healed myocardial infarction 
G32..12 Personal history of myocardial infarction 
G33..00 Angina pectoris 
G330.00 Angina decubitus 
G330000 Nocturnal angina 
G330z00 Angina decubitus NOS 
G331.00 Prinzmetal's angina 
G331.11 Variant angina pectoris 
G332.00 Coronary artery spasm 
G33z.00 Angina pectoris NOS 
G33z000 Status anginosus 
G33z100 Stenocardia 
G33z200 Syncope anginosa 
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G33z300 Angina on effort 
G33z400 Ischaemic chest pain 
G33z500 Post infarct angina 
G33z600 New onset angina 
G33z700 Stable angina 
G33zz00 Angina pectoris NOS 
G34..00 Other chronic ischaemic heart disease 
G340.00 Coronary atherosclerosis 
G340.11 Triple vessel disease of the heart 
G340.12 Coronary artery disease 
G340000 Single coronary vessel disease 
G340100 Double coronary vessel disease 
G341.00 Aneurysm of heart 
G341.11 Cardiac aneurysm 
G341000 Ventricular cardiac aneurysm 
G341100 Other cardiac wall aneurysm 
G341111 Mural cardiac aneurysm 
G341200 Aneurysm of coronary vessels 
G341300 Acquired atrioventricular fistula of heart 
G341z00 Aneurysm of heart NOS 
G342.00 Atherosclerotic cardiovascular disease 
G343.00 Ischaemic cardiomyopathy 
G344.00 Silent myocardial ischaemia 
G34y.00 Other specified chronic ischaemic heart disease 
G34y000 Chronic coronary insufficiency 
G34y100 Chronic myocardial ischaemia 
G34yz00 Other specified chronic ischaemic heart disease NOS 
G34z.00 Other chronic ischaemic heart disease NOS 
G34z000 Asymptomatic coronary heart disease 
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G35..00 Subsequent myocardial infarction 
G350.00 Subsequent myocardial infarction of anterior wall 
G351.00 Subsequent myocardial infarction of inferior wall 
G353.00 Subsequent myocardial infarction of other sites 
G35X.00 Subsequent myocardial infarction of unspecified site 
G36..00 Certain current complication follow acute myocardial infarct 
G360.00 Haemopericardium/current comp folow acut myocard infarct 
G361.00 Atrial septal defect/curr comp folow acut myocardal infarct 
G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn 
G363.00 Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI 
G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct 
G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct 
G366.00 Thrombosis atrium,auric append&vent/curr comp foll acute MI 
G37..00 Cardiac syndrome X 
G38..00 Postoperative myocardial infarction 
G380.00 Postoperative transmural myocardial infarction anterior wall 
G381.00 Postoperative transmural myocardial infarction inferior wall 
G382.00 Postoperative transmural myocardial infarction other sites 
G383.00 Postoperative transmural myocardial infarction unspec site 
G384.00 Postoperative subendocardial myocardial infarction 
G38z.00 Postoperative myocardial infarction, unspecified 
G3y..00 Other specified ischaemic heart disease 
G3z..00 Ischaemic heart disease NOS 
Gyu3.00 [X]Ischaemic heart diseases 
Gyu3000 [X]Other forms of angina pectoris 
Gyu3100 [X]Other current complicatns following acute myocard infarct 
Gyu3200 [X]Other forms of acute ischaemic heart disease 
Gyu3300 [X]Other forms of chronic ischaemic heart disease 
Gyu3400 [X]Acute transmural myocardial infarction of unspecif site 
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Gyu3500 [X]Subsequent myocardial infarction of other sites 
Gyu3600 [X]Subsequent myocardial infarction of unspecified site 
SP00300 Mechanical complication of coronary bypass 
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Read codes used to identify cases of stroke 
 
Read code Description 
  
G6...00 Cerebrovascular disease 
G60..00 Subarachnoid haemorrhage 
G600.00 Ruptured berry aneurysm 
G601.00 Subarachnoid haemorrhage from carotid siphon and bifurcation 
G602.00 Subarachnoid haemorrhage from middle cerebral artery 
G603.00 Subarachnoid haemorrhage from anterior communicating artery 
G604.00 Subarachnoid haemorrhage from posterior communicating artery 
G605.00 Subarachnoid haemorrhage from basilar artery 
G606.00 Subarachnoid haemorrhage from vertebral artery 
G60X.00 Subarachnoid haemorrh from intracranial artery, unspecif 
G60z.00 Subarachnoid haemorrhage NOS 
G61..00 Intracerebral haemorrhage 
G61..11 CVA - cerebrovascular accid due to intracerebral haemorrhage 
G61..12 Stroke due to intracerebral haemorrhage 
G610.00 Cortical haemorrhage 
G611.00 Internal capsule haemorrhage 
G612.00 Basal nucleus haemorrhage 
G613.00 Cerebellar haemorrhage 
G614.00 Pontine haemorrhage 
G615.00 Bulbar haemorrhage 
G616.00 External capsule haemorrhage 
G617.00 Intracerebral haemorrhage, intraventricular 
G618.00 Intracerebral haemorrhage, multiple localized 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified 
G61X000 Left sided intracerebral haemorrhage, unspecified 
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G61X100 Right sided intracerebral haemorrhage, unspecified 
G61z.00 Intracerebral haemorrhage NOS 
G62..00 Other and unspecified intracranial haemorrhage 
G620.00 Extradural haemorrhage - nontraumatic 
G621.00 Subdural haemorrhage - nontraumatic 
G622.00 Subdural haematoma - nontraumatic 
G623.00 Subdural haemorrhage NOS 
G62z.00 Intracranial haemorrhage NOS 
G63..00 Precerebral arterial occlusion 
G63..11 Infarction - precerebral 
G630.00 Basilar artery occlusion 
G631.00 Carotid artery occlusion 
G631.12 Thrombosis, carotid artery 
G632.00 Vertebral artery occlusion 
G633.00 Multiple and bilateral precerebral arterial occlusion 
G63y.00 Other precerebral artery occlusion 
G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
G63y100 Cerebral infarction due to embolism of precerebral arteries 
G63z.00 Precerebral artery occlusion NOS 
G64..00 Cerebral arterial occlusion 
G64..11 CVA - cerebral artery occlusion 
G64..12 Infarction - cerebral 
G64..13 Stroke due to cerebral arterial occlusion 
G640.00 Cerebral thrombosis 
G640000 Cerebral infarction due to thrombosis of cerebral arteries 
G641.00 Cerebral embolism 
G641.11 Cerebral embolus 
G641000 Cerebral infarction due to embolism of cerebral arteries 
G64z.00 Cerebral infarction NOS 
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G64z.11 Brainstem infarction NOS 
G64z.12 Cerebellar infarction 
G64z000 Brainstem infarction 
G64z100 Wallenberg syndrome 
G64z111 Lateral medullary syndrome 
G64z200 Left sided cerebral infarction 
G64z300 Right sided cerebral infarction 
G64z400 Infarction of basal ganglia 
G66..00 Stroke and cerebrovascular accident unspecified 
G66..11 CVA unspecified 
G66..12 Stroke unspecified 
G66..13 CVA - Cerebrovascular accident unspecified 
G660.00 Middle cerebral artery syndrome 
G661.00 Anterior cerebral artery syndrome 
G662.00 Posterior cerebral artery syndrome 
G663.00 Brain stem stroke syndrome 
G664.00 Cerebellar stroke syndrome 
G665.00 Pure motor lacunar syndrome 
G666.00 Pure sensory lacunar syndrome 
G667.00 Left sided CVA 
G668.00 Right sided CVA 
G669.00 Cerebral palsy, not congenital or infantile, acute 
G67..00 Other cerebrovascular disease 
G670.00 Cerebral atherosclerosis 
G670.11 Precerebral atherosclerosis 
G671.00 Generalised ischaemic cerebrovascular disease NOS 
G671000 Acute cerebrovascular insufficiency NOS 
G671100 Chronic cerebral ischaemia 
G671z00 Generalised ischaemic cerebrovascular disease NOS 
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G672.00 Hypertensive encephalopathy 
G673.00 Cerebral aneurysm, nonruptured 
G673000 Dissection of cerebral arteries, nonruptured 
G673100 Carotico-cavernous sinus fistula 
G674.00 Cerebral arteritis 
G674000 Cerebral amyloid angiopathy 
G675.00 Moyamoya disease 
G676.00 Nonpyogenic venous sinus thrombosis 
G676000 Cereb infarct due cerebral venous thrombosis, nonpyogenic 
G677.00 Occlusion/stenosis cerebral arts not result cerebral infarct 
G677000 Occlusion and stenosis of middle cerebral artery 
G677100 Occlusion and stenosis of anterior cerebral artery 
G677200 Occlusion and stenosis of posterior cerebral artery 
G677300 Occlusion and stenosis of cerebellar arteries 
G677400 Occlusion+stenosis of multiple and bilat cerebral arteries 
G678.00 Cereb autosom dominant arteriop subcort infarcts leukoenceph 
G67y.00 Other cerebrovascular disease OS 
G67z.00 Other cerebrovascular disease NOS 
G68..00 Late effects of cerebrovascular disease 
G680.00 Sequelae of subarachnoid haemorrhage 
G681.00 Sequelae of intracerebral haemorrhage 
G682.00 Sequelae of other nontraumatic intracranial haemorrhage 
G683.00 Sequelae of cerebral infarction 
G68W.00 Sequelae/other + unspecified cerebrovascular diseases 
G68X.00 Sequelae of stroke,not specfd as h'morrhage or infarction 
G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries 
G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
G6y..00 Other specified cerebrovascular disease 
G6z..00 Cerebrovascular disease NOS 
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Read codes used to identify cases of CKD 
 
Dialysis codes 
 
Read code Description 
  
14V2.11 H/O: kidney dialysis 
7L1A.00 Compensation for renal failure 
7L1A.11 Dialysis for renal failure 
7L1A000 Renal dialysis 
7L1A011 Thomas intravascular shunt for dialysis 
7L1A100 Peritoneal dialysis 
7L1A200 Haemodialysis NEC 
7L1Ay00 Other specified compensation for renal failure 
7L1Az00 Compensation for renal failure NOS 
7L1B.11 Placement ambulatory dialysis apparatus - compens renal fail 
7L1B000 Insertion of ambulatory peritoneal dialysis catheter 
7L1B100 Removal of ambulatory peritoneal dialysis catheter 
7L1By00 Placement ambulatory apparatus- compensate renal failure OS 
7L1Bz00 Placement ambulatory apparatus- compensate renal failure NOS 
7L1C.00 Placement other apparatus for compensation for renal failure 
7L1C000 Insertion of temporary peritoneal dialysis catheter 
7L1Cy00 Placement other apparatus- compensate for renal failure OS 
7L1Cz00 Placement other apparatus- compensate for renal failure NOS 
8882.00 Intestinal dialysis 
SP01500 Mechanical complication of dialysis catheter 
SP05613 [X] Peritoneal dialysis associated peritonitis 
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TA02.00 Accid cut,puncture,perf,h'ge - kidney dialysis/oth perfusion 
TA02000 Accid cut,puncture,perf,h'ge - kidney dialysis 
TA02011 Accidental cut/puncture/perf/haem'ge during renal dialysis 
TA12000 Foreign object left in body during kidney dialysis 
TA12011 Foreign object left in body during renal dialysis 
TA22000 Failure of sterile precautions during kidney dialysis 
TA22011 Failure of sterile precautions during renal dialysis 
TA42000 Mechanical failure of apparatus during kidney dialysis 
TA42011 Mechanical failure of apparatus during renal dialysis 
TB11.00 Kidney dialysis with complication, without blame 
TB11.11 Renal dialysis with complication, without blame 
U641.00 [X]Kidny dialysis caus abn reac pt/lat comp no misad at time 
Z1A..00 Dialysis training 
Z1A1.00 Peritoneal dialysis training 
Z1A1.11 PD - Peritoneal dialysis training 
Z1A2.00 Haemodialysis training 
Z1A2.11 HD - Haemodialysis training 
Z919.00 Care of haemodialysis equipment 
Z919100 Priming haemodialysis lines 
Z919200 Washing back through haemodialysis lines 
Z919300 Reversing haemodialysis lines 
Z919400 Recirculation of the dialysis machine 
Z91A.00 Peritoneal dialysis bag procedure 
Z91A100 Putting additive into peritoneal dialysis bag 
ZV45100 [V]Renal dialysis status 
ZV56.00 [V]Aftercare involving intermittent dialysis 
ZV56000 [V]Aftercare involving extracorporeal dialysis 
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ZV56011 [V]Aftercare involving renal dialysis NOS 
ZV56100 [V]Preparatory care for dialysis 
ZV56y00 [V]Other specified aftercare involving intermittent dialysis 
ZV56y11 [V]Aftercare involving peritoneal dialysis 
ZV56z00 [V]Unspecified aftercare involving intermittent dialysis 
ZVu3G00 [X]Other dialysis 
  
 
CKD codes 
 
Read code Description 
  K05..00 Chronic renal failure 
K05..11 Chronic uraemia 
K05..12 End stage renal failure 
K050.00 End stage renal failure 
K06..00 Renal failure unspecified 
K06..11 Uraemia NOS 
K060.00 Renal impairment 
K060.11 Impaired renal function 
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Appendix 7    
 
Validation of method used to estimate baseline clinical values 
 
Table A7.1 Validation of method used to estimate baseline clinical values: comparison of 
simple mean and multilevel model results 
 Cases 
Observed and estimated 
baseline mean value (SD) 
F-test 
Observed 
Mean 
value 
model 
Multilevel 
model 
RSS for 
mean 
value 
model 
RSS for 
multilevel 
model 
df for 
multilevel 
model 
F-value 
(p) 
         
SBP 3643 146 142  146 849746 648467 40 28 
  (21) (14) (14)    (<0.0001) 
         
HbA1C 3643 8.6 7.3  8.0 17187 7205 40 125  
  (2.4) (1.2) (1.6)    (<0.0001) 
         
BMI 3643 30.8 30.3  30.5 8590 4170 39 98  
  (6.0) (5.7) (5.7)    (<0.0001) 
         
Total 3643 5.7 5.0  5.5 4835 1656 40 173 
cholesterol  (1.3) (0.9) (1.0)    (<0.0001) 
         
eGFR 3618 72 71  71 212206 126256 40 61  
  (17) (16) (15)    (<0.0001) 
         
Note: Cohort restricted to cases with observed clinical value within 90 days of diagnosis of diabetes. RSS = residual sum of squares. df = 
degrees of freedom  
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Graphs used to compare observed and modelled risk factors 
 
Figure A7.1 Observed and modelled BMI over study period 
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Figure A7.2 Observed and modelled total cholesterol over study period 
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Figure A7.3 Observed and modelled eGFR over study period 
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Log-log plots used to assess PH assumption for each prediction model  
 
Figure A7.4 Log-log plots: smoker at diagnosis of diabetes 
 
Note: Both axes are on logarithmic scales.  
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Figure A7.5 Log-log plots: CHD prior to diabetes or in first 3 months following diabetes 
 
Note: Both axes are on logarithmic scales. 
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Figure A7.6 Log-log plots: stroke prior to diabetes or in first 3 months following 
diabetes 
 
Note: Both axes are on logarithmic scales. 
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Figure A7.7 Log-log plots: CKD prior to diabetes or in first 3 months following diabetes 
 
Note: Both axes are on logarithmic scales.  
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Figure A7.8 Log-log plots: HbA1C 
 
Note: Both axes are on logarithmic scales.  
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Figure A7.9 Log-log plots: BMI 
 
Note: Both axes are on logarithmic scales.  
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Figure A7.10 Log-log plots: High SBP or treated BP compared with low and untreated 
BP 
 
Note: Both axes are on logarithmic scales.  
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Figure A7.11 Log-log plots: High or treated cholesterol compared with low and 
untreated cholesterol 
 
Note: Both axes are on logarithmic scales.  
 253 
 
Management of diabetes and diabetic-related risks 
 
Table A7.2 Percentage of smokers continuing to smoke following diabetes diagnosis 
Years following 
diagnosis 
Percentage still 
smoking 
  
0 100% 
1 99% 
2 94% 
3 80% 
4 63% 
5 47% 
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Table A7.3 Percentage of cases prescribed or using drugs of interest before and after 
diabetes diagnosis 
 
One year 
prior to 
diagnosis 
At 
diagnosis 
3 months 
after 
diagnosis 
One year 
after 
diagnosis 
     
Diabetes management     
Any oral antidiabetic - 5% 32% 46% 
Biguanide - 3% 21% 34% 
Sulphonylurea - 2% 14% 21% 
Glitazone - 0% 6% 23% 
Meglitinide - 0% 2% 6% 
Acarbose / Guarnine - 0% 1% 2% 
     
Insulin - - 3% 3% 
     
Prevention of cardiovascular 
disease 
    
Blood pressure lowering drugs 58% 64% 69% 74% 
Lipid lowering drugs 14% 19% 29% 42% 
Aspirin (prescribed) 23% 28% 34% 41% 
Aspirin (OTC) 2% 4% 6% 8% 
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Results of multilevel models to predict baseline clinical values 
 
 
Table A7.4 Multilevel model used to estimate baseline systolic blood pressure 
          
Systolic BP coefficient  p          95% CI 
  
   
  
    
  
year of diagnosis 1998 0.34 0.525 -0.72 1.41 
(reference year = 2000) 1999 0.07 0.889 -0.86 0.99 
(1998 and 2001 omitted due 2001 -1.20 0.001 -1.93 -0.46 
to collinearity) 2002 -1.79 <0.001 -2.48 -1.10 
2003 -3.14 <0.001 -3.81 -2.46 
  
    
age at diagnosis 35-44 -10.10 <0.001 -10.96 -9.23 
(reference age group = 55-64) 45-54 -3.32 <0.001 -3.94 -2.70 
65-74 2.95 <0.001 2.42 3.47 
75-84 4.92 <0.001 4.28 5.57 
85-94 1.88 0.002 0.67 3.09 
95+ -10.37 0.001 -16.42 -4.32 
  
    male -1.95 <0.001 -2.36 -1.54
smoker -0.28 0.069 -0.59 0.02 
  
    
Townsend quintile (least deprived) 1 -0.06 0.817 -0.52 0.41 
(reference quintile = 3) 2 -0.14 0.561 -0.60 0.33 
4 -0.42 0.072 -0.88 0.04 
(most deprived) 5  -0.55 0.030 -1.04 -0.05 
  
    
region north -0.21 0.391 -0.70 0.27 
(reference = middle) south -0.04 0.887 -0.52 0.45 
  
    comorbidities prior chd -1.40 <0.001 -1.91 -0.90
prior chd 2.07 <0.001 1.62 2.51 
prior stroke 1.32 0.001 0.57 2.06 
  
    drug treatments insulin 2.52 <0.001 1.56 3.49
sulphonylurea 0.40 0.005 0.12 0.67 
biguanide -0.14 0.216 -0.36 0.08 
acarbose -1.40 0.167 -3.37 0.58 
meglitinide 1.22 0.061 -0.06 2.49 
glitazone -0.06 0.824 -0.59 0.47 
statin -1.50 <0.001 -1.71 -1.28 
other lipid lowering -0.83 0.022 -1.53 -0.12 
antianginal(excl. CCB) -1.84 <0.001 -2.26 -1.41 
aspirin -0.01 0.954 -0.25 0.24 
OTC aspirin -9.58 0.104 -21.13 1.97 
other antiplatelet -0.88 0.006 -1.50 -0.25 
angiotensin-II receptor antagonist -1.11 <0.001 -1.46 -0.76 
ACE inhibitor -2.93 <0.001 -3.15 -2.71 
alphablocker -1.67 <0.001 -2.05 -1.29 
calcium channel blocker -2.42 <0.001 -2.71 -2.13 
diuretic -2.44 <0.001 -2.72 -2.15 
  
    slope(per day) -0.004 <0.001 -0.004 -0.003 
intercept 150.89 <0.001 150.05 151.74 
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Table A7.5 Multilevel model used to estimate baseline BMI 
          
BMI coefficient  p          95% CI 
  
   
  
    
  
year of diagnosis 1998 
-1.09 <0.001 -1.46 -0.72 
(reference year = 2000) 1999 0.78 <0.001 0.47 1.09 
(1998 and 2001 omitted due 2001 0.00 0.983 -0.25 0.25 
to collinearity) 2002 -0.66 <0.001 -0.90 -0.42 
2003 -0.18 0.141 -0.41 0.06 
  
 
   
age at diagnosis 35-44 
3.04 <0.001 2.74 3.33 
(reference age group = 55-64) 45-54 1.02 <0.001 0.82 1.23 
65-74 -1.88 <0.001 -2.05 -1.70 
75-84 -4.23 <0.001 -4.45 -4.01 
85-94 -6.25 <0.001 -6.73 -5.76 
95+ -8.36 <0.001 -11.52 -5.20 
  
 
   
male -1.28 <0.001 -1.42 -1.15 
smoker 
-0.23 <0.001 -0.27 -0.18 
  
 
   
Townsend quintile (least deprived) 1 
-0.69 <0.001 -0.86 -0.53 
(reference quintile = 3) 2 
0.18 0.033 0.01 0.34 
4 0.28 0.001 0.12 0.44 
(most deprived) 5  0.66 <0.001 0.49 0.83 
  
 
   
region north 
0.18 0.051 0.00 0.36 
(reference = middle) south -0.22 0.014 -0.40 -0.05 
  
 
   
comorbidities prior chd -0.07 0.382 -0.23 0.09 
prior chd 0.19 0.014 0.04 0.34 
prior stroke -0.01 0.969 -0.28 0.27 
  
 
   
drug treatments insulin 1.06 <0.001 0.94 1.18 
sulphonylurea 0.57 <0.001 0.53 0.60 
biguanide -0.28 <0.001 -0.30 -0.25 
acarbose -0.56 <0.001 -0.82 -0.31 
meglitinide 
0.14 0.105 -0.03 0.30 
glitazone 0.67 <0.001 0.61 0.74 
statin -0.08 <0.001 -0.11 -0.05 
other lipid lowering -0.09 0.073 -0.19 0.01 
antianginal(excl. CCB) 0.12 0.001 0.05 0.18 
aspirin 0.03 0.150 -0.01 0.06 
OTC aspirin 1.28 0.041 0.05 2.50 
other antiplatelet -0.15 0.002 -0.25 -0.05 
angiotensin-II receptor antagonist 0.21 <0.001 0.15 0.27 
ACE inhibitor -0.19 <0.001 -0.22 -0.15 
alphablocker 0.38 <0.001 0.32 0.45 
calcium channel blocker 0.06 0.031 0.01 0.11 
diuretic 0.08 0.003 0.03 0.13 
  
    slope(per day) -0.0003 <0.0010 -0.0003 -0.0002 
intercept 32.04 <0.0010 31.75 32.33 
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Table A7.6 Multilevel model used to estimate baseline total cholesterol 
          
Total cholesterol coefficient  p          95% CI 
  
   
  
    
  
year of diagnosis 1998 0.065 0.061 -0.003 0.133 
(reference year = 2000) 1999 -0.058 0.050 -0.116 0.000 
(1998 and 2001 omitted due 2001 -0.118 0.000 -0.163 -0.072 
to collinearity) 2002 -0.199 0.000 -0.242 -0.157 
2003 -0.263 0.000 -0.305 -0.222 
  
    
age at diagnosis 35-44 -0.061 0.022 -0.114 -0.009 
(reference age group = 55-64) 45-54 0.034 0.076 -0.004 0.072 
65-74 -0.092 0.000 -0.124 -0.059 
75-84 -0.213 0.000 -0.253 -0.173 
85-94 -0.398 0.000 -0.481 -0.316 
95+ -0.630 0.018 -1.152 -0.108 
  
    male -0.369 0.000 -0.395 -0.344 
smoker 0.071 0.000 0.051 0.091 
  
    
Townsend quintile (least deprived) 1 0.012 0.401 -0.016 0.041 
(reference quintile = 3) 2 0.039 0.008 0.010 0.067 
4 -0.001 0.970 -0.029 0.028 
(most deprived) 5  0.007 0.674 -0.024 0.037 
  
    
region north 0.054 0.000 0.024 0.084 
(reference = middle) south 0.003 0.830 -0.027 0.033 
  
    comorbidities prior chd 0.051 0.002 0.019 0.084 
prior chd 0.045 0.002 0.017 0.072 
prior stroke 0.022 0.349 -0.024 0.069 
  
    drug treatments insulin -0.074 0.019 -0.135 -0.012 
sulphonylurea -0.008 0.377 -0.027 0.010 
biguanide -0.046 0.000 -0.061 -0.030 
acarbose 0.143 0.027 0.017 0.269 
meglitinide 0.016 0.699 -0.065 0.097 
glitazone 0.117 0.000 0.084 0.150 
statin -1.162 0.000 -1.176 -1.148 
other lipid lowering -0.126 0.000 -0.168 -0.084 
antianginal(excl. CCB) 0.036 0.016 0.007 0.065 
aspirin -0.012 0.152 -0.029 0.005 
OTC aspirin 0.100 0.320 -0.097 0.297 
other antiplatelet -0.128 0.000 -0.172 -0.084 
angiotensin-II receptor antagonist -0.010 0.478 -0.036 0.017 
ACE inhibitor -0.041 0.000 -0.058 -0.024 
alphablocker -0.106 0.000 -0.135 -0.076 
calcium channel blocker 0.062 0.000 0.040 0.083 
diuretic 0.052 0.000 0.031 0.073 
  
    slope(per day) -0.0003 0.000 -0.0004 -0.0003 
time(CDF) 0.505 0.000 0.476 0.534 
intercept 5.999 0.000 5.946 6.051 
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Table A7.7 Multilevel model used to estimate baseline eGFR 
          
eGFR coefficient  p          95% CI 
  
   
  
    
  
year of diagnosis 1998 1.55 0.000 0.74 2.37 
(reference year = 2000) 1999 0.79 0.026 0.09 1.49 
(1998 and 2001 omitted due 2001 -0.34 0.215 -0.89 0.20 
to collinearity) 2002 -0.43 0.099 -0.94 0.08 
2003 -0.57 0.025 -1.07 -0.07 
  
    
age at diagnosis 35-44 5.07 0.000 4.43 5.71 
(reference age group = 55-64) 45-54 2.24 0.000 1.78 2.69 
65-74 -2.92 0.000 -3.30 -2.53 
75-84 -5.73 0.000 -6.20 -5.26 
85-94 -10.12 0.000 -10.98 -9.26 
95+ -14.07 0.000 -18.17 -9.96 
  
    male 2.39 0.000 2.09 2.70 
smoker 0.68 0.000 0.46 0.91 
  
    
Townsend quintile (least deprived) 1 -0.24 0.170 -0.58 0.10 
(reference quintile = 3) 2 -0.49 0.005 -0.83 -0.15 
4 0.11 0.506 -0.22 0.45 
(most deprived) 5  -0.17 0.345 -0.53 0.19 
  
    
region north -0.46 0.011 -0.82 -0.11 
(reference = middle) south -0.28 0.124 -0.63 0.08 
  
    comorbidities prior chd -1.45 0.000 -1.83 -1.08 
prior chd -19.36 0.000 -19.69 -19.03 
prior stroke -1.20 0.000 -1.75 -0.66 
  
    drug treatments insulin -1.85 0.000 -2.57 -1.13 
sulphonylurea -0.76 0.000 -0.96 -0.55 
biguanide 0.63 0.000 0.46 0.79 
acarbose -1.07 0.179 -2.63 0.49 
meglitinide -1.43 0.004 -2.40 -0.45 
glitazone -0.65 0.001 -1.02 -0.28 
statin 0.07 0.376 -0.09 0.23 
other lipid lowering -3.76 0.000 -4.27 -3.24 
antianginal(excl. CCB) -0.39 0.018 -0.71 -0.07 
aspirin 0.64 0.000 0.45 0.83 
OTC aspirin 1.12 0.305 -1.02 3.25 
other antiplatelet -0.55 0.024 -1.03 -0.07 
angiotensin-II receptor antagonist -0.81 0.000 -1.10 -0.52 
ACE inhibitor -0.49 0.000 -0.66 -0.31 
alphablocker -0.95 0.000 -1.28 -0.62 
calcium channel blocker 0.03 0.825 -0.21 0.26 
diuretic -1.56 0.000 -1.79 -1.33 
  
    slope(per day) -0.001 0.000 -0.001 -0.001 
intercept 81.62 0.000 81.00 82.25 
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